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Abstract 
Children with Down syndrome (DS; trisomy 21, T21) have a 500-fold risk of 
developing acute megakaryoblastic leukaemia (AMKL) in early childhood compared 
to children without DS.  DS-AMKL is preceded by a transient neonatal leukaemia, 
unique to DS, caused by acquired mutations in the GATA1 gene in fetal liver (FL) 
haematopoietic stem/progenitor cells (HSPC). Previous work has shown that T21 
itself perturbs FL haematopoiesis prior to acquisition of GATA1 mutations providing 
a cellular substrate for leukaemic transformation. Similar changes are not reported 
in fetal bone marrow (FBM). The mechanism(s) that perturb FL haematopoiesis in 
DS and the role of the unique fetal microenvironment in DS are unknown.  My 
project investigated the role of the environment in abnormal fetal haematopoiesis in 
DS using both an unbiased approach to evaluate the global gene expression by 
fetal stromal cells and a candidate pathway approach, investigating the specific role 
of the insulin-like growth factor (IGF) signalling pathway, a key regulator of cell 
proliferation previously linked to AMKL development in DS.  
To examine the role of the IGF system in fetal haematopoiesis, I measured 
expression of the IGF signalling proteins in stromal cells. In comparison with adult 
BM MSC, fetal MSC expressed marked differences in components of the IGF 
signalling pathway. In particular, IGF1 was selectively expressed by adult BM MSC 
whilst fetal MSC expressed IGF2 with very little IGF1. I next assessed the 
expression of IGF receptors (R) on FL haematopoietic progenitors. Both normal and 
DS FL CD34+ cells expressed high levels of IGF1R, confirming potential for IGF 
responsiveness, while IGF2R was slightly reduced in DS. IGF2 promoted the 
growth of DS FL megakaryocyte colonies in serum-free clonogenic assays and of 
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megakaryocytes in liquid culture, implicating the IGF pathway in the perturbation of 
DS fetal haematopoiesis. 
To further investigate the DS fetal microenvironment, I derived mesenchymal 
stromal cells (MSCs) from normal and DS FL and FBM and performed gene 
expression profiling using microarray. Analysis identified marked differences 
between normal FL and FBM and between normal and DS populations. In 
particular, several genes which encode secreted proteins, including IGFBP1, 
showed differential expression in DS, suggesting that they may play a role in the 
abnormal haematopoiesis. Furthermore, there were remarkably few differences 
between DS FL and DS FBM MSC indicating strong similarities in the 
transcriptomes of these two microenvironments.   
Finally, I established a co-culture system to assess the effects of primary MSC on 
the differentiation of primary FL HSPC. Intriguingly, preliminary experiments indicate 
that DS MSC, but not normal FL MSC, promote erythroid differentiation of normal 
FL HSPC supporting the hypothesis that differences in the transcriptome of DS fetal 
liver MSC are functionally important. This finding provides strong evidence that the 
FL microenvironment is likely to play a significant role in the disruption of fetal liver 
haematopoiesis in DS.    
  
6 
 
Acknowledgments 
First and foremost, I would like to express my deepest gratitude to my supervisor, 
Professor Irene Roberts, whose support and direction were invaluable throughout 
the project.  Her boundless enthusiasm for the science of haematology will remain 
an inspiration throughout my career. In addition, I would like to thank Professor 
Tassos Karadimitris who provided me with exceptional scientific guidance during my 
time in the lab.  
Many thanks go to the members of the Roberts/Karadimitris lab. In particular, I 
would like to thank Dr Gillian Cowan, whose endless patience when I first started 
this project made my transition into the lab as painless as possible. Special thanks 
also go to several others in the lab who have given me particular help and support 
over the last few years including Dr Katerina Goudevenou, Dr Kelly Makarona, Dr 
Joana Costa, Dr Valentina Caputo, Dr Beth Psaila, Dr Deena Iskander, Dr Andi 
Roy, Dr Neha Bhatnagar, Dr Georg Bohn and Dr Aris Chaidos.  
I would like to thank a number of people for providing samples for the project 
including the staff at the Human Developmental Biology Resource, Dagmar Tapon, 
Professor Phil Bennett, Vinita Nair and many of the midwives and other hospital 
staff. My sincere thanks also go to those who donated fetal tissue, without whom 
this work could not be completed.  
Funding for this work was provided by the Kay Kendall Leukaemia Fund, for which I 
am extremely grateful. 
Finally, I would like to express my heartfelt thanks to Kelly, who has given me 
unfailing support and encouragement throughout the PhD.   
  
7 
 
Table of Contents 
 
Declaration of Originality.………….…………………………………..………………..2 
Copyright Declaration ..…………….……………………………………………………3 
Abstract …………………………………………………………………………………… 4 
Acknowledgments …...……………………………………………………….………….6 
Table of Contents ……………………………………………………………….………..7 
List of Figures ..……………………………………………………………………….…13 
List of Tables …………………………………………………………………….………17 
List of Abbreviations ……………………………………………………………….…..18 
1! Background,and,Aims,..............................................................................................,20!
1.1! Down,syndrome,............................................................................................................,20!
1.1.1! Incidence!and!prevalence!of!DS!....................................................................................!20!
1.1.2! Clinical!features!and!genetics!of!DS!..............................................................................!21!
1.1.3! The!Down!Syndrome!Critical!Region!.............................................................................!22!
1.2! Haematological,abnormalities,in,DS,..............................................................................,23!
1.2.1! Incidence!of!malignancy!in!DS!.......................................................................................!25!
1.2.2! Features!of!MLEDS!.........................................................................................................!25!
1.2.3! Features!of!TAM!............................................................................................................!27!
1.2.4! GATA1!mutations!in!MLEDS!...........................................................................................!30!
1.2.5! Progression!to!MLEDS!....................................................................................................!31!
1.3! Fetal,haematopoiesis,in,Down,syndrome,......................................................................,32!
1.3.1! Ontogeny!of!normal!fetal!haematopoiesis!...................................................................!32!
1.3.2! The!haematopoietic!hierarchy!......................................................................................!32!
1.3.3! Fetal!haematopoiesis!in!DS!...........................................................................................!35!
1.3.4! Role!of!T21!in!disruption!of!DS!fetal!haematopoiesis!...................................................!37!
1.4! The,haematopoietic,niche,in,Down,syndrome,...............................................................,41!
8 
 
1.4.1! The!normal!haematopoietic!niche!................................................................................!41!
1.4.2! The!role!of!the!niche!in!haematological!disorders!........................................................!43!
1.4.3! The!fetal!haematopoietic!niche!....................................................................................!44!
1.4.4! The!role!of!the!niche!in!DS!haematopoiesis!..................................................................!45!
1.5! The,IGF,pathway,...........................................................................................................,47!
1.5.1! IGF1!and!IGF2!................................................................................................................!48!
1.5.2! IGF!receptors!.................................................................................................................!48!
1.5.3! IGF!signalling!.................................................................................................................!49!
1.5.4! The!IGF!pathway!in!fetal!life!..........................................................................................!50!
1.5.5! The!IGF!pathway!in!haematopoiesis!.............................................................................!57!
1.5.6! The!IGF!pathway!in!leukaemia!......................................................................................!58!
1.6! Concluding,Remarks,......................................................................................................,59!
1.7! Aims,..............................................................................................................................,60!
2! Materials,and,Methods,............................................................................................,61!
2.1! Primary,tissue,collection,and,processing,.......................................................................,61!
2.1.1! Sample!collection!..........................................................................................................!61!
2.1.2! Ethics!and!Consent!........................................................................................................!62!
2.1.3! Sample!Processing!.........................................................................................................!62!
2.1.4! CD34+!cell!selection!......................................................................................................!63!
2.1.5! Cryopreservation!of!cells!...............................................................................................!63!
2.1.6! Isolation!and!culture!of!MSC!.........................................................................................!64!
2.2! Cell,line,culture,.............................................................................................................,64!
2.3! Flow,cytometry,and,cell,sorting,.....................................................................................,65!
2.3.1! Surface!antibody!staining!..............................................................................................!65!
2.3.2! Flow!cytometric!analysis!and!sorting!............................................................................!65!
2.3.3! Flow!cytometric!cell!counting!.......................................................................................!66!
2.4! Immunohistochemistry,.................................................................................................,67!
9 
 
2.5! Protein,quantification,...................................................................................................,68!
2.6! Cytospins,.......................................................................................................................,69!
2.7! Primary,cell,cultures,......................................................................................................,70!
2.7.1! Clonogenic!assays!..........................................................................................................!70!
2.7.2! Liquid!cultures!...............................................................................................................!71!
2.7.3! MSC!CoEcultures!............................................................................................................!72!
2.8! Gene,expression,analysis,...............................................................................................,73!
2.8.1! RNA!extraction!..............................................................................................................!73!
2.8.2! cDNA!synthesis!..............................................................................................................!74!
2.8.3! Primer!design!and!testing!.............................................................................................!74!
2.8.4! RTEqPCR!.........................................................................................................................!75!
2.8.5! MSC!genomeEwide!expression!microarray!....................................................................!76!
2.8.6! CD34+!FL!microarray!.....................................................................................................!76!
2.8.7! Microarray!analysis!.......................................................................................................!77!
2.9! IGF2R,null,mice,..............................................................................................................,78!
2.9.1! Maintenance!of!mice!....................................................................................................!78!
2.9.2! Organ!processing!and!analysis!......................................................................................!78!
2.10! Statistics,.....................................................................................................................,78!
3! The,role,of,IGF,signalling,in,the,perturbation,of,fetal,haematopoiesis,in,Down,
syndrome,......................................................................................................................,79!
3.1! Introduction,..................................................................................................................,79!
3.2! Expression,of,IGF,and,IGF,receptors,in,normal,and,DS,tissues,........................................,81!
3.2.1! IGF1R!expression!in!normal!HSPC!.................................................................................!81!
3.2.2! IGF1!and!IGF2!production!in!cells!of!the!normal!haematopoietic!microenvironment!.!83!
3.2.3! IGF1R!expression!in!a!DS!leukaemia!cell!line!................................................................!85!
3.2.4! IGF1R!surface!expression!in!primary!DS!fetal!haematopoietic!cells!.............................!86!
3.2.5! IGF1!and!IGF2!production!in!DS!fetal!MSC!and!CD34+!cells!..........................................!87!
10 
 
3.2.6! Expression!of!the!insulin!receptor!in!fetal!haematopoietic!cells!..................................!89!
3.3! Effect,of,IGF,on,clonogenicity,of,normal,FL,CD34+,cells,..................................................,90!
3.4! Effect,of,IGF,on,clonogenicity,of,normal,adult,BM,CD34+,cells,.......................................,97!
3.5! Effect,of,IGF,on,clonogenicity,of,DS,fetal,HSPCs,...........................................................,100!
3.6! Establishment,of,an,erythroTmegakaryocytic,liquid,culture,system,.............................,103!
3.7! The,effect,of,IGF2,on,normal,FL,erythroid,differentiation,............................................,110!
3.8! Growth,and,differentiation,of,DS,FL,CD34+,cells,in,an,erythroid,liquid,culture,system,in,
the,presence,and,absence,of,IGF2,.........................................................................................,111!
3.9! The,effect,of,IGF2,on,normal,FL,megakaryocyte,differentiation,...................................,113!
3.10! Growth,and,differentiation,of,DS,FL,CD34+,cells,in,a,megakaryocyte,liquid,culture,
system,in,the,presence,and,absence,of,IGF2,.........................................................................,115!
3.11! Summary,and,Discussion,...........................................................................................,118!
3.11.1! IGF2EIGF1R!signalling!is!the!key!IGF!pathway!in!fetal!haematopoietic!cells!.............!118!
3.11.2! The!effect!of!IGF2!on!normal!fetal!HSPC!...................................................................!119!
3.11.3! IGFs!synergise!with!high!EPO!concentrations!in!AdBM!............................................!120!
3.11.4! IGF2!promotes!megakaryopoiesis!in!DS!FL!progenitors!............................................!121!
4! The,role,of,the,IGF2,receptor,in,fetal,haematopoiesis,............................................,124!
4.1! Introduction,................................................................................................................,124!
4.1.1! IGF2R!Function!............................................................................................................!124!
4.1.2! IGF2R!in!malignancy!....................................................................................................!125!
4.1.3! IGF2R!in!fetal!life!.........................................................................................................!126!
4.1.4! IGF2R!in!fetal!haematopoiesis!.....................................................................................!126!
4.2! IGF2R,expression,in,a,MLTDS,cell,line,...........................................................................,127!
4.3! IGF2R,expression,in,normal,FL,haematopoietic,cells,....................................................,129!
4.4! IGF2R,expression,in,DS,fetal,liver,CD34+,cells,..............................................................,132!
4.5! The,functional,relevance,of,IGF2R,expression,in,normal,tissue,....................................,136!
4.6! Fetal,haematopoiesis,in,an,IGF2R,null,mouse,..............................................................,138!
11 
 
4.6.1! Breeding!strategy!for!IGF2R!null!mice!.........................................................................!138!
4.6.2! Confirmation!of!IGF2R!phenotype!..............................................................................!139!
4.6.3! Fetal!haematopoiesis!in!IGF2R!null!mice!....................................................................!140!
4.7! Summary,and,discussion,.............................................................................................,143!
5! The,role,of,mesenchymal,stem,cells,in,abnormal,fetal,haematopoiesis,in,DS,.........,146!
5.1! Introduction,................................................................................................................,146!
5.1.1! The!FL!niche!in!DS!........................................................................................................!146!
5.1.2! Mesenchymal!Stromal!Cells!(MSC)!..............................................................................!148!
5.2! Isolation,and,culture,of,fetal,MSC,................................................................................,149!
5.3! Gene,expression,in,normal,FL,MSC,..............................................................................,151!
5.4! Comparison,of,gene,expression,in,FL,MSC,and,AdBM,MSC,..........................................,153!
5.5! Comparison,of,gene,expression,in,normal,and,DS,FL,MSC,...........................................,161!
5.5.1! Genes!expressed!at!higher!levels!in!DS!FL!MSC!compared!to!normal!FL!MSC!............!167!
5.5.2! Genes!with!reduced!expression!in!DS!FL!MSC!compared!to!normal!FL!MSC!..............!169!
5.5.3! GSEA!of!gene!expression!profiling!data!from!normal!and!DS!FL!MSC!.........................!170!
5.6! Comparison,of,gene,expression,in,normal,FL,and,fetal,BM,MSC,..................................,170!
5.7! Comparison,of,DS,FL,and,FBM,MSC,.............................................................................,173!
5.8! Validation,of,candidate,genes,.....................................................................................,175!
5.9! Development,of,a,primary,cell,coTculture,system,........................................................,176!
5.10! Assessment,of,DS,haematopoietic,cells,in,a,coTculture,system,..................................,181!
5.11! Discussion,.................................................................................................................,183!
5.11.1! Differences!in!normal!FL!and!AdBM!MSC!.................................................................!184!
5.11.2! DS!FL!MSC!showed!marked!differences!to!normal!FL!MSC!.......................................!185!
5.11.3! DS!FL!MSC!promote!erythropoiesis!..........................................................................!186!
6! Discussion,..............................................................................................................,188!
6.1! Background,.................................................................................................................,188!
12 
 
6.2! The,IGF,pathway,displays,developmental,stage,specificity,..........................................,189!
6.3! IGF2,drives,megakaryopoiesis,in,DS,FL,progenitors,......................................................,191!
6.4! The,role,of,IGF2R,in,fetal,haematopoiesis,remains,elusive,..........................................,192!
6.5! MSC,show,developmental,stage,and,tissue,specific,characteristics,..............................,193!
6.6! DS,MSC,promote,erythroid,differentiation,..................................................................,194!
6.7! Directions,for,future,research,......................................................................................,195!
6.8! Conclusion,...................................................................................................................,196!
7! References,.............................................................................................................,197!
8! Appendices,............................................................................................................,235!
8.1! Appendix,1,..................................................................................................................,235!
 
  
13 
 
List of Figures 
 
Figure 1-1 The haematopoietic hierarchy ........................................................................ 33 
Figure 1-2 Multistep development of leukaemia in DS ................................................... 37 
Figure 1-3 Mouse models of DS ....................................................................................... 38 
Figure 1-4 The IGF Pathway .............................................................................................. 47 
Figure 2-1 CD34+ Cell Selection ....................................................................................... 63 
Figure 2-2 Gating strategy used to identify haematopoietic subpopulations .............. 66 
Figure 3-1 Expression of IGF1R on FL, CB and AdBM CD34+ cells ............................. 82 
Figure 3-2 IGF1R Expression on normal FL and AdBM HSC, multipotent progenitors 
and myeloid progenitor subpopulation ................................................................... 83 
Figure 3-3 Expression of IGF1 and IGF2 mRNA by FL and AdBM MSCs  .................... 84 
Figure 3-4 IGF1 and IGF2 expression by immunohistochemistry in normal FL and 
AdBM MSCs ................................................................................................................ 85 
Figure 3-5 Expression of IGF1R on CMK and K562 cells by flow cytometry (MFI), RT-
qPCR and Western blotting ....................................................................................... 86 
Figure 3-6 Expression of IGF1R on normal and DS FL CD34+ cells ............................. 87 
Figure 3-7 Expression of IGF1 and IGF2 by normal and DS FL MSCs .......................... 88 
Figure 3-8 IGF1 and IGF2 gene expression in normal and DS FL CD34+ cells. ........... 89 
Figure 3-9 Expression of InsR on normal and DS FL CD34+ cells ................................ 90 
Figure 3-10 Effect of IGFs on clonogenicity of normal FL CD34+ cells in serum-free 
methylcellulose in the absence of EPO ................................................................... 92 
Figure 3-11 Effect of IGF1 on the clonogenicity of normal FL CD34+ cells at 
increasing EPO concentrations. ............................................................................... 94 
Figure 3-12 Effect of IGF2 on the clonogenicity of normal FL CD34+ cells at 
increasing EPO concentrations ................................................................................ 96 
Figure 3-13 Effect of IGF1 on the clonogenicity of AdBM CD34+ cells at increasing 
EPO concentrations ................................................................................................... 98 
14 
 
Figure 3-14 Effect of IGF2 on clonogenicity of AdBM CD34+ cells at increasing EPO 
concentrations ........................................................................................................... 99 
Figure 3-15 Comparison of the synergism between IGFs and EPO on the growth of 
erythroid colonies from normal FL and AdBM CD34+ cells ................................ 100 
Figure 3-16 Effect of IGF1 and IGF2 on clonogenicity of normal FL and DS FL CD34+ 
cells in serum-free methylcellulose ....................................................................... 102 
Figure 3-17 Development of a megakaryocyte-erythroid liquid culture system for FL 
CD34+ cells: Results of protocol 1A ...................................................................... 105 
Figure 3-18 Development of a megakaryocyte-erythroid liquid culture system for FL 
CD34+ cells: Results of protocol 1B ...................................................................... 106 
Figure 3-19 Growth of normal FL CD34+ cells in an erythroid liquid culture system: 
Protocol 2-Er ............................................................................................................. 107 
Figure 3-20 Megakaryocyte differentiation cultures of normal FL CD34+ cells: Results 
of protocol 2-MK ....................................................................................................... 109 
Figure 3-21 Megakaryocyte differentiation in liquid culture ........................................ 110 
Figure 3-22 Effect of IGF2 on erythroid differentiation of normal FL CD34+ cells in 
liquid culture ............................................................................................................. 111 
Figure 3-23 Comparison of erythroid differentiation of normal and DS CD34+ cells 112 
Figure 3-24 Effect of IGF2 on erythroid differentiation of DS FL CD34+ cells ........... 113 
Figure 3-25 Effect of IGF2 on megakaryocytic differentiation of normal FL CD34+ 
cells ........................................................................................................................... 114 
Figure 3-26 Effect of TPO and TPO/SCF on megakaryocytic differentiation of DS FL 
CD34+ cells ............................................................................................................... 116 
Figure 3-27 Effect of IGF2 on megakaryocytic differentiation of DS FL CD34+ cells 117 
Figure 4-1 IGF2R surface expression in a DS AMKL cell line ...................................... 127 
Figure 4-2 IGF2R protein and mRNA expression in a DS AMKL cell line ................... 128 
Figure 4-3 IGF2R expression in normal FL CD34+ cells .............................................. 130 
Figure 4-4 IGF2R expression in HSC, multipotent progenitor and myeloid 
subpopulations in normal FL .................................................................................. 131 
15 
 
Figure 4-5 Comparison of IGF2R expression in FL, CB and AdBM CD34+ cells ....... 132 
Figure 4-6 IGF2R expression in DS FL CD34+ cells ..................................................... 133 
Figure 4-7 IGF2R in DS FL HSC and myeloid progenitor subpopulations ................. 134 
Figure 4-8 IGF2R mRNA expression in progenitor subpopulations in DS FL ............ 135 
Figure 4-9 Function of IGF2R in CB CD34+ cells .......................................................... 137 
Figure 4-10 Breeding strategy to produce IGF2R null mice ........................................ 139 
Figure 4-11 Confirmation of IGF2R null phenotype ...................................................... 140 
Figure 4-12 Haematopoietic lineages in IGF2R null mice ............................................ 141 
Figure 4-13 HSC populations in IGF2R null mice ......................................................... 142 
Figure 4-14 Myeloid progenitor subpopulations in IGF2R null mice .......................... 143 
Figure 5-1 Morphology of cultured MSC isolated from normal and DS FL ................ 150 
Figure 5-2 Immunophenotype of cultured MSC isolated from normal and DS FL ..... 151 
Figure 5-3 Expression of cytokine genes in normal FL MSC assessed ..................... 152 
Figure 5-4 Differentially expressed genes in normal FL vs AdBM MSC ..................... 154 
Figure 5-5 Microarray expression of cytokine genes in normal FL and AdBM MSC. 155 
Figure 5-6 Enrichment of gene sets in normal FL and AdBM MSC ............................. 161 
Figure 5-7 Differentially expressed genes in normal FL vs. DS FL MSC .................... 162 
Figure 5-8 Enrichment of Hsa21 genes in DS FL MSC ................................................. 164 
Figure 5-9 Expression of cytokine genes in DS FL MSC vs. normal FL MSC ............ 166 
Figure 5-10 Enrichment of IFN-related gene sets in normal FL MSC vs. DS FL MSC 170 
Figure 5-11 Differentially expressed genes in normal FL vs. normal FBM MSC ....... 171 
Figure 5-12 RT-qPCR validation of differentially expressed genes in normal FL and 
DS FL MSC ................................................................................................................ 176 
Figure 5-13 Poor survival of normal FL haematopoietic cells cultured with non-
irradiated FL MSC .................................................................................................... 177 
Figure 5-14 DS FL MSC promote proliferation of normal FL CD34+ cells in a MSC co-
culture system .......................................................................................................... 178 
Figure 5-15 Relative erythroid and megakaryocyte differentiation of normal FL CD34+ 
cells co-cultured with normal FL MSC or DS FL MSC .......................................... 179 
16 
 
Figure 5-16 Erythroid and megakaryocytic differentiation of normal FL CD34+ cells 
co-cultured with normal FL or DS FL MSC ............................................................ 180 
Figure 5-17 Proliferation and relative differentiation of DS FL CD34+ cells co-cultured 
with normal and DS FL MSC ................................................................................... 181 
Figure 5-18 Erythroid and megakaryocytic differentiation of DS FL CD34+ cells co-
cultured with normal and DS FL MSC .................................................................... 182 
  
17 
 
List of Tables 
 
Table 1-1 Haematological Abnormalities in neonates and children with DS 24 
Table 1-2 Risk of acute leukaemia in DS 26 
Table 6-3 IGF knockout mouse models 52 
Table 2-1 Antibodies used for immunohistochemistry 67 
Table 2-2 Antibodies used for Western blotting 69 
Table 2-3 Cytokines used in liquid cultures 72 
Table 2-4 Cytokines used in co-cultures 73 
Table 2-5 Sequences of primers used in RT-qPCR 75 
Table 2-6 R packages used in bioinformatic analysis 77 
Table 5-1 Comparison of significantly differentially expressed genes (p<0.05) in 
normal FL vs. AdBM MSC compared to a published dataset (Martin and Bhatia, 
2005) 156 
Table 5-2 Genes with increased expression in normal FL vs. AdBM MSC 158 
Table 5-3 Genes with reduced expression in normal FL vs. AdBM MSC 159 
Table 5-4 Hsa21 genes with higher expression in DS FL MSC vs. normal FL MSC 165 
Table 5-5 Genes with increased expression in DS FL MSC vs. normal FL MSC 167 
Table 5-6 Genes with decreased expression in DS FL MSC vs. normal FL MSC 168 
Table 5-7 Top differentially expressed genes in FL MSC vs. FBM MSC 173 
Table 5-8 Differentially expressed genes in DS FL MSC vs. DS FBM MSC 175 
Table 5-9 Number of differentially expressed genes with FC>2 184 
 
  
18 
 
Abbreviations 
aCGH Array comparative genome hybridisation 
AdBM Adult bone marrow 
AGM Aorto-gonado-mesonephros 
ALL Acute lymphoblastic leukaemia 
AMKL Acute megakaryoblastic leukaemia 
AML Acute myeloid leukaemia 
ANGPT1 Angiopoietin-1 
BM Bone marrow 
CB Cord blood 
CD Cluster of differentiation 
cDNA Complementary deoxyribonucleic acid 
CI-M6PR Cation-independent mannose-6-phosphate receptor 
CLL Chronic lymphocytic leukaemia 
CML Chronic myeloid leukaemia 
CMP Common myeloid progenitor 
Ct Threshold cycle 
DHPLC Denaturing high performance liquid chromatography 
DMSO Dimethyl sulfoxide 
DS Down syndrome 
DSCR Down Syndrome Critical Region 
E-blast Erythroid blast 
ELISA Enzyme-linked immunosorbent assay 
EPO Erythropoietin 
ESC Embryonic stem cell 
FBM Fetal bone marrow 
FBS Fetal bovine serum 
FC Fold change 
FL Fetal liver 
Flt-3 Fms-like tyrosine kinase 3 
GH Growth hormone 
GlyA Glycophorin A 
GM Granulocyte-monocyte 
GM-CSF Granulocyte-macrophage colony stimulating factor 
GMP Granulocyte-macrophage progenitor 
GSEA Gene Set Enrichment Analysis 
HDBR Human Developmental Biology Resource 
HRP Horseradish peroxidase 
Hsa21 Human chromosome 21 
HSC Haematopoietic stem cell 
HSPC Haematopoietic stem and progenitor cell 
IFN-α Interferon-α 
IGF Insulin-like growth factor 
IGF1 Insulin-like growth factor 1 
IGF2 Insulin-like growth factor 2 
IGF1R Insulin-like growth factor 1 receptor 
19 
 
 
 
  
IGF2R Insulin-like growth factor 2 receptor 
IGFBP Insulin-like growth factor binding protein 
IHC Immunohistochemistry 
IL Interleukin 
InsR Insulin receptor 
iPSC Induced pluripotent stem cell 
ISCT International Society for Cellular Therapy 
IUGR Intrauterine growth restriction 
LMPP Lymphoid-primed multipotent progenitor 
MDS Myelodysplastic syndromes 
MEP Megakaryocyte-erythroid progenitor 
MFI Median fluorescent intensity 
MGG May-Grunwald Giemsa 
miR microRNA 
ML-DS Myeloid leukaemia of Down syndrome 
Mmu16 Mouse chromosome 16 
Mmu17 Mouse chromosome 17 
Mmu10 Mouse chromosome 10 
MPD Myeloproliferative disorder 
MPP Multipotent progenitor 
MSC Mesenchymal stromal cells 
MNC Mononuclear cell 
NGS Next generation sequencing 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
RIN RNA integrity number 
RMA Robust multi-array average 
RNA Ribonucleic acid 
RT-qPCR Reverse transcriptase quantitative polymerase chain reaction  
SCF Stem cell factor 
SDS Sodium dodecyl sulphate 
SEM Standard error of the mean 
shRNA Short hairpin Ribonucleic Acid 
siRNA Small interfering RNA 
SS Sanger sequencing 
T21 Trisomy 21 
TAM Transient abnormal myelopoiesis 
TAR Syndrome Thrombocytopenia absent radii syndrome 
TMD Transient myeloproliferative disorder 
TPO Thrombopoietin 
WHO World Health Organisation 
20 
 
1 Background and Aims 
 
1.1 Down syndrome 
Down syndrome (DS), resulting from constitutional trisomy of chromosome 21 
(trisomy 21; T21), is the most common human aneuploidy, affecting around 1 in 
1,000 live births in Western countries (Roper and Reeves, 2006). It is associated 
with a range of haematological features including abnormalities in fetal 
haematopoiesis and a marked increase in the risk of acute leukaemia in childhood. 
However the mechanisms by which T21 disrupts haematopoiesis remain poorly 
understood. To address this, the work within this thesis investigates the role of the 
fetal haematopoietic microenvironment in abnormal haematopoiesis and leukaemia 
initiation in DS.    
 
1.1.1 Incidence and prevalence of DS 
The National Down Syndrome Cytogenetic Register publishes annual reports on the 
numbers of DS diagnoses and births in England and Wales. The most recent 
figures available from 2012 show that there were 1,982 diagnoses of DS, of which 
64% were made prenatally through the antenatal screening programme (Morris and 
Springett, 2014). Over 90% of prenatal diagnoses result in termination leading to a 
live birth rate of 1.1 per 1000 live births.  
A recent meta-analysis of published survival rates estimates that there are 
approximately 37,000 individuals with DS living in the UK (Wu and Morris, 2013). 
The median life expectancy for an individual born with DS today is 58 years. 
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1.1.2 Clinical features and genetics of DS 
The clinical features of DS show significant variation between individuals although a 
number of features are consistent including typical facial dysmorphism, a small 
hypocellular brain and cognitive impairment (Roper and Reeves, 2006). DS is the 
leading cause of congenital heart disease and is also associated with an increased 
risk of Alzheimer’s disease, Hirschprung’s disease, duodenal atresia, 
hypothyroidism and childhood leukaemia (Bullthe Committee on Genetics, 2011). 
The vast majority of cases of DS occur due to meiotic non-disjunction of 
chromosome 21 resulting in a gamete carrying two copies of chromosome 21 
(Antonarakis, 1998). In 90% of cases the extra chromosome is of maternal origin 
and advanced maternal age is a strong risk factor for DS (Ross et al., 2005). In less 
than 5% of cases, T21 occurs due to a Robertsonian translocation, either due to a 
de novo event or inherited from a parent with a pre-existing balanced translocation 
(Antonarakis, 1998). Rarely, in less than 2% of cases, a mitotic error can result in 
T21 mosaicism. 
Chromosome 21 is the smallest chromosome (48Mb) and has the fewest genes of 
all the autosomes  (http://vega.sanger.ac.uk/Homo_sapiens/Location/ 
Chromosome?r=21%3A1-1000). The conventional view is that the features of DS 
occur due to increased dosage of the genes on chromosome 21. However, recent 
microarray analyses in a variety of both fetal and adult DS tissues indicate that the 
genetic landscape in DS is far more complex (Aït Yahya-Graison et al., 2007; 
Letourneau et al., 2014; Li et al., 2006; Lockstone et al., 2007; Prandini et al., 2007; 
Rozovski et al., 2007; Vilardell et al., 2011). Although these studies find that many 
genes are differentially expressed in DS tissues, only a minority of these genes are 
located on chromosome 21, demonstrating the wider impact of T21 on gene 
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transcription. Furthermore, whilst chromosome 21 genes are overexpressed at a 
higher than expected rate, in general only a fraction of the expressed chromosome 
21 genes are upregulated, suggesting the presence of compensatory mechanisms 
to limit gene transcription (Letourneau et al., 2014). A recent study has also 
explored the epigenetic landscape in DS cells using DNA methylation profiling 
(Kerkel et al., 2010). The authors showed marked changes in the methylation 
profile. Importantly these differences were found in genes across all chromosomes 
and were not limited to chromosome 21.  This conclusion is supported by recent 
work from Antonarakis' group in a unique set of monochorionic twins discordant for 
T21 (Letourneau et al., 2014).  
 
1.1.3 The Down Syndrome Critical Region 
Whilst most individuals with DS have a complete extra copy of chromosome 21, 
rare individuals have features of DS but only possess a fraction of the extra 
chromosome 21 (partial T21). Studies in individuals with partial T21 can be useful to 
link particular phenotypes with specific chromosomal regions or genes. The use of 
this technique led to the proposal of a small region of chromosome 21, termed the 
Down Syndrome Critical Region (DSCR), which was estimated to represent the 
minimal region of genes required for the features of DS (McCormick et al., 1989).  
Although this hypothesis was initially widely accepted, more recent work has 
disputed the existence of the DSCR. The most comprehensive study used array 
comparative genome hybridisation (aCGH) to map genotype-phenotype correlations 
in 30 individuals with partial trisomy or monosomy 21 (Lyle et al., 2009). The 
authors found considerable variability in the position of the chromosomal 
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breakpoints and were unable to identify a single portion of chromosome 21 that is 
essential for features of DS, arguing against the existence of a DSCR.  
In addition, work using DS mouse models has questioned the DSCR hypothesis. 
The human chromosome 21 (Hsa21) maps to three syntenic murine chromosomes: 
mouse chromosome 16 (Mmu16), Mmu17 and Mmu10. Due to limitations in 
studying Hsa21 gene effects in humans, a number of DS mouse models have been 
developed, each of which is trisomic for different portions of Hsa21 (discussed 
further below). These mouse models recapitulate some, but not all, of the 
phenotypic features of DS. Importantly, the Ts1Rhr mouse, which is only trisomic for 
the genes in the putative DSCR, failed to show the typical dysmorphic facial 
features of DS, indicating that the DSCR is not sufficient to recapitulate the features 
of DS (Olson et al., 2004).  
Although progress has been made in the characterisation of the genetic landscape 
in DS, the available evidence highlights the current lack of understanding of the 
mechanism(s) by which T21 results in the phenotypic features of DS. It appears 
clear that the classical model of increased chromosome 21 gene dosage represents 
an oversimplification and that further genetic and epigenetic studies will be required 
to enhance understanding. 
 
1.2 Haematological abnormalities in DS 
It has been known for over 50 years that DS is associated with an increased risk of 
childhood leukaemias (Krivit and Good, 1957). In addition, infants and children with 
DS show frequent abnormalities in all haematopoietic lineages as summarised in 
Table 1-1. 
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Table 1-1 Haematological Abnormalities in neonates and children with DS 
Lineage Affected Abnormalities References  
Neonates/Infants 
Erythrocytes • Polycythaemia 
 
 
• Increased circulating 
erythroblasts 
• Macrocytosis 
 
 
• Dysplastic features 
(Henry et al., 2007; 
Kivivuori et al., 1996; 
Roberts et al., 2013) 
(Roberts et al., 2013) 
 
(Kivivuori et al., 1996; 
Roberts et al., 2013; 
Starc, 1992) 
(Roberts et al., 2013) 
Leucocytes • Neutrophilia 
 
• Circulating blasts 
 
• TAM 
 
• Reduced B cells 
(Henry et al., 2007; 
Roberts et al., 2013) 
(Roberts et al., 2013) 
 
(Massey et al., 2006; 
Zipursky, 2003) 
(de Hingh et al., 2005) 
Platelets • Thrombocytopenia 
 
• Giant platelets and 
abnormal morphology 
(Henry et al., 2007; 
Roberts et al., 2013) 
(Roberts et al., 2013) 
Children 
Erythrocytes • Macrocytosis (Kivivuori et al., 1996) 
Leucocytes • ML-DS 
• MDS 
• ALL 
• Reduced B cells and 
immunodeficiency 
(Hasle et al., 2000) 
(Lange et al., 1998) 
(Hasle et al., 2000) 
(de Hingh et al., 2005; 
Ram and Chinen, 2011) 
Platelets • Thrombocytosis (Kivivuori et al., 1996) 
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1.2.1 Incidence of malignancy in DS 
A comprehensive analysis of cancer registry data in Denmark confirmed that 
children with DS have a 10-20-fold excess risk of acute leukaemia when compared 
to the general population (Hasle et al., 2000). Interestingly, the same study showed 
that the rates of solid organ malignancies were significantly reduced in the DS 
population, indicating that, in general, DS conveys a ‘tumour suppressor’ 
phenotype, coupled with a specific increase in leukaemia risk. These data are 
supported by a similar studies in the US (Yang et al., 2002) and Finland (Patja et 
al., 2006).  
 
1.2.2 Features of ML-DS 
Importantly, the incidence of both acute lymphoblastic leukaemia (ALL) and acute 
myeloid leukaemia (AML) is increased in DS (Table 1-2) suggesting disruption at 
the apex of the haematopoietic hierarchy (Hasle et al., 2000). Children with DS are 
at particular risk of a specific subtype of AML called acute megakaryoblastic 
leukaemia (AMKL), which is extremely rare in children without DS. This form of 
leukaemia is now recognised as a specific entity by the World Health Organisation 
(WHO) and is designated as myeloid leukaemia of Down Syndrome (ML-DS). In 
many cases, ML-DS is preceded by an overt transient leukaemia phase, known as 
transient abnormal myelopoiesis (TAM) or transient myeloproliferative disorder 
(TMD). This is a transient clonal disease occurring during the neonatal period that is 
characterised by the presence of immature megakaryoblasts in the peripheral blood 
(discussed further below).   
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Table 1-2 Risk of acute leukaemia in DS 
Type of Leukaemia Frequency in 
general population 
Frequency in DS Excess risk in 
DS 
Acute leukaemia 1 in 2,800 1 in 100-200 10-20 x 
ALL 1 in 3,500 1 in 300 12 x 
AML 1 in 14,000 1 in 300 46 x 
AMKL 1 in 233,000 1in 500 466 x 
Adapted from data in Hasle et al, 2000.   
ML-DS occurs at a median age of 1.8 years, with almost all cases occurring under 
the age of 4 years (Creutzig et al., 2005; Gamis et al., 2003; Hasle et al., 2008). In 
approximately 70% of cases, ML-DS is preceded by a myelodysplastic phase, 
which may last for months or even years before progression to leukaemia (Lange et 
al., 1998). The peripheral blood in ML-DS shows circulating megakaryoblasts, 
cytopenias and dysplastic changes in all myeloid lineages. In addition, the bone 
marrow aspirate and trephine may reveal abnormal megakaryocytes and a degree 
of myelofibrosis (Roy et al., 2009). The immunophenotype of the blasts shows 
expression of stem/progenitor markers (CD34, CD33, CD117), megakaryocytic 
markers (CD41, CD42b), erythroid markers (CD36, Glycophorin A), myeloid 
markers (CD33) and aberrant expression of the T cell marker, CD7 (Gamis et al., 
2003; Karandikar et al., 2001; Langebrake et al., 2005).  
In addition to the megakaryoblastic phenotype, ML-DS shows a number of other 
differences from sporadic childhood AML. Firstly, the white cell count is usually low 
at presentation in ML-DS (Gamis et al., 2003). Furthermore, unlike sporadic AML, 
ML-DS is rarely associated with the typical favourable cytogenetic abnormalities 
(t(8;21), t(15;17), inv(16))  or with specific AMKL abnormalities seen in children 
without DS (t(1;22), t(1;3)) (Gamis et al., 2003; Malinge et al., 2009).  
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Crucially, ML-DS is invariably associated with mutations in the GATA1 
megakaryocytic-erythroid transcription factor gene (Wechsler et al., 2002; Yoshida 
et al., 2013). Although mutations are varied, they always occur in the second or 
third exon and all result in the production of an N-terminal truncated GATA1 protein 
termed GATA1s (Alford et al., 2011). The mechanism by which GATA1s leads to 
leukaemia remains unclear. The spectrum of mutations which co-operate with 
GATA1 mutations to cause ML-DS has recently been described (Yoshida et al., 
2013). Using whole exome sequencing and targeted next generation sequencing 
(NGS), they found that mutations in the cohesin complex and epigenetic regulators, 
such EZH2, were the most common secondary events (described in more detail 
below)(Yoshida et al., 2013). 
Children with ML-DS have superior survival outcomes to those with sporadic AML, 
despite being prone to increased chemotherapy-related toxicity (Creutzig et al., 
2005; Gamis et al., 2003; Rao et al., 2006). This is likely due to the increased 
sensitivity of ML-DS blasts to chemotherapy as shown in several studies (Taub et 
al., 1999; 1997; Yamada et al., 2001; Zwaan et al., 2002). These findings have led 
to the implementation of reduced intensity chemotherapy regimens without any 
detrimental effect on survival (Sorrell et al., 2012). 
 
1.2.3 Features of TAM 
TAM is a clonal pre-leukaemic disorder that occurs exclusively in neonates with DS. 
As with ML-DS, TAM is associated with mutations in the GATA1 transcription factor 
(Alford et al., 2011; Groet et al., 2003; Klusmann et al., 2008; Roberts et al., 2013) 
which are found in every case provided that sufficiently sensitive methods are 
employed (Roberts et al., 2013; Yoshida et al., 2013). 
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Several retrospective studies have collected data about the clinical features and 
natural history of this disease in over 400 cases of TAM although these studies are 
limited by the fact that GATA1 mutational analysis was not used in the majority of 
cases and diagnoses of TAM were made on the basis of a varying range of clinical 
and haematological features (Gamis et al., 2011; Klusmann et al., 2008; Massey et 
al., 2006; Muramatsu et al., 2008). These studies illustrate the highly variable 
clinical presentation of TAM, ranging from asymptomatic haematological 
abnormalities to life-threatening disease (Gamis et al., 2011; Klusmann et al., 2008; 
Massey et al., 2006). The most common clinical features include 
hepatosplenomegaly, pleural and cardiac effusions and haemorrhagic 
complications. Presentation occurs at a mean age of 3-7 days (range 0-65 days), 
although it may also present antenatally causing hydrops fetalis (Heald et al., 2007; 
Klusmann et al., 2008).  
The majority of patients with TAM experience spontaneous remission and do not 
require treatment. However, early death due to TAM occurs in up to 15-20% of 
patients and is associated with raised white cell count, liver fibrosis and dysfunction, 
disseminated intravascular coagulopathy, pleural effusion and preterm birth (Gamis 
et al., 2011; Klusmann et al., 2008; Massey et al., 2006; Muramatsu et al., 2008). 
Those with life-threatening features are usually treated with chemotherapy in the 
form of low-dose cytosine arabinoside. Although, there is evidence to suggest this 
improves outcomes (Klusmann et al., 2008), the outcome of randomised controlled 
trials are not yet available. Retrospective studies suggest that, of the neonates with 
TAM who enter remission, approximately 20% go on to develop full-blown ML-DS 
within the first 4-5 years of life (Zipursky, 2003). Importantly, GATA1 mutation 
analysis has shown identical patient-specific mutations during the TAM and ML-DS 
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phases confirming that it is the same clone that causes both disorders (Ahmed et 
al., 2004; Alford et al., 2011; Hitzler et al., 2003; Yoshida et al., 2013). 
The exact incidence of TAM has been difficult to estimate. Although the disorder is 
now recognised by the WHO as a specific entity, it remains poorly defined 
(Vardiman et al., 2009). The present WHO definition simply requires the presence 
of excess circulating blasts in a neonate with DS but does not specify the 
percentage of blasts required. Since almost all DS neonates have circulating blasts 
during the neonatal period, there is a pressing need for more stringent criteria 
(Roberts et al., 2013). 
The most accurate estimate of incidence of TAM comes from the recently published 
report of the Oxford-Imperial Down Syndrome Cohort Study Group (Roberts et al., 
2013). In contrast to the previous reports on TAM, this study prospectively recruited 
all babies born with DS and analysed data on clinical findings, blood films, full blood 
count indices and GATA1 mutation screening using both Sanger 
sequencing/denaturing high performance liquid chromatography (SS/DHPLC) and 
targeted NGS. The authors found that 11.5% of neonates had a peripheral blast 
count greater than 10% indicating a diagnosis of TAM. However, only 74% of these 
had detectable GATA1 mutations (using SS/DHPLC and NGS) suggesting that the 
diagnosis of TAM should be limited to those patients with a blast count greater than 
10% and a detectable GATA1 mutation. Intriguingly, GATA1 mutations were also 
detected in 20% of patients who did not have an excess blast count or any clinical 
symptoms, including one patient who went on to develop ML-DS. The authors term 
this group ‘silent TAM’ and suggest that all patients should be screened for GATA1 
mutation(s) to ensure accurate follow-up of those at risk of developing ML-DS. This 
study also confirmed an earlier study which found multiple GATA1 mutations (up to 
4) in ~25% of DS neonates (Ahmed et al., 2004; Roberts et al., 2013). 
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1.2.4 GATA1 mutations in ML-DS 
Mutations in the GATA1 transcription factor gene were first identified in ML-DS by 
John Crispino’s group in 2002 (Wechsler et al., 2002). Since then, a number of 
publications have confirmed the presence of mutations in both ML-DS and TAM 
(Ahmed et al., 2004; Alford et al., 2011; Groet et al., 2003; Hitzler et al., 2003; 
Mundschau et al., 2003; Xu et al., 2003). Although mutations differ, they all result in 
the insertion of a premature stop codon, blocking synthesis of the full length GATA1 
protein, whilst allowing exclusive production of a shorter variant, termed GATA1s, 
which lacks the N-terminal activation domain and has reduced transactivation 
potential (Wechsler et al., 2002). Importantly, similar mutations found in individuals 
without DS are associated with anaemia and leucopenia but do not lead to 
leukaemia, confirming that the mutations are only leukaemogenic in the context of 
T21 (Hollanda et al., 2006). Furthermore, two cases of TAM/ML-DS have been 
described in patients without constitutional DS, but in both cases T21 and GATA1 
mutations were present in the leukaemic blasts (Carpenter et al., 2005). 
Work using knock-out mouse models initially identified GATA1 as a key regulator of 
erythropoiesis, which is essential for embryonic development (Weiss and Orkin, 
1995). Specific targeting of GATA1 gene knockout to megakaryocyte progenitors 
further established that GATA1 is also essential for normal megakaryocyte 
development (Shivdasani et al., 1997; Vyas et al., 1999). Gata1-null 
megakaryocytes show hyperproliferation in liquid culture, deregulated development 
and a failure of platelet production.  
The mechanism by which exclusive production of the GATA1s protein predisposes 
to leukaemia has been explored in murine models. The retroviral-mediated 
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expression of GATA1s in murine fetal GATA1-null megakaryocytes failed to supress 
the excessive proliferation of megakaryocytes (Muntean and Crispino, 2005). In 
addition, expression of the full-length GATA1 protein in a ML-DS cell line (which has 
exclusive expression of GATA1s) promoted erythroid development, suggesting that 
the full-length protein is essential for normal erythroid development. Furthermore, 
elegant work within Stuart Orkin’s lab using mice that only produce GATA1s also 
showed an impairment in erythropoiesis in combination with an increase in 
megakaryocyte proliferation (Li et al., 2005). Importantly, this effect was transient 
and limited to fetal life, in keeping with the fetal origin of this disease.  Overall, this 
evidence indicates that GATA1s mutations lead to a relative block in erythroid 
development and a commensurate increase in megakaryocyte proliferation. 
Whether this is due to a loss of full-length GATA1, an increase in GATA1s, or a 
combination of the two remains unclear.   
1.2.5 Progression to ML-DS 
It is clear that ML-DS requires the presence of T21 and a GATA1 mutation. 
Recently, some of the additional genetic defects required for the progression of 
TAM to ML-DS have also been identified. A number of small studies had previously 
identified JAK2, JAK3 and FLT3 mutations in several cases of ML-DS (de Vita et al., 
2007; Hama et al., 2008; Kiyoi et al., 2007; Klusmann et al., 2007; Malinge et al., 
2008; Walters et al., 2006). However, a recent publication carried out detailed whole 
genome or whole exome sequencing on almost 100 cases of TAM and ML-DS 
(Yoshida et al., 2013). The authors found more than half of the cases carried 
mutations in cohesion components, a complex involved in cell division, DNA repair 
and long range regulation of gene expression. Mutations were also frequently 
identified in CTCF (20%), epigenetic regulators (45%) and the JAK, MPL and RAS 
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pathways (47%). Further work is now required to ascertain the mechanisms by 
which mutations in these genes facilitate the progression of ML-DS. 
1.3 Fetal haematopoiesis in Down syndrome 
1.3.1 Ontogeny of normal fetal haematopoiesis 
Due to obvious limitations, our understanding of the ontogeny of human 
haematopoiesis is largely inferred from murine studies, although human 
haematopoiesis appears to follow a generally similar course. Evidence of 
haematopoiesis is first seen in the yolk sac, in which blood islands containing 
erythroid-biased progenitor cells are evident from 18.5 days in humans (Tavian et 
al., 1999a). The earliest intra-embryonic haematopoietic cells develop in the aorta-
gonado-mesonephros (AGM) in the ventral endothelium of the dorsal aorta (de 
Bruijn et al., 2000; Medvinsky and Dzierzak, 1996). In humans, this wave of 
definitive haematopoiesis occurs from 5 weeks of gestation (Marshall et al., 1999; 
Tavian et al., 1999a).  
From 5 weeks onwards, haematopoietic stem cells (HSC) from the AGM seed the 
fetal liver (FL), which forms the major site of haematopoiesis until after birth 
(Ottersbach et al., 2010; Tavian et al., 1999b). Haematopoiesis begins in the fetal 
bone marrow (FBM) from approximately 10 weeks gestation onwards and will go on 
to become the predominant site of blood development after birth (Tavian et al., 
1999a).  
1.3.2 The haematopoietic hierarchy 
It is now clearly established that haematopoiesis is organised as a developmental 
hierarchy, with multipotent HSC at the apex and terminally differentiated specialised 
cells at the base (Figure 1-1) (Doulatov et al., 2012). Fetal HSC, like adult HSC, 
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have three defining characteristics: (1) multipotency, (2) long-term self-renewal; and 
(3) long-term haematopoietic reconstitution in vivo of myeloablated recipients.  
 
Figure 1-1 The haematopoietic hierarchy 
Haematopoietic stem cells (HSC), differentiate through several progenitor stages to produce 
terminally differentiated cells. Progenitor populations are all CD34+ and are further defined based on 
cell surface immunophenotypes as shown. HSC, multipotent progenitors (MPP) and lymphoid-
primed multipotent progenitors (LMPP) are CD38- and are further subdivided based on CD45RA and 
CD90 expression. The myeloid progenitor compartment consists of common myeloid progenitors 
(CMP), megakaryocytic-erythroid progenitors (MEP) and granulocyte-macrophage progenitors 
(GMP); they are CD38+ and can be further subdivided based on CD45RA and CD123 expression.  
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Improvements in flow cytometry and sorting, and xenotransplantation have refined 
the current immunophenotypic HSC definition, which has allowed isolation of an 
increasingly pure HSC population. At present, human HSC are widely accepted to 
be Lin- CD34+ CD38- CD90+ CD45RA- (Majeti et al., 2007). A recent paper 
suggests that CD49f may also be a specific HSC marker although this work has not 
yet been validated by other groups (Notta et al., 2011). Immediately downstream of 
the HSC, is the multipotent progenitor (MPP), which is fully multipotent but lacks the 
long-term reconstituting ability of the HSC, and can be immunophenotypically 
distinguished from the HSC by loss of CD90 expression (Majeti et al., 2007). 
Until recently, the classical view of the haematopoietic hierarchy postulated a strict 
segregation of the myeloid and lymphoid lineages, with MPP differentiation to a 
common myeloid progenitor (CMP) or common lymphoid progenitor (CLP) (Akashi 
et al., 2000; Kondo et al., 1997). However, recent evidence suggests this is an 
oversimplification. Work in mice identified a CD34+ Flt3hi population, termed the 
lymphoid-primed multipotent progenitor (LMPP), containing combined lymphoid and 
myeloid potential but with limited erythroid-megakaryocyte potential (Adolfsson et 
al., 2005). Subsequent analysis of human haematopoiesis identified a similar 
population accounting for 1% of all CD34+ cells, indicating that the first definitive 
lineage segregation occurs between the myeloid/lymphoid and the erythroid-
megakaryocyte branches (Doulatov et al., 2010; Goardon et al., 2011). 
As shown in Figure 1-1, the MPP can differentiate into either a LMPP or CMP. The 
CMP can, in turn, differentiate into a megakaryocyte-erythroid progenitor (MEP), 
and thereafter into megakaryocytes or erythrocytes, or a granulocyte-macrophage 
progenitor (GMP), with granulocytic-monocytic potential (Doulatov et al., 2012).  
35 
 
Although most of the work described above has been performed in adult bone 
marrow and cord blood, recent work indicates that this model can also be applied to 
fetal haematopoiesis (Roy et al., 2012). 
 
1.3.3 Fetal haematopoiesis in DS 
Many factors indicate that TAM and ML-DS are of fetal origin. First, the natural 
history of TAM shows a predisposition to liver involvement, the major site of fetal 
haematopoiesis, and there is spontaneous resolution within the first few months as 
fetal haematopoiesis regresses completely in the majority of cases (Klusmann et al., 
2008). Second, GATA1 mutations are acquired during fetal life and TAM can even 
present prior to birth. The murine work described earlier also supports the stage 
specific nature of this disease (Li et al., 2005). 
Crucially, work within our lab, and others, has found that the normal pattern of fetal 
haematopoiesis is perturbed in DS prior to the acquisition of GATA1 mutations 
(Chou et al., 2008; Roy et al., 2012; Tunstall-Pedoe et al., 2008), thus establishing a 
direct effect of T21 on fetal haematopoiesis. Through detailed immunophenotypic 
analysis of the FL haematopoietic stem and progenitor cell (HSPC) compartment, 
the authors found a marked expansion of MEP in DS with a commensurate 
reduction in GMP, indicating a megakaryocyte-erythroid bias within fetal life (Chou 
et al., 2008; Tunstall-Pedoe et al., 2008). In addition, compared to disomic FL, DS 
FL HSPC showed a marked increase in clonogenicity in methylcellulose assays, 
mainly due to enhanced megakaryocyte/erythroid colony formation.  
This megakaryocyte-erythroid bias has now been shown to be coupled with a defect 
in lymphocyte development (Roy et al., 2012). Immunophenotypic analysis and cell 
culture found a clear block in B cell differentiation in DS FL. This is extremely 
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interesting given that children with DS are also at increased risk of developing B-
ALL.  
Furthermore, recent work has shown disruption at the very earliest point in the 
haematopoietic hierarchy with an expansion of the immunophenotypic HSC 
compartment (Roy et al., 2012). As with myeloid progenitors, FL HSC in DS show a 
megakaryocyte/erythroid bias in clonogenic assays. This is reinforced by results of 
gene expression analyses which show upregulation of megakaryocyte-erythroid 
genes and downregulation of B-cell genes at the HSC level (Roy et al., 2012). 
In summary, DS fetal haematopoiesis shows clear disruption of haematopoiesis 
throughout the haematopoietic hierarchy and in both major lineages. In relation to 
the development of TAM/ML-DS, a profound megakaryocytic-erythroid bias exists 
even in the absence of GATA1 mutations. It appears that this provides a unique 
substrate upon which GATA1 mutations can act, resulting in the initiation of ML-DS 
(Figure 1-2). 
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Figure 1-2 Multistep development of leukaemia in DS 
Disruption of haematopoiesis in the FL predisposes to acquisition of GATA1 mutations, which in turn 
precipitate TAM and ML-DS. In addition, abnormal lymphoid development may predispose to 
development of ALL.  
 
1.3.4 Role of T21 in disruption of DS fetal haematopoiesis 
As described above, several studies have demonstrated disruption of human DS 
fetal haematopoiesis in the absence of GATA1 mutations (Chou et al., 2008; Roy et 
al., 2012; Tunstall-Pedoe et al., 2008), thus implicating a direct role of T21. 
Chromosome 21 harbours several genes that have known roles in haematopoiesis 
and megakaryopoiesis, and an extra copy of one or more of these genes may result 
in disruption of haematopoiesis.  
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In view of the difficulties inherent in studying human fetal haematopoiesis, most 
studies that have investigated the role of these genes have focused on murine 
haematopoiesis. As it appears likely that the haematological abnormalities seen in 
DS are due to a combination of genes, several mouse models have been used to 
investigate the role of T21 in the disruption of haematopoiesis. As discussed above, 
the genes on Hsa21 are spread across 3 murine chromosomes, with the majority on 
Mmu16. Several murine models of DS exist which have partial trisomy for various 
regions of Mmu16 and recapitulate some features of DS, including facial 
dysmorphism, heart abnormalities and defects in learning and behaviour (Figure 
1-3). In addition, a number of haematopoietic defects have been identified.  
 
Figure 1-3 Mouse models of DS 
Illustration of Hsa21 and the regions of trisomy contained within the various mouse models of DS. 
Note that TC1 is trisomic for almost the entire Hsa21 and that Ts1Rhr is only trisomic for the DSCR. 
Orange region shows the Down syndrome Critical Region (DSCR). Other colours identify regions 
shared between mouse models. (Adapted from (Malinge et al., 2009))  
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The most widely studied model of DS is the Ts65Dn mouse, which is trisomic for 
104 genes on Hsa21 (Reeves et al., 1995). These mice have a macrocytic anaemia 
and some go on to develop a myeloproliferative disorder (MPD) with 
thrombocytosis, megakaryocyte proliferation and myelofibrosis (Kirsammer et al., 
2008). However, this MPD is only seen in older mice and is not present during the 
fetal or neonatal period in contrast to the pattern seen in human DS. Similarly, none 
of the mice developed TAM or ML-DS, indicating that T21 is not sufficient for 
leukaemia initiation in this murine model. Interestingly, knockdown of the ERG 
gene, which is on Hsa21, led to resolution of the MPD, whilst knockdown of another 
haematopoietic gene on Hsa21, RUNX1, had no identifiable effect, strongly 
implicating increased dosage of ERG in the disruption of haematopoiesis (Ng et al., 
2010).  
The Ts1cje murine model, which is trisomic for 81 Hsa21 genes also develops 
macrocytic anaemia, although fails to develop a MPD or leukaemia, even in the 
context of GATA1 gene knockdown (Carmichael et al., 2009). Similarly, the Tc1 
model, which carries an almost complete freely segregating copy of Hsa21, shows 
macrocytic anaemia, splenomegaly and possible thrombocytosis, but does not 
develop leukaemia, even with the introduction of GATA1s (Alford et al., 2010).  
Overall, whilst these models provide some indication that T21 can disrupt murine 
haematopoiesis, none faithfully recapitulate the abnormalities seen in fetal 
haematopoiesis in DS, limiting their value in the investigation of leukaemia initiation. 
Despite the failure of mouse models to accurately reproduce the abnormalities seen 
in DS, many studies have attempted to identify the roles of individual trisomic genes 
in DS haematopoiesis. The two genes that have received the greatest attention are 
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RUNX1 and ERG, both of which are known oncogenes and are essential regulators 
of megakaryopoiesis. 
RUNX1 is a particularly compelling candidate gene as it encodes a transcription 
factor essential for fetal megakaryopoiesis and HSC maintenance, and is known to 
be frequently translocated in AML (Okuda et al., 1996). In addition, it has been 
linked with GATA1 in megakaryopoiesis providing a mechanism by which a GATA1 
mutation could initiate leukaemia (Elagib et al., 2003). However, RUNX1 is not 
overexpressed in either human DS fetal CD34+ cells (Roy et al., 2012; Tunstall-
Pedoe et al., 2008), T21 embryonic stem cells (ESC), T21 induced pluripotent stem 
cells (iPSC) or in ML-DS blasts (Bourquin et al., 2006), questioning its role in DS. 
The ETS family of transcription factor genes also plays a key role in HSC 
maintenance and megakaryopoiesis, with ETS2 as well as ERG, located on Hsa21 
(Loughran et al., 2008; Wang et al., 2002). Forced overexpression of either ERG or 
ETS2 in an erythroblastoid cell line (K562), resulted in megakaryocytic 
differentiation, demonstrating the megakaryocytic bias of these genes (Ge et al., 
2008; Rainis et al., 2005). In addition, overexpression of ERG and ETS2 resulted in 
megakaryocyte expansion in wild type or GATA1 mutant murine FL progenitors 
(Stankiewicz and Crispino, 2009). Furthermore, ERG overexpression immortalised 
GATA1s mutant cells and was associated with an upregulation of the JAK/STAT 
pathway. A recent paper from Shai Izraeli’s group using an ERG/GATA1s double-
transgenic mouse provides the strongest evidence for the role of ERG in leukaemia 
initiation in DS (Birger et al., 2013). The authors showed that ERG overexpression 
alone resulted in MEP expansion in the FL, as previously described in human DS 
(Tunstall-Pedoe et al., 2008). Addition of GATA1s led to further expansion of MEP 
and megakaryocyte progenitors, a gene profile similar to that of human TAM and 
progression to myeloid leukaemia by 3 months of age. This mouse provides the 
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closest approximation of DS haematopoiesis and strongly implicates trisomy of 
ERG in the disruption of haematopoiesis. However, it appears likely that more 
detailed studies using human fetal haematopoietic cells are now required to provide 
further insight into the role of T21 in DS haematopoiesis. 
 
1.4 The haematopoietic niche in Down syndrome 
1.4.1 The normal haematopoietic niche 
The regulation of haematopoiesis involves the complex interplay of a network of 
intrinsic and extrinsic factors. Whilst some factors, such as hormones in the blood, 
are carried from distant sources, many factors will be produced locally and the local 
environment is therefore likely to have a strong influence on haematopoietic cells. 
The concept of the niche as a supportive microenvironment for HSC survival and 
differentiation was first postulated in 1978 by Ray Schofield (Schofield, 1978). 
However, the difficulty in studying haematopoietic cells in their natural environment 
has meant that it is only recently that the full complexity of the niche is beginning to 
be understood. As with fetal haematopoiesis, much of this work has been carried 
out in murine bone marrow (BM) but is still likely to prove valuable in the 
understanding of human haematopoiesis. 
Advances in laboratory techniques have improved understanding of several aspects 
of the niche, including the exact location of HSC within the niche, the identity of 
essential supportive cells and the regulators influencing cell survival and 
differentiation. Although, it has been possible to identify HSC using flow cytometry 
for many years, it is only recently that immunohistochemical staining techniques 
have allowed identification of HSC within the BM. Using two-colour staining 
42 
 
protocols, researchers have been able to localise HSC within the BM and spleen 
and show that they are preferentially located adjacent to sinusoids suggesting that 
HSC are maintained by endothelial or perivascular cells (Kiel et al., 2007; 2005). It 
was later confirmed, using in vivo live imaging that HSC remained in perivascular 
regions for weeks, generating new cells as required (Celso et al., 2008). 
Osteoblasts were the first cell type found to influence HSC maintenance in the niche 
when perturbed in vivo (Calvi et al., 2003). However, further studies have since 
suggested that this reflected an indirect mechanism and that osteoblasts are not 
truly supportive cells (Morrison and Scadden, 2014). Instead, attention has focused 
on the stromal cells that line blood vessels and are therefore in direct contact with 
HSC. Although these mesenchymal stromal cells (MSC) are a relatively 
heterogenous population, several studies have provided strong evidence that they 
are a key component of the perivascular niche. For instance, MSC expressing 
CD146 (Sacchetti et al., 2007) or nestin (Méndez-Ferrer et al., 2010) both express 
high levels of factors that promote HSC maintenance, localise around blood vessels 
and lie in close proximity to HSC. Furthermore, stem cell factor (SCF) and CXCL12, 
two major regulators of HSC function, are both produced mainly by MSC in the 
perivascular region (Ding et al., 2012; Greenbaum et al., 2014; Sugiyama et al., 
2006). Conditional deletion of SCF in perivascular stromal cells (Lepr-Cre) resulted 
in depletion of HSC (Ding et al., 2012). Similarly, deletion of CXCL12 in 
mesenchymal cells depleted HSC in the BM (Sugiyama et al., 2006). Although it is 
clear that there is not a single niche cell, these studies confirm that the perivascular 
MSC population plays a key role in HSC maintenance.  
In addition to locally produced factors, recent work has highlighted the importance 
of other mechanisms in HSC maintenance. Circadian oscillations have been shown 
to influence HSC release and neutrophil clearance (Casanova-Acebes et al., 2013; 
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Méndez-Ferrer et al., 2008), whilst the sympathetic nervous system regulates 
CXCL12 expression and HSC retention (Katayama et al., 2006). Staining using a 
hypoxia marker, pimonidazole, and high levels of HIF1A expression in the 
perivascular region have both implicated hypoxia as an important factor in HSC 
maintenance (Nombela-Arrieta et al., 2013; Takubo et al., 2010). However, more 
recent work suggests that hypoxia may simply reflect the high consumption of 
oxygen during haematopoiesis, and is not an essential requirement for HSC 
function (Spencer et al., 2014). 
Overall, whilst recent work has markedly advanced our understanding of the 
haematopoietic niche, it has also highlighted the complexity of this 
microenvironment. Refinement of in vivo imaging techniques is likely to further 
define the intricate anatomy of the niche and this in turn will drive the identification 
of novel regulating factors and mechanisms.  
 
1.4.2 The role of the niche in haematological disorders 
Whilst the niche is vital in the maintenance of normal haematopoiesis, a growing 
body of literature is uncovering its role in the development and support of 
haematological disorders. Two studies have described the development of MPD in 
mice caused by microenvironment-specific gene deletions of two different genes 
(Rb and RARγ) (Walkley et al., 2007a; 2007b). In addition, a recent paper has for 
the first time shown development of leukaemia in mice secondary to a single 
genetic change specific to the microenvironment. These mice harbour an activating 
mutation of β-catenin that is only present in osteoblasts and go on to develop a 
transplantable AML (Kode et al., 2014). 
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There is also emerging evidence that haematological disorders can themselves 
alter the niche. A paper from Emmanuelle Passegue’s lab has shown that a MPD in 
mice can remodel the niche into a ‘self-reinforcing leukaemic environment’ that 
inhibits normal haematopoiesis and instead supports leukaemic stem cells 
(Schepers et al., 2013).   
 
1.4.3 The fetal haematopoietic niche 
Fetal haematopoiesis shows marked differences to adult haematopoiesis. In 
particular, whilst HSC are mainly in a quiescent state during adult life, they show 
significant expansion and self renewal during fetal development (Morrison et al., 
1995). It is highly likely that this is at least partly due to the influence of the specific 
fetal microenvironment.  
As discussed earlier, the FL forms the major site of haematopoiesis during 
gestation. However, although MSC have been isolated from the AGM, FL and FBM 
(Badillo and Flake, 2006; Campagnoli, 2001), relatively little is known about the fetal 
microenvironment and how this may influence this specific developmental stage of 
haematopoiesis. Experiments using MSC isolated from FL have shown that they are 
capable of supporting in vitro haematopoiesis and that they have inherent 
differences to adult BM MSC including greater proliferation, longer survival and 
increased expression of N-cadherin and osteopontin (Martin and Bhatia, 2005). FL 
MSC also showed an increase in the Wnt signalling pathway and a downregulation 
of Notch signalling compared to adult BM (AdBM) MSC (Martin and Bhatia, 2005). 
In addition, the composition of the MSC population differs in fetal life with the 
majority of cells expressing CD146 (Maijenburg et al., 2012). CD146+ pericytes 
have been shown to express key factors for the support of HSC including nestin, 
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CXCL12 and Lep-R, and have greater capacity for HSC maintenance than CD146- 
cells (Corselli et al., 2013). However, despite these preliminary findings, further 
research is required to establish the nature of the fetal niche and its role in fetal 
haematopoiesis.  
 
1.4.4 The role of the niche in DS haematopoiesis 
As described above, haematopoiesis is significantly perturbed in DS during fetal life. 
Whilst there is currently a lack of definitive evidence, several factors implicate the 
fetal niche in the aetiology of leukaemia in DS. Importantly, TAM develops in the 
liver during fetal life and, in the majority of cases, spontaneously remits as 
haematopoiesis moves to the BM, suggesting that the FL microenvironment is an 
absolute requirement for maintenance of this condition (Roy et al., 2009). In 
addition, the disruption in haematopoiesis seen in DS is unique to fetal life, again 
indicating a reliance on the FL microenvironment.   
These findings present two alternative hypotheses. Firstly, that there are 
abnormalities specific to the DS fetal microenvironment which drive perturbation of 
haematopoiesis and ultimately lead to the emergence of TAM. However, as yet, 
there have been no papers investigating the DS fetal microenvironment. 
Alternatively, it is possible that there is a factor present in the normal FL 
microenvironment that is required for the support of haematopoiesis and 
development of TAM.  
Two papers provide some support to this second hypothesis, implicating the insulin-
like growth factor (IGF) and interferon-α (IFN-α) pathways (Klusmann et al., 2010; 
Woo et al., 2013). Woo et al employed microarray to identify differences between 
wild-type murine fetal and adult megakaryocyte progenitors, showing upregulation 
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of the IFN-α pathway in adult progenitors. Using fetal megakaryocyte progenitors 
derived from GATA1s mice, which show fetal-specific megakaryocyte 
hyperproliferation, they demonstrated that IFN-α reduced proliferation suggesting 
that low IFN-α levels in the fetal microenvironment are important for the abnormal 
megakaryocyte proliferation present in this mouse. However, importantly, IFN-α 
signalling was actually upregulated in primary DS TAM and ML-DS blasts, which 
contradicts this hypothesis. 
A paper by Klusmann et al, published in 2010, provides compelling evidence for a 
role of the IGF pathway in the disruption of DS haematopoiesis (Klusmann et al., 
2010). The IGF pathway, which is discussed in greater detail in the next section, is 
a key regulator of cell proliferation and has been shown to be vital for normal fetal 
growth and development (DeChiara et al., 1990; 1991; Pollak, 2008). In view of this, 
the authors investigated the function of the IGF pathway using DS leukaemia cell 
lines and primary TAM blasts. They demonstrated high expression of the IGF1 
receptor (IGF1R) in DS blasts, associated with an enrichment of IGF-related gene 
sets. DS cells were hyper-responsive to exogenous IGF and cell survival was 
markedly reduced on IGF inhibition using shRNA or a pharmacological inhibitor. 
Intriguingly, experiments using murine megakaryocyte progenitors, revealed a 
stage-specific effect, with IGF1R inhibition blocking cell survival in FL-derived but 
not AdBM-derived cells. Overall, this paper provides strong evidence for a role of 
the IGF pathway in leukaemia in DS and in murine fetal megakaryopoiesis. 
However, the researchers did not explore the function of IGF signalling in the 
context of normal human fetal haematopoiesis and in the perturbation of 
haematopoiesis in DS.  
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1.5 The IGF pathway 
The highly conserved IGF pathway consists of 2 ligands, IGF1 and IGF2, and 2 
receptors, IGF1R and IGF2R (Pollak et al., 2004). Importantly, both IGF1 and IGF2 
signal through IGF1R, leading to downstream activation of a number of key 
modulators of cell proliferation and survival, including the PI3K/Akt/MTOR pathway 
and the Ras/MAPK/ERK pathway (Figure 1-4). IGF2R binds only IGF2, which is 
then internalised and degraded, and therefore functions as a negative regulator of 
the pathway(Ghosh et al., 2003). 
 
Figure 1-4 The IGF Pathway 
IGF1 and IGF2 both activate the IGF1 Receptor (IGF1R) resulting in activation of the 
PI3K/Akt/MTOR pathway and the Ras/MAPK/ERK pathway. Importantly, IGF2R only binds IGF2 
leading to IGF2 degradation.  
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1.5.1 IGF1 and IGF2 
IGF1 acts as both a circulating hormone and a locally released growth factor. Most 
circulating IGF1 is produced by the liver and is largely regulated by growth hormone 
(GH). IGF2 is also produced both by the liver and in extrahepatic sites, although 
release is not regulated by GH. The IGF2 gene is imprinted in humans and, in the 
majority of tissues, only the paternally inherited allele is active (Chao and D’Amore, 
2008). Loss of imprinting, leading to IGF2 overexpression, occurs in several 
diseases (Chao and D’Amore, 2008), the best known of which is Beckwith 
Wiedermann Syndrome, a disorder characterised by fetal overgrowth and a 
predisposition to certain cancers.  
 
1.5.2 IGF receptors 
IGR1R 
IGF1 and 2 share significant sequence homology with insulin (Butler and Le Roith, 
2001). Similarly, the IGF1R has approximately 60% amino acid identity with the 
Insulin receptor (InsR), both having α and β subunits in an α2β2 configuration 
(Belfiore et al., 2009). The α unit of IGF1R is primarily extracellular forming the 
binding site for IGF1 and IGF2. The β subunit spans the cell membrane but is 
predominantly intracellular and encompasses the tyrosine kinase domain. Both 
IGF1 and 2 activate the IGF pathway through binding to IGF1R. Insulin is also able 
to bind to the receptor, albeit with very low affinity (Steele-Perkins et al., 1988). In 
addition, IGF1 and 2 are able to signal through the InsR, although, again, affinity is 
low. 
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IGF2R 
The IGF2 receptor (IGF2R) is a fascinating structure that has several roles within 
normal cell function. Initially independently identified as the cation-independent 
mannose-6-phosphate receptor (CI-M6PR) and the IGF2R, it was many years 
before the two were confirmed to be the same structure (Kiess et al., 1988). 
Although much is known on its role in lysosomal enzyme trafficking, it is only with 
the identification of IGF2R mutations in various cancers that its role as a tumour 
suppressor has gained attention (Hankins et al., 1996). 
The IGF2R is a type-1 integral membrane glycoprotein, which forms a dimer when 
situated in the membrane (Byrd, 2000). However, in keeping with its role in cellular 
trafficking, 90% of the receptor is intracellular at steady state with continual cycling 
between the cytoplasm and the membrane (Brown et al., 2009). The receptor has 
no kinase domain and, despite several previous studies suggesting otherwise, it 
does not seem to have any direct signaling role (Ghosh et al., 2003). Once bound to 
IGF2R, IGF2 is internalised and degraded, leading to reduced IGF2 activity (Nolan 
et al., 1990; Oka et al., 1985). Blockade of IGF2R has been shown to inhibit IGF2 
degradation but importantly does not affect IGF signaling (Kiess et al., 1987). 
 
1.5.3 IGF signalling 
The IGF1R is able to activate at least two pathways, the most important of which 
are the PI3-K/Akt/MTOR pathway and the Ras/MEK/ERK pathway, summarised in 
Figure 1-4. The ability of IGF1R to regulate two key proliferative pathways makes it 
a powerful mediator of cell metabolism and growth. Studies have demonstrated that 
both IGF1 and 2 can promote cell cycle progression in human and murine cells, 
thereby stimulating cell proliferation (Adesanya et al., 1999; Zhang et al., 1999). The 
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IGF pathway has also been shown to be a key regulator of differentiation in a wide 
variety of cell types including myoblasts, osteoblasts, adipocytes, oligodendrocytes, 
neurons and haematopoietic cells (Baserga, 2000). It remains unclear exactly how 
IGF1R is able to mediate both proliferation and differentiation but work by Valentinis 
and colleagues suggests that competition between IRS1 and Shc binding plays an 
important role (Valentinis et al., 1999). Studies in murine 32D haematopoietic cells 
showed that IGF1 was able to promote myeloid differentiation through Shc 
phosphorylation and activation of the Ras/MAPK pathway. Overexpression of IRS1 
inhibited differentiation and instead activated the Akt/MTOR pathway resulting in 
malignant transformation (Valentinis, 2000). This work suggests a balance is 
required between these two pathways to ensure normal cell growth and 
development. 
 
1.5.4 The IGF pathway in fetal life 
Several lines of enquiry have identified the IGF pathway as a major regulator of 
mammalian fetal growth and development. The most compelling evidence is 
provided by knockout mouse models targeting both the IGF ligands and receptors, 
which elegantly demonstrate that IGF function is essential for normal murine fetal 
development (see below). In addition, a number of epidemiological studies and the 
identification of rare mutations in humans have also confirmed the importance of the 
IGF pathway in human fetal development.  
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1.5.4.1 Murine studies: insight into the role of the IGF pathway from 
transgenic mice 
Much of the evidence supporting the role of IGF1 and 2 in fetal life is based on 
mouse models that allow investigation of the effects of the knockout of genes 
encoding individual, or multiple, components of the pathway (Table 1-3) (Baker et 
al., 1993; DeChiara et al., 1991; Liu et al., 1993; Ludwig et al., 1996; Wang et al., 
1994). 
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Although IGF2 is commonly considered the fetal mediator of the pathway and IGF1 
the key postnatal mediator, the murine studies suggest this clear-cut distinction is 
an oversimplification. In fact, both IGF1- and IGF2-deficient mice show reduced 
birthweight, at around 60% of wild-type littermates (Baker et al., 1993; DeChiara et 
al., 1991; Liu et al., 1993). Furthermore, most IGF1 null mice die perinatally whilst 
IGF2 null mice generally survive. Importantly, though, surviving IGF1 null mice show 
ongoing reduced postnatal growth whilst postnatal growth is normal in IGF2 null 
mice (Baker et al., 1993; DeChiara et al., 1990; Liu et al., 1993), indicating that 
IGF1 can regulate both fetal and postnatal growth whilst IGF2 primarily functions 
during fetal life. Furthermore, it has been noted that IGF2 null mice exhibit growth 
retardation from E11, whilst IGF1 knockout mice do not show retardation until E13, 
suggesting IGF2 may have a greater role in early fetal development (Baker et al., 
1993; Liu et al., 1993). Knockout of a placenta-specific IGF2 transcript results in 
decreased placental size from E12 and fetal growth retardation from E16, 
highlighting an additional role for IGF2 in normal placental growth (Constância et al., 
2002).    
Mice lacking the IGF1R virtually all die perinatally and show more extreme growth 
retardation than either IGF1 or IGF2 null mice, with a birthweight 45% that of wild-
type littermates (Liu et al., 1993). The addition of IGF1 knockout to the IGF1R 
knockout model does not alter the phenotype, whereas, interestingly, the 
combination of IGF1R/IGF2 knockout results in further growth retardation and a 
birthweight 30% of normal (Liu et al., 1993; Ludwig et al., 1996). This finding 
suggests that IGF2 can signal even in the absence of IGF1R, most likely via the 
InsR.  
As discussed earlier, IGF2R functions primarily as a negative regulator of the IGF 
pathway through the degradation of IGF2. Knockout mice deficient for the IGF2R 
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exhibit significant fetal overgrowth and organ abnormalities and almost all die at 
birth (Lau et al., 1994; Ludwig et al., 1996; Wang et al., 1994). Circulating IGF2 is 
increased 2-4-fold compared to wild-type mice, suggesting overgrowth is secondary 
to increased IGF2 signalling. Intriguingly, combined IGF1R/IGF2R knockout mice 
have normal birthweight and survive into adulthood, albeit with reduced postnatal 
growth (Ludwig et al., 1996). This model implies that increased circulating IGF2, 
due to reduced IGF2R, is sufficient for normal fetal growth even in the absence of 
IGF1R signalling, presumably through InsR activation.    
 
1.5.4.2 Human studies: insight from mutations in IGFs and IGFRs 
Although it is believed that the IGF pathway is also the major determinant of growth 
during human fetal life, most evidence is based on epidemiological studies and 
several case studies detailing mutations in IGF pathway components (Reviewed in 
(Randhawa and Cohen, 2005).  
Homozygous IGF1 mutations resulting in IGF1 deficiency have only been described 
in 4 patients (Bonapace et al., 2003; PhD et al., 2011; Woods et al., 1997). Features 
were similar in all cases with severe IUGR, reduced postnatal growth, sensorineural 
deafness and mild developmental delay. As with mice, this indicates a role for IGF1 
in both fetal and postnatal growth in humans. Laron Syndrome, in which mutations 
in the GH receptor gene lead to GH insensitivity, results in high circulating GH and 
undetectable levels of IGF1 (Laron, 1999). Patients show a mild reduction in 
birthweight and length, and marked postnatal growth retardation. As patients do not 
display the severe IUGR seen in homozygous IGF1 mutations, this would suggest 
that fetal IGF1 production is not under the control of GH signalling. 
55 
 
Interestingly, IGF2 mutations are yet to be reported in humans, suggesting that 
homozygous IGF2 deficiency may be incompatible with life. Two disorders have, 
however, recently been linked with abnormal IGF2 expression; Russell-Silver 
Syndrome and Beckwith-Wiedermann Syndrome. Russell-Silver Syndrome is 
characterised by low birthweight and length, a lack of postnatal catch-up growth, 
skeletal abnormalities but otherwise normal development (Bartholdi et al., 2008). 
Until recently, the major genetic abnormality had not been identified, although 
maternal uniparental disomy of chromosome 7 had been reported in around 5% of 
patients. This changed with the finding of hypomethylation at the IGF2/H19 
imprinting control region in more than 40% of patients (Bartholdi et al., 2008). This 
results in reduced IGF2 expression and is associated with a more severe 
phenotype. Contrary to this, patients with Beckwith-Wiedermann Syndrome display 
macrosomia, hemihypertrophy, abdominal wall defects, advanced bone age and are 
prone to malignancies in childhood, particularly Wilm’s tumour and hepatoblastoma 
(Choufani et al., 2010). The majority of cases have now been shown to be due to 
altered methylation at the 11p15.5 region, which includes the IGF2 gene and results 
in increased expression (Choufani et al., 2010; Jacob et al., 2013). Thus, two 
diseases associated with reduced or increased IGF2 expression are characterised 
by reduced or increased fetal growth respectively, clearly implicating IGF2 in the 
control of fetal growth in humans.   
Heterozygous IGF1R deletions have also been reported in several patients and 
result in a similar phenotype to IGF1 deficiency, although without sensorineural 
deafness (de Lacerda et al., 1999; Randhawa and Cohen, 2005). It is important to 
note that mice heterozygous for the IGF1R gene display a normal phenotype with 
no evidence of abnormal growth highlighting important differences in the IGF 
system in mice and humans (Liu et al., 1993). Homozygous IGF1R deletions have 
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not been reported in humans, which, again, suggests this may not be compatible 
with life.  
A large number of studies have evaluated IGF1 and IGF2 levels in maternal blood 
and cord blood (CB) through pregnancy in an attempt to identify an association with 
birthweight (Reviewed in (Murphy et al., 2006)). Although IGF1 and IGF2 levels in 
maternal blood do increase through pregnancy, studies to assess the relationship to 
birthweight show conflicting results. However, this is not surprising given that 
previous work has shown maternal IGFs do not cross the placenta (Callan and 
Milne, 2009).  
Epidemiological studies have shown conclusively that IGF1 levels in CB correlate 
with birthweight (Murphy et al., 2006). Furthermore, a single study has shown that 
IGF1 levels are proportionate to CD34+ cells in CB (Baik et al., 2005). However, in 
general, levels of IGF2 show no correlation. It is possible to speculate that IGF2 
levels earlier in pregnancy may determine fetal growth, but this has not yet been 
examined. Instead, two studies have shown a correlation between reduced 
placental IGF2 levels and low birthweight (Guo et al., 2008; Koukoura et al., 2011). 
Interestingly, IGF2 is maternally imprinted and loss of imprinting was demonstrated 
in a significant proportion of small for gestational age (SGA) infants. However, this 
showed no obvious correlation with IGF2 expression level (Koukoura et al., 2011).  
In summary, there is significant evidence to show that the IGF pathway is a key 
regulator of fetal growth. However, a number of questions remain as to the exact 
contribution of individual components, particularly in humans. The differences 
between the mouse knockout models and human mutations suggests that there are 
likely to be key differences in the function of the IGF system in different species, 
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meaning that further work in humans will be required to fully understand how the 
IGF system influences human fetal development. 
 
1.5.5 The IGF pathway in haematopoiesis 
Although many in vitro studies have demonstrated that IGF1 and 2 are growth 
factors for haematopoietic cells, many of the experiments were performed in the 
presence of serum and none of the studies used highly purified cells and so the 
exact role of the IGF pathway in normal haematopoiesis remains poorly 
characterised. IGF1 and 2 can enhance clonogenicity of AdBM and CB CD34+ cells 
and myeloid and erythroid colonies in serum-supplemented and serum-free culture, 
although other growth factors, including erythropoietin (EPO) and SCF are also 
required (Akahane et al., 1987; Merchav et al., 1988a; 1988b; Panzenböck et al., 
1998; Ratajczak et al., 1998; Sanders et al., 1993; Schwartz et al., 1996). The 
effects of IGF1 on erythroid and myeloid precursors are reported to be reduced by 
the addition of anti-IGF1 and anti-IGF1R antibodies suggesting that they are 
mediated by the IGF1R (Merchav et al., 1988a; 1988b).   
There is now good evidence that IGF2 has a vital role in normal murine fetal 
haematopoiesis. Lodish and colleagues found that a population of FL stromal cells 
produces IGF2, supporting HSC expansion (Chou and Lodish, 2010). In addition, 
Mascarenhas et al demonstrated upregulation of IGF2 in E11 aorta, with a 
corresponding downregulation in IGF2R in the HSC enriched fraction, suggesting 
upregulation of this pathway. They also found that IGF2 exhibited a dual role, 
blocking differentiation in immature CFU-Mix colonies, whilst promoting BFU-E 
colony formation in erythroid precursors (Mascarenhas et al., 2009). However, at 
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present, there is no evidence describing the role of IGF signaling in human fetal 
haematopoiesis.  
 
1.5.6 The IGF pathway in leukaemia 
Although interest in the role of the IGF pathway in malignancy has only recently 
increased, basic in vitro studies completed more than 20 years ago demonstrated 
enhanced clonogenicity in leukaemic cell lines in response to both IGF1 and IGF2 
(Blanchard et al., 1988; Hizuka et al., 1987; Kellerer et al., 1990). Later, erythroid 
precursors from patients with polycythaemia rubra vera were found to be highly 
sensitive to IGF1 when cultured in methylcellulose (Correa et al., 1994), an effect 
that has since been shown to be induced by the common V617F mutation in the 
JAK2 gene (Staerk et al., 2005).  
Whilst studies have suggested a role for IGF signaling in chronic lymphocytic 
leukaemia (CLL) (Schillaci et al., 2005), chronic myeloid leukaemia (CML) 
(Randhawa et al., 1998) and myelodysplastic syndromes (MDS) (He et al., 2010; Qi 
et al., 2005), the most detailed research has been in AML. Several studies have 
shown by various techniques that primary AML cells express the IGF1R and IR-A 
proteins (Chapuis et al., 2010; Doepfner et al., 2007; Wahner Hendrickson et al., 
2009). Autocrine production of IGF1 and IGF2 by AML blasts has also been shown 
using PCR and ELISA techniques (Chapuis et al., 2010; Wahner Hendrickson et al., 
2009).  
The function of IGF signaling in AML has been best confirmed by the recent work of 
Chapuis and colleagues (Chapuis et al., 2010). As PI3K is already known to be 
constitutively activated in 50% of AML cases, the authors aimed to assess the 
functional importance of the IGF1R in this pathway. Using primary AML samples 
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they first confirmed a correlation between constitutive phosphorylation of PI3K and 
IGF1R expression, using Western blotting after cells had been in serum-free 
conditions. They then demonstrated that specific IGF1R inhibition, using an IGF1R 
antibody, resulted in decreased phosphorylation of PI3K and Akt in 70% of PI3K-
activated samples. Having demonstrated that exogenous IGF1 further increased 
activation of IGF1R and PI3K they went on to inhibit autocrine IGF1 using an IGF1 
antibody and IGF1 siRNA, resulting in reduced phosphorylation of IGF1R and Akt. 
Importantly, although ERK1/2 was phosphorylated in many samples, IGF1R 
inhibition did not affect its activity, suggesting an alternate upstream mechanism for 
the activation of this pathway. Finally, the authors demonstrated reduced 
clonogenicity in serum-supplemented methylcellulose assays and a reduction in 
thymidine incorporation when cells were exposed to the IGF1R antibody. Although 
further work is needed to clarify the role of IGF in leukaemia, this study provides 
important evidence that the pathway is likely to be a major mediator of proliferation 
and survival in haematological malignancies.  
   
1.6 Concluding Remarks 
The multi-step model of leukaemia in DS provides a paradigm for the study of the 
aetiology of childhood leukaemias. Whilst great progress has been made in the 
understanding of this process, significant questions remain unanswered. In 
particular, the natural history of ML-DS strongly implicates the fetal 
microenvironment in the perturbation of haematopoiesis and the development of 
leukaemia. However, despite this, the role of the niche in DS fetal haematopoiesis 
remains largely unexplored. For instance, nothing is known about the supportive 
cells that constitute the DS fetal niche and if they differ from the normal FL niche.  
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So far, the work by Klusmann et al provides the only clear evidence for a link 
between the abnormalities seen in DS fetal haematopoiesis and a specific fetal 
signalling pathway. The importance of the IGF pathway in normal fetal development 
makes it plausible that IGF signalling could play a significant role in the disruption of 
haematopoiesis in DS.  
 
1.7 Aims 
The overall aim of my project is to explore the role of the FL microenvironment in 
the disruption of haematopoiesis in DS, with particular focus on the IGF pathway. 
The specific aims are: 
1. To investigate the hypothesis that significant differences exist in the DS FL 
niche through the characterisation of normal and DS fetal stromal cells.  
2. To investigate the hypothesis that IGF signalling acts as a driver of abnormal 
haematopoiesis in DS. 
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2 Materials and Methods 
2.1 Primary tissue collection and processing 
2.1.1 Sample collection 
Primary samples were collected from several sources: 
(i) Fetal T21 samples were collected from elective second trimester (12-20 weeks 
gestational age) surgical terminations after identification of a T21 pregnancy by 
antenatal ultrasound, serum screening and confirmation of karyotype by chorionic 
villus sampling or amniocentesis. Gestational age of the fetus was determined by 
crown rump length by ultrasound. (n = 9, median gestational age: 14 weeks; range 
12- 18 weeks) 
 (i) Normal fetal tissue was provided by the Human Developmental Biology 
Resource (HDBR) tissue bank. Samples were collected from fetuses without T21 
undergoing surgical termination usually for social reasons. All pregnant women 
undergoing termination had had at least one routine antenatal ultrasound scan and 
no structural anomalies were detected in the fetuses. All fetuses had karyotyping 
performed by the HDBR to confirm absence of T21 and other abnormalities (n = 19; 
median gestational age: 13 weeks, range 11- 20 weeks). 
(iii) CB was collected during elective caesarean deliveries. Blood was aspirated 
from the umbilical vein, as soon as possible after the umbilical cord was cut, using 
21G needles and immediately transferred to a 50ml Falcon (Becton-Dickinson, UK) 
containing preservative-free heparin at a concentration of 10-50 IU/ml (CP 
Pharmaceuticals, UK). 
(iii) AdBM CD34+ cells were purchased from All Cells LLC (Alameda, CA, USA). 
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2.1.2 Ethics and Consent 
Prior to commencement of the project, all sampling, consent and experimental 
procedures were approved by the Hammersmith, Queen Charlotte’s & Chelsea and 
Acton Hospitals Ethics Committee, reference 04/Q0406/145. All pregnant women 
gave specific written informed consent for the collection and use of the fetal tissue. 
All samples were anonymised on receipt and assigned a study number. 
 
2.1.3 Sample Processing  
FL was identified and washed twice with phosphate buffered saline (PBS) (Sigma-
Aldrich, Dorset, UK). The tissue was disrupted by pressing it through a 40µm cell 
filter (Becton-Dickinson, Oxford, UK) using the blunt end of a plastic syringe plunger 
to produce a single-cell suspension. The cells were washed with PBS and 
centrifuged at 1800rpm for 5 minutes. The supernatant was discarded and the pellet 
re-suspended in PBS. 
FBM was obtained from the long bones. Following dissection, PBS was flushed 
through each bone using a 23G needle. Cells were then washed in PBS. 
Mononuclear cells (MNC) were isolated from CB and FL samples by density 
gradient separation. Samples were diluted 1:2 with PBS and layered onto 1/3 
volume Histopaque-1077 (Sigma-Aldrich, Dorset, UK) and centrifuged at 1800rpm 
for 30 minutes. The interface layer of MNC was collected and washed twice before 
further processing.  
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2.1.4 CD34+ cell selection 
CD34+ selection was performed using the MiniMACS Separator kit as per 
manufacturer's instructions (Miltenyi Biotech Ltd, Surrey, UK). Briefly, cells were 
incubated for 30 minutes with CD34 microbeads (Miltenyi Biotech Ltd, Surrey UK), 
washed and passed once or twice through a MS positive selection column (Miltenyi 
Biotech Ltd, Surrey, UK), depending on requirements. Typical purity was  >75% 
CD34+ cells for a single column pass and >95% for a double column pass (Figure 
2-1). 
 
Figure 2-1 CD34+ Cell Selection 
Mononuclear cells were stained with CD34 microbeads, washed and passed once or twice through a 
magnetic positive selection column. CD34+ yield was >75% for a single pass and >95% for a double 
pass.  
 
2.1.5 Cryopreservation of cells 
Cells were cryopreserved in freezing medium (90% Fetal Bovine Serum (FBS) 
supplemented with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, Dorset, UK)) at 
a maximum concentration of 107 cells/ml of freezing medium. Immediately after 
suspension in the freezing medium, they were frozen in -80°C in an isopropanol-
containing Nalgene Cell Freezing Container (Sigma-Aldrich, Dorset, UK) for up to 
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two days before long-term storage in liquid nitrogen. In order to thaw the 
cryopreserved cells, they were incubated for 1 minute in a 37°C water bath. They 
were then resuspended in medium warmed to 37°C. 
 
2.1.6 Isolation and culture of MSC  
Unselected MNC from FL, FBM and AdBM were plated at a density of 105 cells/cm2 
in Glutamax α-MEM cell media (Gibco, Invitrogen, Paisley, UK) containing 10ml/L 
penicillin/streptomycin (Sigma-Aldrich, Dorset, UK) and 10% FBS and incubated at 
37°C in 5% CO2. After 72 hours, medium was replaced, removing all non-adherent 
cells. Remaining cells were allowed to expand to near confluence and were then 
passaged using Trypsin-EDTA (Sigma-Aldrich, Dorset, UK).    
MSC were photographed in culture using an EVOS XL digital inverted microscope 
(Electron Microscopy Services, Hatfield, PA, USA). 
 
2.2 Cell line culture 
Two cell lines were used during the project; CMK, a ML-DS cell line (Komatsu et al., 
1989; Sato et al., 1989) and K562, an erythroleukaemia cell line (Lozzio and Lozzio, 
1975). Both cell lines were cultured in RPMI 1640 with L-glutamine and sodium 
bicarbonate (Sigma-Aldrich, Dorset, UK) containing 10ml/L penicillin/streptomycin 
and 10% FBS and incubated at 37°C in 5% CO2. Cell density was maintained at 
approximately 3-5x105/ml.  
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2.3 Flow cytometry and cell sorting 
2.3.1 Surface antibody staining 
Cells were suspended in PBS/2% FBS buffer, incubated with fluorophore-
conjugated monoclonal antibodies (see Appendix 1 for list of all antibodies used) for 
30 minutes at 4°C, washed and re-suspended in 350µl buffer for analysis or cell 
sorting.  
 
2.3.2 Flow cytometric analysis and sorting  
Samples were analysed using a BD LSRFortessa or sorted on a FACSAria machine 
(Beckton Dickinson, Oxford, UK). Compensation settings for 8-10 colour analysis 
were set using single-stained samples.  Data were analysed on FlowJo software 
(Tree Star, Oregon, USA).  
Gating strategies for identification of haematopoietic progenitor subpopulations are 
shown in Figure 2-2, gating first on viable Lin- cells. 
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Figure 2-2 Gating strategy used to identify haematopoietic subpopulations 
The early progenitor compartment, containing HSC, MPP and LMPP, was identified by gating CD34+ 
CD38- cells, and then further subdivided based on CD45RA and CD90 expression. The myeloid 
progenitor compartment was selected by gating on CD34+ CD38+ cells and further subdivided 
based on CD123 and CD45RA expression, allowing identification of CMP, GMP and MEP (Majeti et 
al., 2007). 
 
2.3.3 Flow cytometric cell counting  
Cell counting was performed using CountBright Absolute Counting Beads 
(Invitrogen, Paisley, UK) as per manufacturer’s instructions. Briefly, a fixed number 
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of beads (10uL) was added to each sample immediately prior to flow cytometry. The 
number of beads could then be used to calculate the absolute cell number. 
 
2.4 Immunohistochemistry 
Cultured MSCs were seeded onto polyL lysine-coated CC2 chamber slides (Lab-
Tek, Nalge Nunc International, Roskilde, Denmark).  Cells were either cultured for 3 
hours to allow attachment onto the slide or grown until confluent.  
For immunohistochemistry, cells were fixed in ice cold methanol (Sigma-Aldrich, 
Dorset, UK) for 10 minutes at -20oC.  Cells were blocked in PBS containing 20% 
FBS and 5% BSA, followed by the avidin-biotin blocking kit (Vector Laboratories, 
Peterborough, UK). Primary antibodies (Table 2-1) were then added and incubated 
overnight at 4oC.  After 2x5 minute washes in PBS, cells were incubated with 
appropriate secondary antibodies for 30 minutes.  Cells were then washed in PBS 
and incubated with Streptavidin-HRP for 30 minutes, followed by DAB and 
counterstained with haematoxylin.  
For negative controls, primary antibody was replaced with normal goat serum. 
Images were captured using a Nikon Eclipse E400 microscope and a Nikon DN100 
digital camera. 
Table 2-1 Antibodies used for immunohistochemistry 
Target Species Manufacturer 
Primary Antibodies 
IGF1 Rabbit Abcam, Cambridge, UK 
IGF2 Rabbit Abcam, Cambridge, UK 
Secondary Antibodies 
Anti-Rabbit HRP Goat Dako, Cambridgeshire, 
UK 
 
68 
 
2.5  Protein quantification 
Cells were washed in PBS and resuspended in 50µl 2x loading buffer (0.25M Tris-
HCl, pH:6.8, 20% β-mercaptoethanol, 40% glycerol, 16% SDS, and bromophenol 
blue; all Sigma-Aldrich, Dorset, UK). Samples were heated to 90°C for 5min to lyse 
cells and denature proteins. 20µl of each sample was loaded onto a 12% 
polyacrylamide gel and run at 150V in 1x SDS-running buffer (5x SDS-running 
buffer: 15,1gr Trizma, 72gr Glycine, 5gr SDS in 1L water; all Sigma-Aldrich, Dorset, 
UK). In addition, a broad-range protein marker (Cell signaling technology, New 
England Biolabs Ltd, Herts, UK) was run to allow measurement of protein bands. 
The gel was then transferred onto a PVDF membrane using a semi-dry approach 
(BioRad, UK) at 15V for 40 min in 1x transfer buffer (5.92g Trizma, 2.93g Glycine in 
1L water). Following transfer, the membrane was blocked in 5% skimmed milk 
(Sigma-Aldrich, Dorset, UK) in PBS+0.1%Tween20 for 1hour at room temperature 
and then washed twice in PBS+0.1%Tween20. The membrane was then incubated 
overnight in the primary antibody at a 1:2000 dilution in PBS+0.1%Tween20. 
Following further washes, the membrane was incubated for 30min in the secondary 
antibody at a 1:2000 dilution in PBS+0.1%Tween20. After washing the membrane 
three times in PBS+0.5%Tween20, ECL detection reagent (GE healthcare, UK) was 
added for 1 minute and then developed onto X-ray films (Kodak, NY, USA). All 
antibodies are shown in Table 2-2. 
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Table 2-2 Antibodies used for Western blotting 
Target Species Manufacturer 
Primary Antibodies 
IGF1R Rabbit Cell Signalling 
Technology, Beverly, MA, 
USA 
IGF2R Rabbit Abcam, Cambridge, UK 
β-Actin Goat Polyclonal Dako, Cambridgeshire, 
UK 
Secondary Antibodies 
Anti-Goat HRP Rabbit Dako, Cambridgeshire, 
UK 
Anti-Rabbit HRP Goat Dako, Cambridgeshire, 
UK 
 
Following analysis of the primary protein of interest, the membrane was stripped 
using a stripping buffer (Tris-HCl 20mM, pH 7.5, 6M Glutamic acid hydrochloride 
(GaHCl), 0.2% Nonyl phenoxypolyethoxylethanol-40 (NP-40) and 0.1M β-
mercaptoethanol; all Sigma-Aldrich, UK), washed, and incubated with the β-actin 
antibody at a dilution of 1:1000 in blocking solution (5% milk in PBS+ 
0.1%Tween20). Antibody was then detected as described above. 
To quantify the protein, images were scanned and analysed using ImageJ software 
(http://rsbweb.nih.gov/ij/). Specifically, protein bands were quantified and the 
background levels were subtracted to provide a true intensity value. This value was 
then normalized to the β-actin level. 
 
2.6 Cytospins 
To allow examination of cell morphology, cytospins were performed using a 
Shandon Cytospin 2 (Thermo Fisher Scientific, Rockford, IL) onto SuperFrost Ultra 
Plus slides (VWR International Ltd, Leicestershire, UK). Cells were suspended in 
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100µl PBS/2% FBS buffer and spun for 5 minutes at 400rpm. Slides were allowed 
to dry and then fixed in 100% methanol. Staining was performed using a May-
Grunwald Giemsa Stain (MGG). The May-Grunwald stain was made by diluting 
May-Grunwald Eosin Stain (Sigma-Aldrich, Dorset, UK) 1:1 with pH 6.8 buffered 
distilled water. The Giemsa stain was prepared by diluting Giemsa Stain (Sigma-
Aldrich, Dorset, UK) 1:10 with pH 6.8 buffered distilled water. Slides were placed in 
May-Grunwald for 7 minutes and then placed straight into the Giemsa stain for 20 
minutes with no washing in between. Slides were then washed in distilled water and 
allowed to dry. Slides were mounted with PTX mountant (Sigma-Aldrich, Dorset, 
UK) and covered with a 50x25mm coverslip (VWR International Ltd, Leicestershire, 
UK).  Cytospins were assessed using a Nikon eclipse E400 microscope (Nikon, UK) 
and photographs were taken using 40x and 100x magnification lenses. 
 
2.7 Primary cell cultures 
2.7.1 Clonogenic assays  
Methylcellulose haematopoietic progenitor assays were performed using Serum-
free Methocult H4236 (Stem Cell Technologies, Vancouver, Canada) in the 
presence of interleukin-3 (IL-3 ; 20ng/mL), IL-6 (10 ng/mL), IL-11 (10 ng/mL), Stem 
Cell Factor (SCF; 10 ng/mL), Flt3 ligand (Flt3; 10 ng/mL), Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF; 50 ng/mL), thrombopoietin (TPO; 50 ng/mL), 
penicillin/streptomycin (100U/mL) and either erythropoietin (EPO; 4 u/mL) or IGF1 
(300 ng/mL) or IGF2 (300 ng/mL).  Cytokines used were based on previous work by 
Manz et al (Manz et al., 2002) and within our lab (Roy et al., 2012; Tunstall-Pedoe 
et al., 2008). All cytokines were from Peprotech (Peprotech Inc, NJ, USA) except 
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EPO, IGF1 and IGF2, which were purchased from R&D (R&D Systems Europe, 
UK).   
Cells were sorted directly into 1mL methylcellulose in 1.5mL tubes and then plated 
into 24-well tissue culture plates. Cultures were incubated at 37°C in 5% CO2 for 14 
days and colonies identified on the basis of morphology. In cases in which 
morphological identification was unclear, colony identity was confirmed with 
cytospins and/or flow cytometry.  
 
2.7.2 Liquid cultures 
The system used for primary cell liquid cultures was based on protocols kindly 
provided by Dr Benjamin Ebert, Harvard Medical School, Boston, USA, as 
previously published (Ebert et al., 2005; 2008). All cultures were performed using 
StemSpan Serum-Free Expansion Medium (Stem Cell Technologies, Vancouver, 
Canada).  
Following optimisation of protocols (detailed in Chapter 3), 2 liquid culture systems 
were used; an erythroid-specific system (Protocol 2-Er) and a megakaryocytic 
system (Protocol 2-MK). The erythroid system utilised a 2-phase method, in which 
EPO was at low concentration for phase 1 (day 0-7; 0.5U/mL) and high 
concentration for phase 2 (day 7-14; 4U/mL). However, other than the cytokines 
used, the method was essentially the same in both systems. Cytokines are shown 
in Table 2-3. Human LDL was purchased from Merck Millipore (Watford, UK). 
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Table 2-3 Cytokines used in liquid cultures 
Protocol 2-Er Media Protocol 2-MK Media 
SCF 100ng/mL TPO 50ng/mL 
IL3 10ng/mL LDL 
IL6 10ng/mL Penicillin/Streptomycin 100U/mL 
EPO 0.5U/mL (Phase 1) 
EPO 4U/mL (Phase 2 
 
Penicillin/Streptomycin 100U/mL  
 
For each culture, either 100 or 1000 lin- CD34+ cells were sorted directly into 1.5mL 
tubes containing 200uL prepared cell medium. Cells were then plated into 96-well 
flat-bottom plates and incubated at 37°C in 5% CO2. Half medium changes were 
performed twice weekly and cells transferred to larger plates as they neared 
confluence. Cultures were analysed at day 7, day 10 and day 14. During analysis, 
the entire contents of the well was removed from the plate, washed and 
resuspended in flow cytometry staining buffer. Cells were then stained with 
antibodies to determine differentiation and flow cytometry performed as described 
above. Cells were also counted using counting beads as described earlier and 
cytospins performed.  
 
2.7.3 MSC Co-cultures 
The protocol used for MSC co-cultures was optimised as described in Chapter 5. 
The final system cultured lin- CD34+ cells on a layer of irradiated primary MSC to 
assess the effect of stromal cells on haematopoietic differentiation.  
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Firstly, MSC were trypsinised, washed and suspended in culture medium. They 
were than irradiated at 20Gy and plated onto 24-well tissue culture plates at 3x104 
cells/well in 400uL medium and incubated at 37°C in 5% CO2. After 24 hours, 100 
or 1000 Lin- CD34+ cells were sorted and plated onto the MSC layer in similar 
culture medium to that used in the liquid cultures (Table 2-4). Half medium changes 
were performed twice weekly and cultures were analysed at day 7, day 10 and day 
14. Analysis was performed using flow cytometry and counting beads as for the 
liquid cultures.  
Table 2-4 Cytokines used in co-cultures 
Erythroid/Megakaryocyte 
SCF 100ng/mL 
IL-3 10ng/mL 
IL-6 10ng/mL 
EPO 0.5U/mL (Phase 1) 
EPO 4U/mL (Phase 2) 
TPO 50ng/mL 
Penicillin/Streptomycin 100U/mL 
 
 
2.8 Gene expression analysis 
2.8.1 RNA extraction 
RNA extraction was performed with the Qiagen RNeasy Micro Plus kit (Qiagen, 
West Sussex, UK) as per the manufacturer’s instructions. Briefly, cells were 
suspended in lysis buffer, homogenised by vortexing and then RNA extracted using 
the Qiagen RNeasy microcolumn. Following extraction, RNA was quantified using 
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spectroscopic photometry using a NanoDrop Lite (Thermo Scientific, USA) and 
stored at -80°C. 
 
2.8.2 cDNA synthesis 
cDNA synthesis was performed using the Promega GoScript kit (Promega, 
Southampton, UK) as per manufacturer’s instructions. Briefly, RNA was incubated 
with Oligo dT for 5 minutes at 70°C before adding reverse transcriptase, MgCl2, 
nucleotide mix and RNase inhibitor, and incubating in a thermocycler using the 
following programme:  
1. 25°C for 5 minutes 
2. 42°C for 60 minutes 
3. 70°C for 15 minutes 
CDNA was stored at -20°C. 
 
2.8.3 Primer design and testing 
Primers for use in RT-qPCR were designed using NCBI Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and tested for dimer and hairpin 
formation using the OligoCalc software 
(http://www.basic.northwestern.edu/biotools/OligoCalc.html). Primers were 
designed to span two exons, amplify sequences shared by all splicing variants, 
have annealing temperature of 60°C and have GC content 40-60%. The amplicon 
size was between 90bp and 150bp.  
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All primers used during this project are shown in Table 2-5. Primers were purchased 
from Sigma-Aldrich (Dorset, UK) and tested to ensure linearity. For this step, RT-
qPCR was run using serial dilutions of cDNA, eg. 1x, 0.1x, 0.01x and 0.001x. The 
threshold cycle (Ct) values obtained were plotted against the concentration and the 
linear regression formula was calculated on Microsoft Excel. All primers had an R2 
between 0.9-1.0.  
Table 2-5 Sequences of primers used in RT-qPCR 
Gene Forward Primer Reverse Primer 
IGF1 CATGTCCTCCTCGCATCTCT ATCCACGATGCCTGTCTGA 
IGF2 ACACCCTCCAGTTCGTCTGT GAAACAGCACTCCTCAACGA 
IGF1R TGAAAGTGACGTCCTGCATTTC GGTACCGGTGCCAGGTTATG 
IGF2R GAGGGAAGAGGCAGGAAAG TCTGTGGCAGGCATACTCAG 
GAPDH GAAATCCCATCACCATCTTCCAGG GAGCCCCAGCCTTCTCCATG 
IGFBP1 ATCCTTTGGGACGCCATCAG AGTTCTATTCGGCAGGGCTC 
MIR155 ATCGTGATAGGGGTTTTTGCC ATGTAGGAGTCAGTTGGAGGC 
IL6 CCACCGGGAACGAAAGAGAA GAGAAGGCAACTGGACCGAA 
 
2.8.4 RT-qPCR 
Gene expression was assessed using SYBR Green-based RT-qPCR. Maxima 
SYBR Green/ROX qPCR Master Mix (2X) (Fermentas, UK) was used and reactions 
run in the Applied Biosystems 7500 Real Time PCR Systems (Life Technologies, 
USA) using the following programme: 
1. 95°C for 10min 
2. 42 cycles of 94°C for 15sec, 60°C for 30sec, 72°C for 33sec  
3. 95°C for 15sec, 60°C for 1min, 95°C for 15sec, 60°C for 15sec.  
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Samples were run in triplicate and data were analysed using the ABI software to 
calculate the mean Ct of each reaction. To ascertain levels of expression, the ΔCt 
equation was used in which the expression level is normalized against a 
housekeeping gene (GAPDH). 
 
2.8.5 MSC genome-wide expression microarray 
RNA was extracted from MSC using the Qiagen RNeasy Micro Plus kit (Qiagen, 
West Sussex, UK) as described above. RNA was quantified using a NanoDrop Lite 
(Thermo Scientific, USA) and integrity was measured using an Agilent Bioanalyser 
2100 (Agilent, Santa Clara, CA, USA). Only samples with an RNA integrity number 
(RIN) greater than 8.0 were used for microarray. 
Microarray was performed in collaboration with Dr. Robert Geffers (Helmholtz 
Centre for Infection Research, Braunschweig, Germany). RNA was labelled using 
the Ambion WT Expression Kit (Life Technologies, Carlsbad, CA, USA) and arrays 
were run using the Affymetrix GeneChip Gene ST 2.0 Array (Affymetrix UK Ltd., 
High Wycombe UK). 
 
2.8.6 CD34+ FL microarray 
RNA was extracted as above. Microarray was performed in collaboration with Dr 
Ollie Tunstall and Dr Andi Roy (in our lab) and Professor Vasker Saha (University of 
Manchester, UK). RNA was labeled using the Ambion WT Expression Kit and 
arrays were run using the Human Exon 1.0 ST Array (Affymetrix UK Ltd, High 
Wycombe, UK).  
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2.8.7 Microarray analysis 
Bioinformatic analysis of microarray data was performed using R/Bioconductor 
(http://www.R-project.org/). Analysis was based on R scripts kindly provided by Dr 
Binbin Liu, University of Oxford. Additional Bioconductor packages including xps 
and limma were used for normalisation and further analysis (Table 2-6). 
Data was background corrected and normalised using the robust multi-array 
average (RMA) technique. In addition, probes were limited to those expressed in 
>50% samples. Genes showing significant (p<0.05) differential expression were 
identified using LIMMA (Smyth et al., 2005).  Gene Set Enrichment Analysis 
(GSEA) was performed as previously described (Subramanian et al., 2005). 
Table 2-6 R packages used in bioinformatic analysis 
Package Developer Information 
xps Stratowa C, Vienna and Austria. xps: Processing and Analysis of 
Affymetrix Oligonucleotide Arrays including Exon Arrays, Whole 
Genome Arrays and Plate Arrays. R package version 1.24.0 
limma  Smyth GK (2005). “Limma: linear models for microarray data.” In 
Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W 
(eds.), Bioinformatics and Computational Biology Solutions Using 
R and Bioconductor, pp. 397–420. Springer, New York. 
biobase Gentleman RC, Carey VJ, Bates DM and others (2004). 
“Bioconductor: Open software development for computational 
biology and bioinformatics.” Genome Biology, 5, pp. R80. 
genefilter Gentleman R, Carey V, Huber W and Hahne F. genefilter: 
genefilter: methods for filtering genes from microarray 
experiments. R package version 1.46.1. 
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2.9 IGF2R null mice 
2.9.1 Maintenance of mice 
IGF2R null mice were kindly provided by Professor Denise Barlow (University of 
Vienna) (Wang et al., 1994). Mice were bred and maintained in-house at Imperial 
College in accordance with the 1986 Animal Scientific Procedures Act and under a 
United Kingdom Government Home Office–approved project license. The breeding 
scheme is shown in Chapter 4. This work was done with the help of Dr Gillian 
Cowan. 
 
2.9.2 Organ processing and analysis 
Embryos were harvested at E18.5. Genotype was confirmed using PCR detection of 
the 1.2kB neo cassette, which had been introduced at the point of the gene deletion 
(Wang et al., 1994). Embryos were dissected and the liver removed. The liver was 
disrupted by pressing it through a 40µm cell filter using the blunt end of a plastic 
syringe plunger into a 50 ml Falcon to produce a single-cell suspension. Cells were 
washed and resuspended in flow buffer for analysis. 
  
2.10 Statistics 
Statistical analysis (other than microarray) was performed using Graphpad Prism 
version 5 (Graphpad, San Deigo, CA, USA). The difference in means for two 
sample groups was tested for significance using Student’s unpaired T-test. Further 
analysis was performed using 1-way and 2-way ANOVA and Bonferroni’s post-test. 
Data are expressed as the mean ± SEM (standard error of the mean) unless 
otherwise indicated. 
79 
 
3 The role of IGF signalling in the perturbation of fetal 
haematopoiesis in Down syndrome 
3.1 Introduction 
Previous work from our lab has demonstrated significant perturbation of fetal 
haematopoiesis in DS with disruption of the HSC compartment and a marked 
megakaryocyte-erythroid differentiation bias (Roy et al., 2012; Tunstall-Pedoe et al., 
2008). However, although studies have implicated several chromosome 21 genes in 
the aetiology of these abnormalities (Birger et al., 2013; Elagib et al., 2003; 
Stankiewicz and Crispino, 2009), the exact mechanisms involved remain unknown.   
Recent work by Klusmann et al has implicated the IGF pathway in the disruption of 
fetal haematopoiesis in DS (Klusmann et al., 2010). The authors demonstrated 
upregulation of the IGF pathway in ML-DS compared to other non-DS myeloid 
leukaemias. They went on show that ML-DS blasts were hyper-responsive to 
exogenous IGF stimulation and underwent cell death in response to inhibition of IGF 
signalling. Importantly, experiments using murine megakaryocytic progenitors 
indicated that the response to IGF signalling was fetal-specific.     
The IGF pathway functions as a potent supporter of cell proliferation and survival 
through the activation of two important proliferative downstream pathways; the 
PI3K/AKT pathway and the RAS/MAPK/ERK pathway (Pollak et al., 2004). Whilst 
there are two IGF receptors, IGF1R is the only signalling receptor and is activated 
through the binding of either IGF1 or IGF2. Although there is significant homology 
with the insulin pathway, allowing binding of insulin to IGF1R and binding of IGF1 
and IGF2 to the insulin receptor, the affinity of insulin binding to IGF1R, and of IGF 
binding to the insulin receptor, is low (Frasca et al., 2008).     
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Mouse models have demonstrated that the IGF pathway is a key regulator of 
murine fetal growth although relatively little is known of its function in human fetal 
development (Baker et al., 1993; DeChiara et al., 1990; Randhawa and Cohen, 
2005). In addition, the increasing awareness of the importance of the IGF pathway 
in many solid organ and haematopoietic malignancies has greatly enhanced interest 
in this area and has led to the development of a number of IGF receptor inhibitors 
(Reviewed in (Pollak, 2012)). These dual central roles played by the IGF system in 
both fetal growth and malignancy make it a compelling candidate for involvement in 
the aetiology of childhood leukaemias, including ML-DS, which are known to 
develop in utero (Greaves, 2006). 
Whilst the work by Klusmann et al suggests that the IGF pathway is important in the 
development of ML-DS, many of the experiments employed cell lines or murine 
cells. To establish a role for IGF signalling in the perturbation of fetal 
haematopoiesis in DS, it would be important to investigate the IGF pathway in 
primary human fetal cells. Therefore, the aim of this chapter was to utilise primary 
fetal tissue to investigate the function of the IGF pathway in normal and DS fetal 
haematopoiesis.  
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3.2 Expression of IGF and IGF receptors in normal and DS tissues 
3.2.1 IGF1R expression in normal HSPC 
The IGF pathway consists of 2 main ligands, IGF1 and IGF2, both of which signal 
through the IGF1R via high affinity binding. To establish the potential for 
haematopoietic cells to respond to IGFs, I first measured surface expression of 
IGF1R on AdBM, CB and second trimester FL CD34+ cells using flow cytometry. 
IGF1R was expressed by virtually all FL CD34+ cells (95.6%±1.65) at a relatively 
uniform level (Figure 3-1A). Similarly, it was expressed by the majority of CB CD34+ 
cells (94.7%±3.25). However, in contrast, a significantly smaller fraction of AdBM 
CD34+ cells expressed IGF1R compared to FL CD34+ cells (20.9%±7.48, 
p=0.0052) (Figure 3-1A+B), consistent with the hypothesis that IGF signalling via 
IGF1R is a key regulator of normal fetal haematopoiesis. Further analysis of the 
level of expression using the mean fluorescent intensity (MFI) revealed significantly 
higher IGF1R expression in FL CD34+ cells compared to AdBM (p<0.01) with an 
intermediate level of expression on CB CD34+ cells (Figure 3-1C). This correlation 
with developmental stage supports the hypothesis that IGF signalling is important 
for HSPC during fetal life.  
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Figure 3-1 Expression of IGF1R on FL, CB and AdBM CD34+ cells 
A) Representative flow cytometry plots showing IGF1R expression on FL, CB and AdBM CD34+ 
cells. B) Percentage of CD34+ cells that express IGF1R in FL, CB and AdBM CD34+ cells. C) 
Intensity of IGF1R staining calculated by median fluorescent intensity (MFI) in FL, CB and AdBM 
CD34+ cells. *p<0.05; **p<0.01  
 
To investigate whether there were differences in the level of expression between 
individual HSC, multipotent progenitor (MPP and LMPP) and myeloid progenitor 
(CMP, MEP and GMP) subpopulations, I compared IGF1R expression levels within 
these subpopulations in FL and AdBM. However, as shown in Figure 3-2, IGF1R 
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expression, both in terms of the percentage of cells expressing IGF1R and MFI, 
was relatively consistent within each population, suggesting that IGF signalling is 
important throughout the HSPC compartment.  
 
Figure 3-2 IGF1R expression on normal FL and AdBM HSC, multipotent 
progenitors and myeloid progenitor subpopulations 
A) Percentage of cells that express IGF1R by flow cytometry in each progenitor subpopulation in FL 
and AdBM. B) Intensity of IGF1R expression by flow cytometry in each progenitor subpopulation in 
FL and AdBM. *p<0.05; ***p<0.001 
 
3.2.2 IGF1 and IGF2 production in cells of the normal haematopoietic 
microenvironment  
Given the high expression of IGF1R on fetal HSPC I then went on to investigate IGF 
production in the fetal haematopoietic microenvironment. I used fetal mesenchymal 
stromal cells (MSC) which I either isolated myself from FL or AdBM MNCs (see 
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methods) or I used MSC which had been isolated by other members of the lab and 
banked for future use. Whilst AdBM MSCs expressed both IGF1 and IGF2 mRNA 
by qPCR, FL MSC expressed large amounts of IGF2 but almost no IGF1 was 
detectable (Figure 3-3).  
 
 
Figure 3-3 Expression of IGF1 and IGF2 mRNA by FL and AdBM MSCs 
measured by RT-qPCR.  
Expression levels are normalised to GAPDH. *p<0.05 
 
These findings were confirmed using immunohistochemical (IHC) staining of FL and 
AdBM MSCs demonstrating prominent IGF1 and IGF2 staining in AdBM but only 
IGF2 staining in FL (Figure 3-4). Interestingly, IHC of hepatocytes in FL sections 
from normal second trimester human FL also showed strong IGF2 staining but 
almost undetectable IGF1 (Gillian Cowan, personal communication). 
Importantly, these results confirm that IGFs are present in the fetal 
microenvironment and that haematopoietic progenitors have the potential to 
respond to IGF pathway activation via high levels of IGF1R expression. 
85 
 
 
Figure 3-4 IGF1 and IGF2 expression by immunohistochemistry in normal FL 
and AdBM MSCs 
 
3.2.3 IGF1R expression in a DS leukaemia cell line 
Klusmann et al previously showed overexpression of IGF1R in a ML-DS cell line 
when compared to other myeloid leukaemia cell lines, suggesting that the IGF 
pathway is an important driver of this malignancy (Klusmann et al., 2010). However, 
IGF1R overexpression was only demonstrated at the transcriptional level by RT-
qPCR and not at the protein level. To address this, I assessed IGF1R expression in 
CMK cells, a ML-DS cell line, using three methods; RT-qPCR, flow cytometry and 
western blotting. Levels were compared to an erythroblastic leukaemia cell line, 
K562, which has only 2 copies of Hsa21.  
As shown in Figure 3-5, IGF1R expression was found to be higher in CMK cells 
using all three techniques. Importantly, the relative level of expression in the two cell 
lines was consistent across the three methods. This indicates a strong correlation 
between the level of mRNA transcription, the total cell protein level and the level of 
expression at the cell surface. However, it is unclear whether high levels of IGF1R 
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on CMK cells is directly related to the fact that these cells are leukaemic or whether 
it could be secondary to trisomy 21.  
 
Figure 3-5 Expression of IGF1R on CMK and K562 cells by flow cytometry 
(MFI), RT-qPCR and Western blotting 
A) IGF1R MFI measured by flow cytometry in K562 and CMK cells (n=5). B) IGF1R mRNA 
expression measured by RT-qPCR in in K562 and CMK cells (n=3). Normalised to GAPDH 
expression. C) IGF1R protein level measured by Western blotting in K562 and CMK cells (n=3). 
Normalised to β-Actin.  *p<0.05  **p<0.01 
 
3.2.4 IGF1R surface expression in primary DS fetal haematopoietic cells 
I therefore went on to specifically investigate the role of IGF signalling in non-
leukaemic T21 FL haematopoietic cells, ie cells that had not yet acquired GATA1 
mutations.  First, I assessed IGF1R expression level by flow cytometry in second 
trimester DS FL CD34+ cells and compared this to normal second trimester FL 
CD34+ cells.  As shown in Figure 3-6, virtually all DS FL CD34+ cells, like normal 
FL CD34+ cells, expressed IGF1R at the cell surface. However, in contrast to CMK 
cells and primary ML-DS cells (Klusmann et al., 2010), the level of IGF1R 
expression, as reflected by the IGF1R MFI ratio, was not increased on DS FL 
CD34+ cells compared to normal FL CD34+ cells (Figure 3-6C) suggesting that 
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upregulation of IGF1R occurs after leukaemia initiation and is unlikely to be due to 
trisomy 21 itself. 
 
Figure 3-6 Expression of IGF1R on normal and DS FL CD34+ cells 
A) Representative flow cytometry plots showing IGF1R expression in normal FL (n=8) and DS FL 
(n=6) CD34+ cells. B) Percentage of CD34+ cells that express IGF1R in normal and DS FL. C) 
IGF1R expression intensity on normal and DS CD34+ cells.   
 
3.2.5 IGF1 and IGF2 production in DS fetal MSC and CD34+ cells 
To investigate whether T21 altered the production of IGFs in the haematopoietic 
microenvironment, I compared the expression of IGF1 and IGF2 by DS FL MSC 
and normal FL MSC using qPCR. As shown in Figure 3-7, DS FL MSC showed the 
same pattern of IGF expression as normal FL with sole production of IGF2 and 
virtually no IGF1. The levels of IGF2 mRNA were also similar in the DS FL MSC 
compared to the normal FL MSC.  
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Figure 3-7 Expression of IGF1 and IGF2 by normal and DS FL MSCs 
IGF1 and IGF2 mRNA measured by RT-qPCR. Normalised to GAPDH. 
 
Since autocrine IGF production by AML cells (Chapuis et al., 2010) and other 
malignant cells (Macaulay et al., 1990; Ohmura et al., 1990), has been reported to 
promote their growth, I also examined whether DS FL CD34+ cells expressed IGFs 
by analysing microarray data generated in the lab as part of another project.  
Interestingly, only IGF2 was expressed in FL CD34+ cells (Figure 3-8) consistent 
with the data from FL MSC and hepatocytes. This confirms the selectivity of IGF2 
versus IGF1 production in fetal life in humans and suggests that IGF2-mediated 
autocrine signaling might contribute to the survival, proliferation and/or 
differentiation of FL HSPC. Interestingly, IGF2 expression levels were higher in DS 
cells, although this was not significant due to the small number of samples available 
for analysis (normal, n=3; DS, n=4) and the variability in IGF expression between 
the different DS samples.   
89 
 
 
Figure 3-8 IGF1 and IGF2 gene expression in normal and DS FL CD34+ cells.  
 
3.2.6 Expression of the insulin receptor in fetal haematopoietic cells 
As discussed earlier, IGF1 and IGF2 are also able to bind to, and activate, the InsR, 
although with lower affinity than when binding to IGF1R. Since cells of the fetal 
microenvironment produce large amounts of IGF2 and activation of IGF signalling in 
DS FL haematopoietic cells might be mediated by increased InsR expression, I 
investigated InsR expression on FL HSPC. Flow cytometry confirmed expression of 
the InsR at the cell surface; however, both normal FL and DS FL showed similar 
levels of expression with >90% CD34+ cells showing InsR expression (Figure 
3-9A). In addition, CD34+ microarray data showed InsR expressed at a similar level 
in normal and DS FL, and that expression levels were comparable to IGF1R 
expression (Figure 3-9B). 
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Figure 3-9 Expression of InsR on normal and DS FL CD34+ cells 
A) Representative flow cytometry plots showing InsR expression on normal and DS FL CD34+ cells. 
B) Intensity of InsR expression on normal and DS FL CD34+ cells. 
 
3.3 Effect of IGF on clonogenicity of normal FL CD34+ cells 
To investigate the effect of IGFs on the growth of clonogenic HSPC, FL CD34+ cells 
were plated in serum-free methylcellulose cultures. A serum-free culture system 
was used to ensure the absence of exogenous IGFs since IGFs are present in fetal 
bovine serum. A standard haematopoietic cytokine cocktail (SCF, FLT-3, TPO, GM-
CSF, IL-3, IL-6 and IL-11) was used in all assays (Manz et al., 2002) as this was the 
same as the cocktail used in previous work by the lab for clonogenic assays of 
normal and DS FL CD34+ cells (Roy et al., 2012). However, assays were 
performed both in the presence and absence of EPO since synergy between IGFs 
and EPO has previously been reported in serum-free methylcellulose cultures of 
adult BM CD34+ haematopoietic cells (Ratajczak et al., 1998). IGF1 and IGF2 were 
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added in a concentration of 300 ng/ml since previous experiments in the lab had 
shown that this was the optimal concentration in clonogenic cultures of normal CB 
CD34+ cells.  
As shown in Figure 3-10, although IGF1 and IGF2 had no significant effects on the 
overall clonogenicity of normal FL CD34+ cells, colony formation was altered. Both 
IGF1 and IGF2 promoted EPO-independent erythroid colony formation although this 
was only significantly increased with IGF2 (Figure 3-10B; p<0.05). This was 
associated with a small, but insignificant, decrease in granulocyte-monocyte (GM) 
colonies (Figure 3-10C) and neither IGF1 nor IGF2 had any effect on the growth of 
normal FL megakaryocyte progenitors.  
 
  
92 
 
 
 
Figure 3-10 Effect of IGFs on clonogenicity of normal FL CD34+ cells in 
serum-free methylcellulose in the absence of EPO 
A) Overall clonogenicity and colony type of normal FL CD34+ cells grown in serum-free 
methylcellulose in the presence or absence of IGF1 and IGF2. Table beneath graph shows the 
cytokines included in each condition. B) Erythroid clonogenicity in the presence or absence of IGF1 
and IGF2. C) Granulocyte/macrophage clonogenicity in the presence or absence of IGF1 and IGF2. 
*p<0.05 
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To determine whether there was synergy between IGFs and EPO on the growth of 
FL CD34+ cells, clonogenic assays were repeated using increasing doses of EPO 
with or without IGF1 or IGF2. Although IGF1 promoted erythroid colony formation 
(Figure 3-11A and Figure 3-11B) at lower concentrations of EPO, this did not quite 
reach statistical significance. There was a similar degree of inhibition of CFU-GM 
numbers (Figure 3-11C) but there was considerable variation between samples and 
this difference was not significant.  
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Figure 3-11 Effect of IGF1 on the clonogenicity of normal FL CD34+ cells at 
increasing EPO concentrations. 
A) Overall clonogenicity and colony type of normal FL CD34+ cells in the presence or absence of 
IGF1 at increasing EPO concentrations (n=3). B) Erythroid colony formation. C) GM colony 
formation. 
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IGF2 increased erythroid colony formation by normal FL CD34+ cells at all EPO 
concentrations (Figure 3-12A and Figure 3-12B). The effect of IGF2 was greatest at 
lower EPO concentrations (p<0.05) but was still evident in the presence of high 
EPO (4 u/ml), in contrast to IGF1, suggesting that they may employ different 
downstream signalling pathways. IGF2 consistently inhibited the growth of normal 
FL CFU-GM at all concentrations of EPO, although this did not reach significance. 
IGF2 may therefore, like IGF1 and EPO, influence HSPC commitment to the 
erythroid lineage although the increased numbers of total erythroid progenitors in 
the presence of IGF2 and 4 u/ml EPO suggests that IGF2 may also stimulate 
erythroid progenitor proliferation as well as commitment (Figure 3-12).  There was 
no consistent effect of IGF2 on normal FL clonogenic megakaryocyte progenitors. 
Further analysis based on the erythroid-to-myeloid ratio was also completed but did 
not show any significant differences (graphs not shown). 
  
96 
 
 
Figure 3-12 Effect of IGF2 on the clonogenicity of normal FL CD34+ cells at 
increasing EPO concentrations 
A) Overall clonogenicity and colony type of normal FL CD34+ cells in the presence or absence of 
IGF2 at increasing EPO concentrations (n=3). B) Erythroid colony formation. C) GM colony 
formation. *p<0.05 
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These data support the contention that IGF1R on FL CD34+ cells is functional, that 
it is able to respond both to IGF2 and that the main effect of stimulating IGF1R on 
FL CD34+ cells is to promote the development of erythroid progenitors.  Since, as 
shown above, I found that IGF2, but not IGF1, is produced by human FL stromal 
cells, this supports the hypothesis that IGF2/IGF1R signalling plays an important 
role in regulating human FL haematopoiesis. IGF2 may therefore contribute to 
mediating developmental differences in erythropoiesis in fetal versus post-natal life 
and the specific physiological need for red blood cell, rather than white blood cell, 
production during the second trimester. 
  
3.4 Effect of IGF on clonogenicity of normal adult BM CD34+ cells 
Since IGF1R expression on AdBM CD34+ cells was very low, I hypothesized that 
IGF may play little role in regulating the growth and differentiation of normal AdBM 
HSPC under steady state conditions. To determine whether the effects of IGFs 
were developmental stage-specific, clonogenic assays were repeated using AdBM 
CD34+ cells. In contrast to normal FL, neither IGF1 nor IGF2 stimulated EPO-
independent erythroid colony formation from AdBM CD34+ cells (Figure 3-13 and 
Figure 3-14). IGF1 and IGF2 stimulated normal AdBM erythroid progenitors in the 
presence of higher concentrations of EPO, increasing both the % and number of 
erythroid progenitor cells consistent with synergism between EPO and each of the 
IGFs. IGF2 consistently inhibited AdBM CFU-GM, similar to its effects in normal FL 
while the effects of IGF1 on normal AdBM CFU-GM were not significant.  There was 
no effect of IGF1 or IGF2 on AdBM megakaryocyte progenitors although assays in 
a megakaryocyte specific culture system (eg Megacult) would be needed to confirm 
this.  
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Figure 3-13 Effect of IGF1 on the clonogenicity of AdBM CD34+ cells at 
increasing EPO concentrations 
A) Overall clonogenicity and colony type of AdBM CD34+ cells in the presence or absence of IGF1 
at increasing EPO concentrations (n=3). B) Erythroid colony formation. C) GM colony formation. 
*p<0.05 
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Figure 3-14 Effect of IGF2 on clonogenicity of AdBM CD34+ cells at increasing 
EPO concentrations 
A) Overall clonogenicity and colony type of AdBM CD34+ cells in the presence or absence of IGF2 
at increasing EPO concentrations (n=3). B) Erythroid colony formation. C) GM colony formation. 
*p<0.05 
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These results indicate that IGFs can induce erythroid colony formation in both FL 
and AdBM. However, this effect is greatest at low EPO concentrations in FL and at 
high EPO concentrations in AdBM (Figure 3-15). In FL, IGF2 appears to exert more 
potent effects on erythroid progenitors than IGF1 whereas both IGFs exhibit similar 
effects on AdBM erythroid progenitors. IGF2 also inhibits normal FL and AdBM 
CFU-GM. This may help to preserve the erythroid drive in fetal life whereas in post-
natal life, where IGF1 is produced in large amounts and IGF1R expression of 
CD34+ cells is low, this effect of IGF2 in vitro may be of no physiological relevance 
in vivo.  
 
Figure 3-15 Comparison of the synergism between IGFs and EPO on the 
growth of erythroid colonies from normal FL and AdBM CD34+ cells 
A) Effect of IGFs on clonogenicity of FL CD34+ cells at increasing EPO concentrations (n=3). B) 
Effect of IGFs on clonogenicity of AdBM CD34+ cells at increasing EPO concentrations (n=3). 
 
3.5 Effect of IGF on clonogenicity of DS fetal HSPCs 
Previous work by our group and others has shown that DS FL CD34+ cells have 
markedly enhanced clonogenicity (4-5 fold) in serum-containing methylcellulose 
cultures with a bias towards megakaryocytic and erythroid colony formation 
compared to normal FL CD34+ cells (Chou et al., 2008; Roy et al., 2012; Tunstall-
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Pedoe et al., 2008). Since both normal and DS FL cultures contained the same 
exogenous cytokines (TPO, SCF, IL3, IL6, IL11, GM-CSF, Flt3 and EPO), it is 
unclear if the increased clonogenicity is dependent upon a specific factor or factors 
present in the serum. The fact that TAM and ML-DS blasts are reported to be 
dependent on IGF signaling (Klusmann et al., 2010), raises the possibility that IGFs 
in the serum-containing culture system are responsible for the enhanced 
clonogenicity in DS FL cells 
To address this, I first assessed the clonogenicity of DS FL CD34+ cells in 
comparison to normal FL CD34+ cells in a serum-free methylcellulose system in the 
presence and absence of EPO. Although the clonogenicity of DS FL CD34+ cells 
cultured in serum-free medium with EPO is slightly higher (~10%) than normal FL 
CD34+ cells cultured under identical conditions (Figure 3-16, Column 4), this 
contrasts with the dramatically higher clonogenicity when DS FL CD34+ cells are 
cultured with the same cytokines (TPO, SCF, IL3, IL6, IL11, GM-CSF, Flt3 and 
EPO) in serum-containing medium (Roy et al., 2012; Tunstall-Pedoe et al., 2008).  
Indeed, in the absence of both EPO and serum, DS FL CD34+ cells were less 
clonogenic than normal FL CD34+ cells (Figure 3-16, Column 1) in contrast to the 
previously reported 4-5-fold increase in clonogenicity in DS FL CD34+ cells 
compared to normal FL CD34+ cells. These findings support the hypothesis that the 
enhanced clonogenicity in DS cells is due to a particular factor within serum.  
In contrast to normal FL CD34+ cells, IGF1 did not support the growth of EPO-
independent erythroid progenitors from DS FL CD34+ cells (Figure 3-16, Column 
2). In addition, IGF1 had no effect on the numbers of myeloid or megakaryocyte 
colonies grown from DS FL CD34+ cells. This suggests that IGF1 is not an 
important growth factor for DS FL myeloid progenitor cells and also that there may 
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be significant differences in IGF-mediated and EPO-mediated signalling in DS FL 
CD34+ cells compared to normal FL CD34+ cells.  
 
Figure 3-16 Effect of IGF1 and IGF2 on clonogenicity of normal FL and DS FL 
CD34+ cells in serum-free methylcellulose 
A) Clonogenicity of normal FL CD34+ cells in the presence or absence of IGF1, IGF2 or EPO (n=3).    
B) Clonogenicity of DS FL CD34+ cells in the presence or absence of IGF1, IGF2 or EPO (n=3). 
 
IGF2 supported the growth of only a very small number of EPO-independent 
erythroid progenitors, and to a much lesser extent than the effects of IGF2 on 
normal FL CD34+ cells (Figure 3-16, Column 3). This was despite the presence of 
similar numbers of erythroid progenitors grown from both normal and DS FL CD34+ 
cells under standard control conditions in the presence of 4 u/ml of EPO (Figure 
3-16, Column 4) supporting the hypothesis that IGF and EPO-mediated signalling 
are perturbed in DS FL CD34+ cells. These results contrast with adult 
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myeloproliferative disorders, which are characterised by EPO-independent erythroid 
progenitor growth, largely in association with activation of the JAK-STAT signalling 
pathway. Despite the lack of effects of IGF2 on the growth of pure erythroid 
progenitors, IGF2 stimulated large numbers of megakaryocyte-erythroid, erythroid 
blast (E-blast) and myeloblast colonies in DS FL CD34+ cells (Figure 3-16, column 
3). These data suggest that DS FL megakaryocyte and megakaryocyte-erythroid 
progenitors are selectively sensitive to IGF2 despite the fact that both IGF1 and 
IGF2 exert their effects through IGF1R. In addition, even in the absence of IGF2, 
DS FL CD34+ cells gave rise to small numbers of megakaryocyte progenitor cells, 
perhaps due to autocrine IGF2 production as suggested from the microarray 
experiments, although normal FL cells also gave rise to very occasional 
megakaryocyte colonies in the absence of serum. This strongly supports the 
hypothesis that IGF2 is a driving factor in the perturbation of haematopoiesis in DS 
FL.  
 
3.6 Establishment of an erythro-megakaryocytic liquid culture 
system  
3.6.1 Combined erythroid-megakaryocyte differentiation cultures (Protocol 1A 
and 1B) 
To further investigate the role of the IGFs in fetal haematopoiesis, I developed a 
serum-free liquid culture system to serially assess proliferation and differentiation of 
FL CD34+ cells over a 14-day period. As with the methylcellulose assays, I chose to 
use a serum-free liquid culture system to ensure absence of exogenous IGFs. I 
initially used a system directed towards both erythroid and megakaryocytic 
differentiation (Protocol 1A), as these were the two lineages of primary interest. The 
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system was based on protocols kindly provided by Dr Benjamin Ebert, Harvard 
Medical School, Boston, USA, as previously published (Ebert et al., 2005; 2008). 
The system employs StemSpan, a commercially available serum-free 
haematopoietic expansion medium (Stem Cell Technologies, Vancouver, Canada), 
with the addition of IL3, IL6, TPO, EPO and SCF. As per protocol, 1000 lin- CD34+ 
FL cells were sorted into medium, plated into 96 well round-bottom plates and 
analysed by flow cytometry at day 7, 10 and 14 of culture.  
As shown in Figure 3-17, the cultures maintained good cell viability and allowed 
excellent cell proliferation. However, unexpectedly, the majority of cells appeared to 
be granulocytic/monocytic as assessed by morphology (cytospins) and by flow 
cytometry with expression of CD11b/CD14 (Figure 3-17C). Whilst there was limited 
megakaryocytic differentiation, the cells failed to show erythroid differentiation with 
complete absence of the erythroid marker Glycophorin A (GlyA) (Figure 3-17D). The 
cytospins revealed some erythroid-type cells but they appeared apoptotic 
suggesting a block to full erythroid differentiation (Figure 3-17D). These findings 
were in contrast to published findings, and findings from our own lab, using cord 
blood cells. However, FL cells showed a much higher rate of proliferation 
suggesting that overcrowding of cells within the culture plate was responsible for the 
unexpected lack of erythroid differentiation. 
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Figure 3-17 Development of a megakaryocyte-erythroid liquid culture system 
for FL CD34+ cells: Results of protocol 1A 
A) Representative flow cytometry plot demonstrating good cell viability in liquid cultures at day 14. B) 
Graph showing increase in viable cell number over time (n=3). C) Flow cytometry plot and cytospin 
demonstrating GM bias in protocol 1A. D) Flow cytometry plot and cytospin demonstrating minimal 
erythroid differentiation with abnormal morphology in protocol 1A. 
 
I therefore repeated the cultures but transferred cells to larger tissue culture plates 
as cell numbers increased (Protocol 1B). Using this approach, the majority of cells 
showed clear erythroid differentiation (CD71+ GlyA+) by day 10 of culture (Figure 
3-18A), which was confirmed by cytospin of the cells (Figure 3-18C) Although there 
was also evidence of megakaryocyte differentiation with a small population of 
CD41+ cells, these cells failed to acquire CD42 indicating that there was a block to 
full megakaryocyte differentiation (Figure 3-18B) perhaps because of the presence 
of non-megakaryocyte cytokines in the culture system, such as IL3 or EPO. I 
therefore decided to employ two separate lineage-specific culture systems for 
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further experiments; an erythroid system (see 3.6.2) and a megakaryocytic system 
(see 3.6.3).  
 
Figure 3-18 Development of a megakaryocyte-erythroid liquid culture system 
for FL CD34+ cells: Results of protocol 1B 
A) Representative flow cytometry plot showing significant erythroid differentiation at day 10 of 
cultures. B) Representative flow cytometry plot showing limited megakaryocytic differentiation at day 
14 of cultures. C) Cytospins demonstrating erythroid maturation over 14 days of culture.  
 
3.6.2 Development of a specific erythroid culture system (Protocol 2-Er)  
To promote pure erythroid differentiation, I adapted the erythroid liquid culture 
system by omitting TPO from the culture medium; the medium was otherwise 
identical to the previous serum-free erythro-megakaryocytic system (Protocol 1B) 
and contained IL3, IL6, EPO and SCF (Protocol 2-Er). Due to the extremely high 
rate of proliferation of FL cells in the previous system, I also reduced the starting 
cell number to 100 from 1000. Protocol 2-Er gave excellent erythroid differentiation 
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by day 7 of culture, with an increase in erythroid cell number until day 14 when 
cultures were terminated (Figure 3-19A & B). Interestingly, although cell number 
continued to increase to day 14, the percentage of GlyA+ erythroid cells showed a 
small decrease (Figure 3-19C), most likely due to cells becoming apoptotic as seen 
on cytospin (Figure 3-19D). 
 
Figure 3-19 Growth of normal FL CD34+ cells in an erythroid liquid culture 
system: Protocol 2-Er 
A) Representative flow cytometry plots showing erythroid differentiation over 14 days of culture. B) 
Graph showing erythroid cell number over 14 days of culture (n=3). C) Graph showing erythroid 
percentage over 14 days of culture (n=3). D) Cytospin showing apoptosis of erythroid cells at day 14.  
 
3.6.3. Development of a specific megakaryocyte culture system (Protocol 2-
MK) 
As megakaryocyte differentiation was sub-optimal in Protocol 1, I simplified the 
system by removing IL3, IL6 and EPO, leaving only TPO and SCF. This is in 
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agreement with several previously reported megakaryocyte differentiation assays, 
which have used TPO with or without the addition of SCF (Bluteau et al., 2014; 
Ciurea et al., 2007; Tanaka et al., 1992). First, to optimise the liquid cultures for 
megakaryocyte differentiation I compared 3 different TPO- or SCF-containing 
media; 1) TPO 50ng/mL only; 2) TPO 50ng/mL, SCF 50ng/mL; 3) TPO 50ng/mL, 
SCF 100ng/mL. For each culture, 1000 lin- CD34+ cells were sorted and plated into 
96-well flat bottom plates. As with Protocol 2-Er, cells were transferred to larger 
wells as cell numbers increased.  
As shown in Figure 3.20, in the presence of TPO alone, there was a progressive 
increase in the number of total cells, almost all of which expressed the early and 
late maturation markers CD41 and CD42b respectively by day 10 of culture (Figure 
3-20). In the presence of TPO plus SCF, there was a dose-dependent increase in 
the total number of cells and in the number of CD41+ cells (Figure 3-20A and B).   
However, SCF also stimulated non-megakaryocytic cells within the culture despite 
the presence of TPO and, particularly when added at the higher concentration (100 
ng/ml), SCF appeared to inhibit megakaryocyte maturation (Figure 3-20D and E).  
In subsequent experiments I decided to use both the TPO alone culture system, 
which had the advantage of promoting almost 100% megakaryocyte differentiation 
and the TPO+SCF medium, with SCF added at the lower concentration (50 ng/ml) 
as this produced better megakaryocyte maturation. Cytospins confirmed 
megakaryocyte differentiation in both systems (Figure 3-21). 
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Figure 3-20 Megakaryocyte differentiation cultures of normal FL CD34+ cells: 
Results of protocol 2-MK 
A) Effect of SCF on total cell number. B) Effect of SCF on megakaryocyte cell number. C) Effect of 
SCF on CD41 percentage. D) Representative flow cytometry plots showing megakaryocyte 
differentiation at day 14 of culture. E) Effect of SCF on CD41/CD42 expression at day 14 of culture. 
All experiments are n=3. 
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Figure 3-21 Megakaryocyte differentiation in liquid culture 
Cytospins show megakacyocyte differentiation in the two megakaryocyte systems at days 7, 10 and 
14. All photographs are at x100 magnification. 
3.7 The effect of IGF2 on normal FL erythroid differentiation 
The effect of IGF2 on erythroid differentiation of normal FL was tested using the 
optimised erythroid culture system, Protocol 2-Er. I chose to focus only on IGF2, 
rather than IGF1, as my previous work had shown that this is the predominant IGF 
present in fetal life and had a greater effect on erythroid colony formation by normal 
FL CD34+ cells than IGF1. 100 lin- CD34+ cells were sorted and plated into 96-well 
flat-bottom plates and cultured for 14 days. In contrast to the effects of IGF2 in 
promoting erythroid progenitor specification in methylcellulose cultures (Figure 
3-12), IGF2 did not increase either the number or percentage of erythroid cells 
(Figure 3-22A and B) or their stage of maturation (Figure 3-22C) in liquid culture 
suggesting that it has little or no effect on erythroid differentiation/maturation 
downstream of the erythroid progenitor.  
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Figure 3-22 Effect of IGF2 on erythroid differentiation of normal FL CD34+ 
cells in liquid culture 
A) Effect of IGF2 on GlyA expression over 14 days of culture (n=3). B) Effect of IGF2 on cell number 
(expressed as fold change) over 14 days of culture (n=3). C) Cytopsins showing effect of IGF2 on 
morphology of erythroid cells at day 7, 10 and 14. 
 
3.8 Growth and differentiation of DS FL CD34+ cells in an 
erythroid liquid culture system in the presence and absence of 
IGF2  
First, to determine whether erythroid differentiation was increased in DS FL CD34+ 
cells compared to normal FL CD34+ cells, 100 lin- DS CD34+ cells were sorted and 
plated into 96-well flat bottom plates and cultured for 14 days in the Protocol 2-Er 
serum-free erythroid system.  Compared to normal FL CD34+ cells cultured under 
identical conditions, DS FL cells displayed markedly enhanced proliferation with 
increased cell numbers at day 7 and day 10 (Figure 3-23A). In addition, they 
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showed accelerated differentiation as assessed by their more rapid acquisition of 
surface GlyA expression (Figure 3-23B and C) and earlier haemoglobinisation on 
morphology (Figure 3-23D). This probably explains the reduction in the number of 
GlyA+ cells by day 14 as these cells rapidly differentiated to mature red cells.  
 
Figure 3-23 Comparison of erythroid differentiation of normal and DS CD34+ 
cells 
A) Comparison of erythroid cell number in normal FL and DS FL liquid cultures (n=3). B) Comparison 
of GlyA expression in normal FL and DS FL liquid cultures showing rapid GlyA acquisition in DS FL 
cells (n=3). C) Representative flow cytometry plots of DS FL erythroid differentiation in liquid 
cultures. D) Cytospins showing erythroid morphology at day 7, 10 and 14 of culture. **p<0.01 
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Similarly to normal FL, IGF2 had no effect on erythroid proliferation or differentiation 
of DS FL CD34+ cells in liquid culture (Figure 3-24). It is difficult to interpret the 
significance of the lower numbers of GlyA+ cells on day 14 since most of the cells 
were already fully differentiated or dying. 
 
Figure 3-24 Effect of IGF2 on erythroid differentiation of DS FL CD34+ cells 
A) Effect of IGF2 on GlyA expression over 14 days of culture (n=3). B) Effect of IGF2 on cell number 
over 14 days of culture (n=3). ***p<0.001 
 
3.9 The effect of IGF2 on normal FL megakaryocyte differentiation 
To test the effects of IGF2 on megakaryocyte differentiation of normal FL CD34+ 
cells, 1000 lin- DS CD34+ cells were sorted and plated into 96-well flat bottom 
plates and cultured for 14 days in serum-free medium with TPO or TPO + SCF (50 
ng/ml) in the presence and absence of IGF2. In the presence of TPO + SCF, IGF2 
had no effect on the numbers or percentage of CD41+ cells, CD42+ cells or 
megakaryocyte maturation (Figure 3-25).  However, in the presence of TPO alone, 
whilst IGF2 had little effect on the % of CD41+ or CD41+CD42b+ cells, it caused a 
slight, but significant reduction in the numbers of CD41+ cells and CD41+CD42+ 
cells (p<0.05). Whether this was due to terminal megakaryocyte maturation and/or 
cell death was not clear either from flow cytometric analysis or from examination of 
the cytospins (Figure 3-25E).   
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Figure 3-25 Effect of IGF2 on megakaryocytic differentiation of normal FL 
CD34+ cells 
A) Percentage of cells expressing CD41 at day 14 of culture. B) Number of CD41+ cells at day 14 of 
culture expressed as FC. C) Percentage of cells expressing CD41 and CD42 at day 14 of culture. D) 
Number of CD41/42+ cells at day 14 of culture expressed as FC. E) Cytospins of megakaryocytes at 
day 14 of culture. All at x100 magnification. All experiments are n=3. *p<0.05 
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3.10 Growth and differentiation of DS FL CD34+ cells in a 
megakaryocyte liquid culture system in the presence and 
absence of IGF2 
Given the megakaryocytic bias of DS FL CD34+ cells in methylcellulose assays, I 
first investigated whether DS FL CD34+ cells also showed increased 
megakaryocyte proliferation in response to TPO or TPO plus SCF. While DS FL 
CD34+ cells gave rise to similar numbers of megakaryocytes to normal FL CD34+ 
cells when cultured in the presence of TPO plus SCF, megakaryocyte proliferation 
of DS FL CD34+ cells in response to TPO alone was markedly impaired (Figure 
3-26). Maturation of DS FL CD34+ cells in response to both TPO and TPO plus 
SCF appeared to be normal as assessed by acquisition of CD42b (Figure 3-26E).   
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Figure 3-26 Effect of TPO and TPO/SCF on megakaryocytic differentiation of 
DS FL CD34+ cells 
A) Percentage of cells expressing CD41 in a TPO only liquid culture system. B) Percentage of cells 
expressing CD41 in a TPO/SCF liquid culture system. C) Number of CD41+ cells in a TPO only 
liquid culture system. C) Number of CD41/42+ cells in a TPO/SCF liquid culture system. E) 
Percentage of CD41+ and CD41/42+ cells in a TPO only and TPO/SCF liquid culture system. All 
experiments are n=3. 
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IGF2 caused marked proliferation (more than 3-fold) of megakaryocytes from DS FL 
CD34+ cells in the presence of TPO (Figure 3-27), completely compensating for the 
impaired response to TPO alone (see Figure 3-26C) in contrast to the lack of effect 
of IGF2 on normal FL CD34+ cells in liquid culture (Figure 3-25). IGF2 caused a 
smaller, non-significant increase in megakaryocytes in the presence of TPO plus 
SCF (Figure 3-27B) suggesting that IGF2 and SCF may share downstream 
signalling pathways.  
 
Figure 3-27 Effect of IGF2 on megakaryocytic differentiation of DS FL CD34+ 
cells 
A) Effect of IGF2 on the number of CD41+ cells in a TPO-only liquid culture system (n=4). B) Effect 
of IGF2 on the number of CD41+ cells in a TPO/SCF liquid culture system (n=2). C) Effect of IGF2 
on CD41/CD42 expression in a TPO-only and TPO/SCF liquid culture system. D) Effect of IGF2 on 
CD41+ cell number in a TPO only culture system. All experiments are n=3.  
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3.11 Summary and Discussion  
The results presented in this chapter represent the first investigation of the IGF 
pathway in human fetal haematopoiesis. The data implicate the IGF pathway in the 
regulation of normal fetal haematopoiesis and provide strong evidence that IGF 
signalling plays a key role in the disruption of haematopoiesis evident in DS fetal 
life.  
 
3.11.1 IGF2-IGF1R signalling is the key IGF pathway in fetal haematopoietic 
cells 
The activating receptor, IGF1R, was consistently expressed in virtually all FL 
CD34+ cells, clearly showing potential for IGF-mediated signalling. This was in 
contrast to AdBM CD34+ cells, of which only a minority expressed IGF1R. This 
strongly supports the contention that IGF signalling in HSPC is more important 
during fetal than postnatal life.  
In addition, of the two IGF proteins, only IGF2 was produced in both haematopoietic 
and non-haematopoietic cells in FL, including FL MSC and FL CD34+ cells. These 
findings are in keeping with previous evidence in mice implicating IGF2 as the 
dominant mediator of IGF signalling during early fetal development, with IGF1 of 
greater importance in perinatal and postnatal growth (Chou and Lodish, 2010; 
Randhawa and Cohen, 2005). Overall, these data suggest that IGF2 signalling via 
IGF1R comprises the major IGF pathway in fetal haematopoiesis. 
Importantly, although the ML-DS cell line CMK showed  increased expression of the 
IGF1R compared to a non-DS erythroleukaemia line (K562), IGF1R expression in 
primary DS FL CD34+ cells was similar to normal FL cells. Therefore, the 
differences in IGF response in DS cells, discussed below, are unlikely to be due to 
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differences in receptor expression. In addition, it suggests that IGF1R upregulation 
occurs at a later point in leukaemia development, and that this may be an important 
component of disease progression. Alternatively increased IGF1R on CMK may 
reflect their fetal origin.  
 
3.11.2 The effect of IGF2 on normal fetal HSPC  
The clonogenic assays provide strong support for IGFs, particularly IGF2, in the 
promotion of normal fetal erythropoiesis. Whilst IGF2 induced erythroid colony 
formation at all EPO concentrations, the effect was most apparent at lower doses, 
although synergy between IGF2 and EPO was still apparent in the presence of high 
EPO concentrations (4 u/ml). Importantly, IGF2 was able to promote erythroid 
colony formation even in the complete absence of EPO. This effect was not present 
in AdBM, suggesting the existence of an alternative, fetal-specific erythroid 
pathway. It would be interesting to further interrogate this pathway through 
assessment of downstream signalling, although such experiments are difficult in the 
context of low cell numbers. IGF2 had no effect on the clonogenicity of normal FL 
megakaryocyte progenitors but consistently inhibited the growth of normal FL CFU-
GM at all concentrations of EPO suggesting that it may specifically direct HSPC 
commitment towards the erythroid lineage. These data support a functional role for 
IGF1R on FL CD34+ cells and suggest that the main effect of stimulating IGF1R on 
FL CD34+ cells is to promote the development of erythroid progenitors.  
Given these results, I had expected IGF2 to also promote erythroid differentiation 
and proliferation in the liquid culture system. However, it had little effect in the 
erythroid system used; there are several possible explanations for these findings. 
Firstly, it could suggest that IGFs are more important in support of early erythroid 
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progenitors but have little impact on late proliferation and differentiation. 
Alternatively, the methylcellulose experiments show the effect of IGF2 is strongest 
at lower EPO concentrations and, therefore, the higher EPO concentration used in 
the liquid cultures (0.5u/ml in phase 1 and 4U/ml in phase 2) may have masked any 
effects of IGF2. Similarly, the concentration of SCF is higher in the liquid culture 
system (100ng/mL vs. 10ng/mL), which again may mask the effect of IGF2. Hence, 
It would be useful to carry out further liquid cultures using lower doses of both SCF 
and EPO. Finally, the exact constituents of StemSpan, the liquid culture media 
used, are not provided by the manufacturer and it is therefore possible that other 
growth factors in StemSpan interfere with the effect of IGF2. In particular, 
StemSpan contains a high concentration of insulin, which could cause cross 
activation of the IGF downstream pathways via the InsR. To exclude this possibility, 
it would be necessary to use culture medium in which all constituents were added 
‘in-house’.   
In addition to the promotion of erythropoiesis in normal FL, the addition of IGF2 
reduced megakaryocyte differentiation and proliferation in the megakaryocyte liquid 
cultures. Interestingly, this was only seen in the absence of SCF, suggesting that 
the presence of SCF overcomes the inhibitory effect of IGF2. Although this is only a 
preliminary result it raises the intriguing possibility that IGF2 can enhance normal FL 
erythroid development whilst concurrently inhibiting megakaryocyte differentiation, 
thereby acting as a determinant of megakaryocyte-erythroid potential.   
 
3.11.3 IGFs synergise with high EPO concentrations in AdBM 
As discussed above, IGFs had no effect on AdBM clonogenicity in the absence of 
EPO. However, they were able to synergise with EPO at high concentrations, 
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promoting an increase in erythroid colony formation. Interestingly, synergy between 
IGFs and EPO has previously been described in AdBM cells in the context of 
polycythaemia vera (Staerk et al., 2005).  These results indicate that IGFs can act 
as erythroid growth factors in both FL and AdBM HSPCs. Importantly though, they 
demonstrate a difference between FL and AdBM CD34+ cells in their response to 
IGF. Whilst FL CD34+ cells show a response to IGFs at all EPO concentrations, the 
effect is most pronounced at lower concentrations. In contrast, AdBM CD34+ cells 
only respond to IGFs at high EPO concentrations. It is possible to speculate that 
this effect reflects the relative microenvironments and that EPO concentration is 
lower in the FL than adult BM. However, it is extremely difficult to measure in vivo 
EPO concentrations. Current estimates of EPO levels in fetal life are based on in 
utero CB samples, but the true tissue concentrations of EPO during fetal 
development are unknown (Ostlund et al., 2000; Schmidt et al., 2004; Teramo and 
Widness, 2009).  
 
3.11.4 IGF2 promotes megakaryopoiesis in DS FL progenitors  
In clonogenic assays of DS FL CD34+ cells IGF2 dramatically increased the 
numbers of megakaryocyte and megakaryocyte-erythroid colonies with very modest 
effects on the numbers of erythroid colonies suggesting that in DS FL, IGF2 
promotes megakaryopoiesis at the expense of erythropoiesis. Consistent with this, 
whilst IGF2 had no effect on the proliferation and differentiation of erythroid cells 
from DS FL CD34+ cells cultured in erythroid liquid culture systems, IGF2 markedly 
enhanced megakaryocyte differentiation particularly in the presence of TPO alone. 
Furthermore, there was no evidence of EPO independent erythroid differentiation of 
DS FL CD34+ cells in liquid culture, a hallmark of adult myeloproliferative 
syndromes.   
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Taken together, my data suggest that, IGF2 regulates the balance of fetal 
megakaryocyte-erythroid differentiation. In normal FL, IGF2 promotes erythopoiesis 
at the expense of granulopoiesis with little or no effect on megakaryopoiesis. By 
contrast, in DS FL, IGF2 enhances megakaryopoiesis at the expense of 
erythropoiesis and granulopoiesis.  Thus, IGF2 is a compelling candidate as a 
mediator of the disruption of DS fetal haematopoiesis.  
Intriguingly, IGF1 had no effect in clonogenic assays, demonstrating that the effects 
on megakaryocytes are specific to IGF2, the only IGF produced in the liver during 
the second trimester of fetal life. This suggests that IGF1 and IGF2 mediate 
different effects despite binding to the same receptor (IGF1R).  
However, an alternative explanation is that signalling is occurring, at least partly, 
through the insulin receptor (IR). The IR exists in two forms, due to alternate 
splicing of exon 11; IR-A and IR-B (Frasca et al., 2008). Importantly, IR-A 
demonstrates high affinity for IGF2 as well as insulin, allowing IGF signaling via this 
pathway (Frasca et al., 1999). In vitro work in an IGF1R deficient leiomyosarcoma 
cell line demonstrated IGF2, but not IGF1, signaling exclusively through the IR-A 
receptor, led to strong activation of the shc/ERK pathway (Sciacca et al., 2002). 
Significantly, IR-A has been found to be preferentially expressed in embryonic 
tissues, with IR-B expressed in adult tissues, suggesting that IR-A has a key role in 
fetal growth (Frasca et al., 1999; Louvi et al., 1997).  
This evidence raises the possibility that the promotion of megakaryocyte 
clonogenicity and proliferation seen in DS FL progenitors, which was specific to 
IGF2, may occur through the activation of IR-A receptors by IGF2. Although I have 
shown that the IR is expressed at similar levels in both normal and DS FL 
progenitors, the antibody used was not specific for IR-A or IR-B. It would therefore 
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be useful to repeat this measurement using antibodies specific to each IR subtype 
to ascertain whether any differences in receptor expression exist. Further 
experiments using inhibitors of the IGF1 and insulin receptors would also provide 
further clarity on how IGF2 mediates these effects.   
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4 The role of the IGF2 receptor in fetal haematopoiesis 
 
4.1 Introduction 
Activation of the IGF pathway occurs via binding of IGF1 or IGF2 to IGF1R. In 
contrast, the only IGF which can bind to the IGF2 receptor (IGF2R) is IGF2. 
Following IGF2-IGF2R binding IGF2 is degraded, thus IGF2R functions as a 
negative regulator of IGF signalling since less IGF2 is available to bind to IGF1R 
(Nolan et al., 1990; Oka et al., 1985). 
 
4.1.1 IGF2R Function 
IGF2R is a multi-functional receptor and has several potential roles in normal cell 
function in addition to IGF2 degradation. At the cell surface, in vitro studies have 
shown that IGF2R can bind several other important mediators of cell growth and 
proliferation including TGF-β (Dennis and Rifkin, 1991), retinoic acid (Kang et al., 
1999; 1997) and leukaemia inhibitory factor (LIF) (Blanchard et al., 1999). However, 
there is little additional evidence that IGF2R influences any of these key pathways 
and it is therefore currently unclear if IGF2R actually plays a role in their regulation. 
In contrast, the intracellular role of IGF2R in the trafficking of lysosomal enzymes is 
clearly defined. Within the cell, acid hydrolases are tagged with mannose-6-
phosphate (M6P) recognition signals in the late Golgi, allowing recognition and 
binding by the IGF2R at the surface of the trans-Golgi network (Rohrer and 
Kornfeld, 2001). The enzymes are packaged into clathrin-coated vesicles and 
delivered to early endosomes, (Klumperman et al., 1993) with the rate of vesicle 
formation governed by IGF2R concentration (Le Borgne and Hoflack, 1997). In 
keeping with this role, 90% of IGF2R is intracellular at steady state with continual 
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cycling occurring between the cytoplasm and the membrane (Brown et al., 2009). 
Importantly, the receptor does not have a tyrosine kinase domain (Pollak et al., 
2004) and, despite several previous studies suggesting G protein activity (Okamoto 
et al., 1990; Takahashi et al., 1993), the role for IGF2R as a cell signalling receptor 
remains disputed (Körner et al., 1995; Pollak et al., 2004). 
 
4.1.2 IGF2R in malignancy 
Recently, IGF2R has emerged as an important oncogene in many tumour types. It 
was initially implicated in the pathogenesis of hepatocellular carcinomas in which 
De Souza and colleagues found loss of heterozygosity (LOH) in the IGF2R gene in 
70% of human hepatocellular tumours with mutations identified in 25% of the 
remaining normal alleles (De Souza et al., 1995). Since then, LOH and mutation of 
the IGF2R gene has been shown to occur in many other types of cancers, including 
breast, ovarian, colonic and lung (Hankins et al., 1996; Kong et al., 2000; 
Leboulleux et al., 2001; Rey et al., 2000). 
In vitro work in IGF2R deficient cell lines has shown that these cells exhibit 
increased growth rates in response to IGF2 when compared to IGF2R positive cells 
(Osipo et al., 2001). Similarly, induced expression of the receptor in an IGF2R 
deficient mouse mammary tumour cell line led to decreased proliferation, although 
there was no effect on apoptosis (Li and Sahagian, 2004). Similar effects have been 
shown in human breast cancer cells with increased IGF2R expression resulting in a 
marked reduction in tumourigenicity and reduced expression producing an 
increased growth rate and lower apoptotic rate (Chen et al., 2002; Lee et al., 2003). 
Furthermore, O’Gorman and colleagues showed that IGF2R knockdown in 
choriocarcinoma cells led to an increased growth rate in vitro and increased 
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tumourigenicity in mice (O'Gorman et al., 1999; 2002). These findings provide 
strong evidence for the role of IGF2R as a tumour suppressor through the 
regulation of the IGF pathway. 
 
4.1.3 IGF2R in fetal life  
As IGF2 has been shown to be particularly important in fetal life, it is feasible that 
IGF2R also has a key role during this developmental phase. At present, the 
strongest evidence for this is provided by the description of IGF2R deficient mice. 
These mice exhibit significant fetal overgrowth and organ abnormalities and almost 
all die at birth (Lau et al., 1994; Ludwig et al., 1996; Wang et al., 1994). Circulating 
IGF2 is increased 2-4-fold compared to wild type mice, suggesting overgrowth is 
secondary to increased IGF2 signalling. Importantly, additional knockout of IGF2 or 
IGF1R completely rescues the IGF2R null mice, clearly implicating an excess of 
IGF2-IGF1R signalling in the development of the phenotype (Ludwig et al., 1996). 
 
4.1.4 IGF2R in fetal haematopoiesis 
Importantly, whilst the IGF2R null mice identify a role for IGF2R in murine fetal 
development, there has not been any research into the role of IGF2R in fetal 
haematopoiesis, either in mice or humans. The results presented in chapter 3 
clearly identify a role for IGF signalling in normal fetal haematopoiesis and in the 
disruption of haematopoiesis in DS fetal life. However, whether IGF2R is important 
in the regulation of this pathway and in the development of leukaemia in DS is not 
known. To address this, this chapter explores the role of IGF2R in normal and DS 
fetal haematopoiesis. 
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4.2 IGF2R expression in a ML-DS cell line 
Previous work has shown enrichment of IGF target genes in ML-DS cell lines and 
primary blasts (Klusmann et al., 2010). Furthermore, blasts showed hyper-
responsiveness to IGF stimulation and reliance on the IGF pathway for survival. As 
IGF2R is a key negative regulator of IGF2 signalling during fetal life and has been 
shown to function as an oncogene, I hypothesised that downregulation of the 
receptor may be important in the aetiology of ML-DS.  
To address this hypothesis, I first assessed IGF2R expression at the cell surface 
using flow cytometry in CMK, a ML-DS cell line, and compared this to K562, an 
erythroblastic leukaemia cell line. As shown in Figure 4-1, CMK had significantly 
lower IGF2R surface expression (p=0.02).  
 
Figure 4-1 IGF2R surface expression in a ML-DS cell line 
A) Representative flow cytometry plots showing IGF2R expression in CMK vs. K562. B) Percentage 
of cells in each cell line that express IGF2R. C) Intensity of IGF2R expression in each cell line. All 
experiments are n=5. *p<0.05 
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As 90% of the IGF2R protein is located intracellularly (Brown et al., 2009), it is 
possible that the level of cell surface expression is not representative of the total 
amount of IGF2R in the cell. For instance an abnormality in protein trafficking might 
affect cell surface expression in the context of normal total cell IGF2R. I therefore 
also assessed the level of IGF2R protein in the cell using Western blotting. This 
confirmed a reduction in total cell IGF2R in CMK in comparison with K562 (Figure 
4-2A).  
To determine whether the reduction in IGF2R was due to a decrease in gene 
transcription or due to a post-transcriptional mechanism, I assessed IGF2R mRNA 
levels using qRT-PCR. This showed a decrease in IGF2R mRNA in CMK cells 
(p=0.0003; Figure 4-2B) suggesting that IGF2R downregulation occurs due to a 
decrease in IGF2R transcription. 
 
Figure 4-2 IGF2R protein and mRNA expression in a ML-DS cell line 
A) IGF2R protein quantification in CMK vs. K562 (n=1). B) IGF2R mRNA expression in CMK vs. 
K562 (n=5). ***p<0.001 
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4.3 IGF2R expression in normal FL haematopoietic cells 
These results suggested that IGF2R downregulation might be a factor in the 
pathogenesis of ML-DS. However, it is unclear if IGF2R downregulation is a late 
event in DS leukaemogenesis or if downregulation might also play a role in the 
perturbation of growth and proliferation of DS fetal haematopoietic cells. To address 
this I first assessed IGF2R expression in normal FL haematopoietic HSPC using 
flow cytometry. 
As shown in Figure 4-3, IGF2R expression in normal FL lin- CD34+ cells showed 
marked variability between different fetal samples with between 2-83% of cells 
showing surface IGF2R expression by flow cytometry. This is in contrast to IGF1R, 
which was universally expressed in all FL samples. It is possible that the variability 
in IGF2R expression occurs due to continuous trafficking of the receptor between 
the cytoplasm and the cell surface, although further experiments, which would not 
be feasible in the small number of primary fetal cells available, would be necessary 
to confirm this. 
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Figure 4-3 IGF2R expression in normal FL CD34+ cells 
A) Representative flow cytometry plots demonstrating variation in expression of IGF2R in 3 different 
samples of normal FL CD34+ cells. B) Percentage of normal FL CD34+ cells expressing IGF2R 
(n=19). C) Intensity of IGF2R expression in normal FL CD34+ cells.  
 
I next investigated whether the level of IGF2R expression differed between different 
FL HSPC subpopulations. However, although IGF2R appeared slightly higher in the 
HSC population, there were no significant differences between the subpopulations 
(Figure 4-4). 
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Figure 4-4 IGF2R expression in HSC, multipotent progenitor and myeloid 
subpopulations in normal FL 
A) Representative flow cytometry plots showing IGF2R expression in progenitor subpopulations. B) 
IGF2R % expression in each progenitor subpopulation. No significant differences were found (n=8). 
 
Given the marked variability of IGF2R expression in FL HSPC, I went on to 
compare IGF2R expression in CD34+ cells from FL, CB and AdBM. Interestingly, 
IGF2R expression was far more consistent within these two tissues, with 
significantly lower IGF2R intensity in CB (p<0.05) and moderate IGF2R expression 
in AdBM (Figure 4-5). As with FL, the level of IGF2R was consistent across all 
HSPC subpopulations. Given these findings, it is possible that the variability in 
IGF2R expression on fetal haematopoietic cells reflects a specific role in fetal life, 
particularly on HSC, but the exact function of the receptor remains unclear. 
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Figure 4-5 Comparison of IGF2R expression in normal FL, CB and AdBM 
CD34+ cells 
A) Representative flow cytometry plots showing IGF2R expression in CB and AdBM CD34+ cells. B) 
IGF2R percentage expression in normal FL (n=19), CB (n=7) and AdBM (n=5) CD34+ cells. C) 
IGF2R expression intensity in normal FL, CB and AdBM CD34+ cells. *p<0.05 
 
4.4 IGF2R expression in DS fetal liver CD34+ cells 
In the previous chapter I showed that DS FL CD34+ cells differ in their response to 
IGF2 compared to normal FL CD34+ cells. In view of the reduced IGF2R 
expression seen in the ML-DS cell line, I hypothesised that DS FL HSPC may also 
show reduced IGF2R expression, which might contribute to the altered response to 
IGF2. To investigate this, I assessed IGF2R surface expression in primary DS FL 
CD34+ cells. As with normal FL CD34+ cells, there was marked variability in the 
expression of IGF2R in different samples (Figure 4-6). However, although the 
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median percentage and intensity of expression were slightly lower in DS FL 
samples than in normal FL, this was not significant (Figure 4-6B and C). 
 
Figure 4-6 IGF2R expression in DS FL CD34+ cells 
A) Representative flow cytometry plots demonstrating variability in IGF2R expression in DS FL 
CD34+ cells. B) IGF2R percentage expression in DS FL CD34+ cells (n=8). C) Intensity of IGF2R 
expression in DS FL CD34+ cells.  
 
The level of IGF2R expression was relatively consistent across all DS HSPC 
subpopulations. As with total CD34+ cells, the IGF2R expression level in each 
subpopulation was slightly lower than in normal FL, although, again, these 
differences did not reach significance (Figure 4-7).  
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Figure 4-7 IGF2R in DS FL HSC, multipotent and myeloid progenitor 
subpopulations 
A) Representative flow cytometry plots showing IGF2R expression in DS FL subpopulations 
compared to normal FL subpopulations. B) IGF2R percentage expression in each DS FL 
subpopulation compared to normal FL. No significant differences were found. C) IGF2R expression 
intensity in each DS FL subpopulation compared to normal FL.  
 
Data generated using the Fluidigm gene expression platform for a separate project 
in our lab showed that expression of the IGF2R gene was significantly reduced in 
DS FL HSC but also confirmed the variability in IGF2R mRNA expression in normal 
FL HSC (Figure 4-8; Anindita Roy, personal communication). This would suggest 
that it might be physiologically important for HSC to rapidly alter IGF2R expression 
levels. 
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Figure 4-8 IGF2R mRNA expression in HSC, multipotent and myeloid 
progenitor subpopulations in DS FL 
IGF2R mRNA expression in each DS FL subpopulation compared to normal FL (n=3). Expression 
measured using Fluidigm gene expression platform. Data provided by Dr Anindita Roy (personal 
communication). ***p<0.001 
 
In summary, I have shown that IGF2R surface expression shows marked variation 
between samples both in normal and DS FL HSPC and that levels are relatively 
consistent across HSPC subpopulations. The slightly higher expression of surface 
IGF2R on normal FL HSC compared to progenitors, which is more marked at the 
transcriptional level, may indicate that IGF2R plays a role in a sub-population of 
HSC since expression both by flow cytometry and qPCR is heterogeneous. There is 
a reduction in IGF2R gene expression in DS FL CD34+ cells although this was less 
apparent on the cell surface and was much more marked in CMK cells suggesting 
that the reduction in IGF2R expression may occur later in the progression to ML-
DS.  
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4.5 The functional relevance of IGF2R expression in normal tissue 
Although I have found differences in IGF2R expression levels in FL compared to CB 
and AdBM, the function of the receptor within haematopoiesis remains elusive. To 
address this question, I aimed to sort cells based on the level of IGF2R expression 
to investigate whether this would select for a population with specific lineage 
differentiation bias. I chose to use CB CD34+ cells in this experiment as CB cells 
are more readily available than FL cells and show a consistent pattern of IGF2R 
expression, with around 10-20% of cells positive for the receptor. This allowed me 
to sort CB CD34+ cells into two populations based on IGF2R expression; an 
IGF2Rlo population and an IGF2Rhi population (Figure 4-9A).  
Cells were sorted and plated into serum-free methylcellulose and cultured in the 
presence or absence of EPO, IGF1 and IGF2. As shown in Figure 4-9, both the 
number and types of colony were similar in the IGF2Rhi and IGF2Rlo populations. 
Overall these data suggest that the level of IGF2R expression does not determine 
lineage commitment.  
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Figure 4-9 Function of IGF2R in CB CD34+ cells 
A) Flow cytometry plot showing typical pattern of IGF2R expression in normal CB CD34+ cells. B) 
CB CD34+ cells were sorted into two populations, based on IGF2R surface expression, and plated in 
serum-free methylcellulose (containing SCF, TPO, Flt3, GM-CSF, IL3, IL6, IL11) in the presence or 
absence of IGF1, IGF2 and/or EPO. Graph shows number of colonies in each condition at day 14 of 
cultures. C) Colony type in IGF2Rlo cultures (Left graph) and IGF2Rhi cultures (Right graph). 
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4.6 Fetal haematopoiesis in an IGF2R null mouse 
As an alternative strategy to investigate the role of IGF2R in fetal haematopoiesis, I 
studied the numbers, frequency and function of haematopoietic cells in an IGF2R 
null mouse model (kindly provided by Prof Denise Barlow, University of Vienna 
(Wang et al., 1994)). These mice were originally generated through the introduction 
of a 4.7Kb deletion spanning the promoter and exon 1 of the igf2r gene. As 
previously discussed, IGF2R null mice exhibit fetal overgrowth and organ 
abnormalities and almost all die at birth (Lau et al., 1994; Ludwig et al., 1996; Wang 
et al., 1994). However, there are no data about haematopoiesis within this mouse 
model.  
 
4.6.1 Breeding strategy for IGF2R null mice  
The breeding strategy to produce IGF2R null mice is shown in Figure 10. As IGF2R 
is an imprinted gene and is only expressed by the maternally-inherited copy, female 
mice heterozygous for the IGF2R gene deletion were bred with wild type males. As 
shown in  Figure 4-10, 50% of the offspring should inherit the null IGF2R maternal 
allele and would therefore be IGF2R deficient. 
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 Figure 4-10 Breeding strategy to produce IGF2R null mice 
IGF2R is an imprinted gene and only expressed from the maternal allele. Therefore female mice 
carrying a single IGF2R deletion were mated with wild type male mice to produce IGF2R null 
offspring.  
 
4.6.2 Confirmation of IGF2R phenotype 
As IGF2R deficiency is usually embryonically lethal, embryos were harvested at 
embryonic day 18.5 (E18.5). Of the 9 embryos collected, 4 were shown to be IGF2R 
null through PCR detection of the 1.2kB neo cassette, which had been introduced at 
the point of the gene deletion (Figure 4-11A). As previously described, IGF2R null 
mice showed significant fetal overgrowth with a birthweight approximately 30% 
greater than wild type littermates (p=0.04; Figure 4-11B-D).  
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Figure 4-11 Confirmation of IGF2R null phenotype 
A) Upper panel: Confirmation of presence of neo (red arrow) cassette by PCR in IGF2R null mice 
embryos (C-F). Lower panel: Beta (B) globin was used as control- a band of the expected size (grey 
arrow) can be seen in all of the 9 mice. B) Weight of embryos. IGF2R null mice shown in red 
(corresponding to bands C-F in Figure 4.11A). C) Average weight of IGF2R null mice (n=4) 
compared to wild type mice (n=5). *p<0.05. D) Photograph demonstrating increased size of IGF2R 
null mice embryos.  
 
4.6.3 Fetal haematopoiesis in IGF2R null mice 
To investigate fetal haematopoiesis, FL was harvested from embryonic day 18.5 
(E18.5) fetuses. No obvious macroscopic differences were apparent in the livers 
from the two different populations. Similarly, there was no significant difference in 
the number of total FL haematopoietic cells (CD45+) between the IGF2R null mice 
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and wild type mice (Figure 4-12A and B). There was also no difference in the 
proportion of B cells (B220+) or erythroid cells (Ter119+) (Figure 4-12A, C and D).  
 
Figure 4-12 Haematopoietic lineages in IGF2R null mice 
A) Representative flow cytometry plots showing percentage expression of CD45, B220, Ter119 and 
Gr1 in wild type (n=3) and IGF2R null (n=5) mice. B) CD45 percentage expression C) B220 
(lymphoid) expression. D) Ter119 (Erythroid) percentage.   
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The relative proportions of HSPC subpopulations were determined in order to 
assess whether any of the features of DS haematopoiesis, such as the MEP 
expansion, were recapitulated in the IGF2R null mouse. However, both long-term 
and short-term HSCs were present at similar levels to those found in wild type mice 
(Figure 4-13).   
 
Figure 4-13 HSC populations in IGF2R null mice 
A) Gating strategy used to identify Long-term (LT) HSC and Short-term (ST) HSC and representative 
flow cytometry plots showing relative percentages. B) Comparison of HSC subpopulations in wild 
type (n=13) and IGF2R null (n=11) mice.  
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Myeloid progenitor subpopulations including MEP were also present at similar levels 
(Figure 4-14). These results suggest that IGF2R does not play an important role in 
murine fetal haematopoiesis.  
 
Figure 4-14 Myeloid progenitor subpopulations in IGF2R null mice 
A) Gating strategy used to identify myeloid subpopulations. B) Comparison of myeloid progenitor 
subpopulations in wild type (n=13) and IGF2R null (n=11) mice. 
 
4.7 Summary and discussion 
Overall, despite using both human and murine primary cells, the results presented 
in this chapter do not identify the function of IGF2R in fetal haematopoiesis. Normal 
FL CD34+ cells did show a different pattern of IGF2R expression compared to CB 
and AdBM with marked variation between different samples, even though all 
samples were from second trimester fetuses with normal karyotypes. This variation 
in expression was not present in CB or AdBM samples, although the reason for this 
difference is not clear.  
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Whilst the CB methylcellulose cultures and mouse studies failed to identify a 
function for IGF2R, a role in human fetal haematopoiesis cannot be entirely 
excluded. Whilst CB cells provide a plausible and commonly used alternative to 
fetal tissue, it is possible that the use of primary fetal cells may show a different 
result. Due to the variability between FL samples it would be difficult to repeat the 
cultures using IGF2Rhi and IGF2Rlo cells from defined HSC and progenitor sub-
populations and so an alternative approach would be required. Potentially the most 
robust experiment would be to knockdown IGF2R in human FL cells using shRNA 
technology to see if this had any effect on clonogenicity. In addition, liquid cultures 
could be employed to further interrogate differentiation and proliferation. However, 
such experiments are extremely difficult in primary FL samples due to the large cell 
number that would be required. In addition, it is also possible that IGF2R has a 
specific function in DS FL haematopoiesis. Again, this would require further 
experiments using defined primary DS fetal HSC and progenitor populations. 
The experiments in IGF2R null mice suggested that IGF2R is unlikely to play a 
significant role in murine fetal haematopoiesis under physiological conditions. 
However, to confidently exclude such a role it would be necessary to repeat the 
experiments under conditions of haematopoietic stress (eg after radiation) and to 
carry out competitive transplantation experiments to investigate whether IGF2R null 
cells might have a competitive advantage.  
Although these experiments did not detect a function for IGF2R in normal 
haematopoiesis, previous work has clearly shown IGF2R plays a key role in various 
cancers. It is therefore interesting that IGF2R expression was extremely low in a 
ML-DS cell line when compared to a non-DS leukaemic cell line, K562. The ML-DS 
cell line has previously been shown to be hyper-responsive to exogenous IGF2 and 
is extremely sensitive to inhibition of IGF signalling (Klusmann et al., 2010). It is 
145 
 
possible therefore, that IGF2R downregulation heightens the response to IGF2 
stimulation and therefore enhances proliferative and anti-apoptotic mechanisms. 
Further experiments are needed to test this hypothesis, such as overexpression of 
the IGF2R to investigate whether this affects cell survival and proliferation. It would 
also be useful to explore IGF2R expression in primary TAM and ML-DS blasts to 
identify the point during leukaemic transformation at which IGF2R downregulation 
occurs.  
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5 The role of mesenchymal stem cells in abnormal fetal 
haematopoiesis in DS 
 
5.1 Introduction 
The haematopoietic niche is a specific microenvironment that regulates HSC and 
supports their differentiation (Morrison and Scadden, 2014). Niches exist in diverse 
sites throughout ontogeny as haematopoiesis migrates from the AGM to the FL and 
finally to the BM. Given the changes that occur in haematopoiesis through 
development (Morrison et al., 1995), and ontogeny-related changes in the murine 
haematopoietic microenvironment (Charbord et al., 2002), it is highly likely that 
similar changes occur within the niche in human ontogeny and that these changes 
influence alterations in haematopoiesis. However, despite substantial advances in 
the understanding of the AdBM niche (Morrison and Scadden, 2014), the human FL 
niche remains largely unexplored.  
 
5.1.1 The FL niche in DS 
The development of leukaemia in DS provides a unique context in which to study 
the fetal haematopoietic niche. The natural history of the disease strongly implicates 
the FL microenvironment in the aetiology of leukaemia. Disruption of 
haematopoiesis occurs early in DS fetal life with an expansion of HSC and MEP 
(Chou et al., 2008; Roy et al., 2012; Tunstall-Pedoe et al., 2008). Whether this 
phenotype is cell intrinsic, secondary to the microenvironment or both, is currently 
unknown. Furthermore, the FL microenvironment appears integral to the 
development of TAM, the transient leukaemia-like condition unique to DS. This 
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disease presents in the neonatal period following acquisition of GATA1 mutations in 
haematopoietic cells (Ahmed et al., 2004; Hitzler et al., 2003; Mundschau et al., 
2003; Rainis et al., 2003). Although often asymptomatic, some cases result in 
severe liver fibrosis, suggesting the liver is the primary site of the disease 
(Klusmann et al., 2008; Massey et al., 2006). Importantly, TAM does not occur later 
than the first few weeks of life, which strongly supports the notion that it can only 
develop in the context of the FL microenvironment. The spontaneous resolution of 
TAM in the first few weeks, or occasionally months, of life as haematopoiesis 
completes the transition from the FL to the BM, adds further weight to this 
hypothesis.       
As discussed in chapter 1, the importance of the FL niche in DS presents two 
alternative hypotheses. Firstly, that there are abnormalities unique to the DS fetal 
microenvironment which drive perturbation of haematopoiesis and ultimately lead to 
the emergence of TAM. Given that several studies have already shown that 
alterations in the microenvironment can promote the development of MPDs and 
leukaemia in mice (Kode et al., 2014; Walkley et al., 2007a; 2007b), it is possible 
that alterations in the microenvironment secondary to T21 could drive the 
development of leukaemia in DS. Alternatively, it is possible that the same factors 
present in the normal FL microenvironment that are required for the support of 
normal haematopoiesis also promote the proliferation of T21 fetal haematopoiesis 
and the acquisition and/or expansion of mutant GATA1 clones. Interestingly, a 
single study using normal fetal MSC showed that normal FL MSC, but not FBM 
MSC, supported a ML-DS cell line in vitro (Miyauchi and Kawaguchi, 2014), 
suggesting that the FL microenvironment may be an absolute requirement for 
leukaemia development in DS. Furthermore, in chapter 3, I have already shown that 
DS HSPCs show an abnormal response to IGF2, a growth factor strongly linked 
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with fetal development. However, it remains possible that other factors within the FL 
microenvironment influence DS FL haematopoiesis.  
 
5.1.2 Mesenchymal Stromal Cells (MSC) 
There are several cell types within the FL that have been implicated in the 
regulation of FL haematopoiesis; hepatoblasts and hepatocytes, endothelial cells 
and MSC (Swain et al., 2014). For instance, Chou et al demonstrated that a subset 
of SCF+ hepatoblasts isolated from murine FL were able to support murine HSC ex 
vivo (Chou and Lodish, 2010). Similarly, Iwasaki et al showed that perisinusoidal 
endothelial cells can also maintain murine HSC (Iwasaki et al., 2010). However, it is 
likely that stromal cells are the major supporters of fetal haematopoiesis as has 
been found in BM (Morrison and Scadden, 2014). Although MSC have been 
isolated from the AGM, FL and FBM (Badillo and Flake, 2006; Campagnoli, 2001), 
relatively little is known about their role in the regulation of fetal haematopoiesis.  
MSC form a heterogenous cell population although the International Society for 
Cellular Therapy (ISCT) has fairly recently formulated minimal criteria for defining 
MSC in order to create a consensus for more uniform characterisation of these cells 
(Dominici et al., 2006). These criteria stipulate that MSC must be plastic adherent 
when maintained in culture, must express CD73, CD105 and CD90 and lack 
expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR, and 
must have the potential to differentiate into osteoblasts, adipocytes and 
chondroblasts in vitro. However, even with these criteria, it is likely that several 
subpopulations exist under the broader MSC umbrella (Dominici et al., 2006). 
 As discussed earlier, little is known about fetal MSC function. The most detailed 
publication is a study from Mickie Bhatia’s lab involving characterisation of FL MSC 
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(Martin and Bhatia, 2005). The authors demonstrated that FL MSC are capable of 
supporting in vitro haematopoiesis and that they have inherent differences to AdBM 
MSC including greater proliferation, longer survival and increased expression of N-
cadherin and osteopontin. FL MSC also showed an increase in the Wnt signalling 
pathway and a downregulation of Notch signalling compared to AdBM MSC (Martin 
and Bhatia, 2005). In addition, the composition of the MSC population differs in fetal 
life with the majority of cells expressing CD146 (Maijenburg et al., 2012). 
At present, no similar studies exist using DS FL MSC. Therefore, this chapter aims 
to address this through the isolation and characterisation of DS fetal MSC through 
gene expression profiling of DS FL and FBM MSC and comparison to their normal 
counterparts and through the use of functional studies. Using these techniques, I 
aimed to identify differences between DS and normal fetal MSC that may provide 
potential mechanisms for the disruption of DS fetal haematopoiesis.  
 
5.2 Isolation and culture of fetal MSC 
MSC were isolated from fetal tissue using techniques previously established in our 
lab, as detailed in chapter 2. Briefly, nucleated cells were plated in αMEM media 
containing 10% serum. After 72 hours, non-adherent cells were removed, and 
adherent cells were allowed to proliferate to near confluence. Cells could then be 
passaged every 1-2 weeks.  
MSC were isolated from both normal and DS FL. As shown in Figure 5-1, no 
morphological differences were apparent between the normal and DS FL MSC.  
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Figure 5-1 Morphology of cultured MSC isolated from normal (A) and DS (B) 
FL  
Representative images from 4 normal and 5 DS FL samples. 
 
The immunophenotype of both normal and DS FL MSC was in keeping with the 
current ICST definition with cells showing expression of CD105, CD73 and CD90 
and lacking expression of any haematopoietic markers (Figure 5-2) (Dominici et al., 
2006). In addition, unlike adult MSC, FL MSC were found to uniformly express 
CD146. This is in keeping with the previous work showing high CD146 expression 
in fetal MSC (Martin and Bhatia, 2005; Miyauchi and Kawaguchi, 2014). No 
differences in the immunophenotype of normal and DS FL MSC were seen (Figure 
5-2). 
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Figure 5-2 Immunophenotype of cultured MSC isolated from A) Normal and B) 
DS FL 
 
5.3 Gene expression in normal FL MSC 
To investigate whether there were any differences in gene expression between 
normal FL and DS FL MSC, I first performed microarray analysis on normal FL MSC 
isolated from 5 different second trimester FL samples. Details of the microarray 
techniques used, including analysis of data, can be found in Chapter 2. Quality 
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control analyses for all microarray experiments were within the manufacturer’s 
recommendations. 
Firstly, I assessed expression levels of a number of cytokines known to be 
important in haematopoiesis. As shown in Figure 5-3A, FL MSC expressed SCF 
and CXCL12, which have both been shown to be vital for the maintenance and 
support of HSC (Morrison and Scadden, 2014). In addition, analysis showed 
expression of a number of other factors important in haematopoietic differentiation 
including particularly high levels of IL6. Importantly, FL MSC did not express IL3, 
TPO or EPO, in accordance with recently published ELISA data (Miyauchi and 
Kawaguchi, 2014). In addition, in agreement with data described in Chapter 3, FL 
MSC expressed far higher levels of IGF2 than IGF1 (Figure 5-3B). 
 
Figure 5-3 Expression of cytokine genes in normal FL MSC assessed by 
microarray 
A) Microarray expression levels of key cytokines involved in haematopoiesis. B) Microarray 
expression levels of IGF1 and IGF2 in normal FL MSC (n=5). 
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5.4 Comparison of gene expression in FL MSC and AdBM MSC 
I next compared FL MSC to AdBM MSC using a publicly available AdBM MSC 
microarray dataset, which was generated using low passage AdBM MSCs cultured 
in similar conditions to those used in my experiments and arrayed using the same 
microarray platform (Walenda et al., 2013). Data were normalised and analysed for 
differential expression of genes. Genes were included if they were found to be 
significant using LIMMA at p<0.05, and had a fold change (FC) greater than 2. 
Using this method, 486 genes showed higher levels of expression in AdBM and 412 
were expressed at higher levels in FL. Hierarchical clustering using this gene set 
effectively separated FL and AdBM MSC (Figure 5-4).  
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Figure 5-4 Differentially expressed genes in normal FL vs AdBM MSC 
Heatmap shows significantly differentially expressed genes with a FC>2 identified using LIMMA at 
p<0.05. Data used are derived from published results from 3 normal AdBM samples (Walenda et al, 
2013) and 5 normal FL MSC samples (data from my experiments presented in this chapter). 
 
As shown in Figure 5-5, cytokine levels were similar in FL MSC and AdBM MSC. 
Interestingly, IL7 showed significantly higher expression in AdBM MSC than FL 
MSC, albeit at a low level. IL7 is particularly important in lymphocyte development 
(Fry and Mackall, 2002) and so this may reflect the higher level of lymphocyte 
production in AdBM.  
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Figure 5-5 Microarray expression of cytokine genes in normal FL and AdBM MSC. 
Data used are derived from published results from 3 normal AdBM samples (Walenda et al, 2013) 
and 5 normal FL MSC samples (data from my experiments presented in this chapter). * p<0.05 
 
One previous study has compared FL MSC to AdBM MSC using microarray (Martin 
and Bhatia, 2005). In this study, the authors identified increased expression of 
genes of the Wnt signalling pathway in FL and of Notch2 in AdBM. In agreement 
with these findings, my data also showed significantly higher Notch2 expression in 
AdBM (FC 1.46) and upregulation of several components of the Wnt pathway in FL 
including WNT7B, WNT5A, DKK2, and DKK3. Furthermore, the authors identified a 
group of 43 genes that code for either secreted or membrane-bound proteins and 
that were differentially expressed in FL and AdBM MSC. Importantly, my data 
showed a similar pattern of differential expression in more than 80% of these genes 
(Table 5-1). 
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Table 5-1 Comparison of significantly differentially expressed genes (p<0.05) 
in normal FL vs. AdBM MSC compared to a published dataset (Martin and 
Bhatia, 2005) 
 
Data used are derived from published results from a previous comparison of FL and AdBM MSC 
(Martin and Bhatia, 2005), which is compared to my own comparison of 5 normal FL MSC samples 
with a separate AdBM MSC dataset (Walenda et al., 2013). Genes that show the same pattern of 
differential expression in these two comparisons are shown in blue. Those that show differences are 
shown in red. 
 
Gene Increased*Expression*(Martin*et*al) Increased*Expression*(My*Data)
FBLN5 FL FL
LOXL2 FL FL
ThBS1 FL FL
CXCL12 AdBM AdBM
DCN AdBM AdBM
IGFBP5 FL FL
IGFBP7 AdBM AdBM
INHBC AdBM FL
DKK3 FL AdBM
SEMA3A FL FL
SFRP1 FL FL
ENT5A FL FL
LOX FL AdBM
MFAP2 FL AdBM
PLAT FL FL
PLTP FL FL
PROS1 AdBM AdBM
CLDN1 FL FL
ITGA2 FL FL
ITGA6 FL FL
CD58 AdBM AdBM
PCDHB16 AdBM AdBM
ITGBL1 AdBM AdBM
FLT1 FL FL
GFRA1 AdBM FL
ADAM19 FL FL
DPP4 FL AdBM
GABARAPL3 FL FL
SDC1 FL FL
IL11RA AdBM AdBM
NOTCH2 AdBM AdBM
SLC8A1 FL FL
STEAP AdBM AdBM
OPN3 FL FL
OXTR FL FL
PPAP2B AdBM AdBM
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The top 50 differentially expressed genes in each population are shown in Table 5-2 
and Table 5-3. Interrogation of this list highlights several genes that may contribute 
to differences between adult and fetal haematopoiesis (Red text in Table 5-2 and 
Table 5-3). As expected, IGF1 shows significantly higher expression in AdBM in 
agreement with data in Chapter 3. In addition, expression of several genes involved 
in osteogenesis and chondrogenesis (PRG4, SCRG1, IBSP, EBF2) was 
significantly higher in AdBM MSC compared to fetal MSC suggesting that AdBM 
MSC are already primed for differentiation into bone and cartilage respectively.  
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Table 5-2 Genes with increased expression in normal FL vs. AdBM MSC 
 
Data used are derived from published results from 3 normal AdBM samples (Walenda et al., 2013) 
and 5 normal FL MSC samples (data from my experiments presented in this chapter). 
 
Genes%with%increased%expression%%in%normal%FL%MSC%vs.%AdBM%MSC
Gene%symbol Gene%Name Fold%Increase
ACTG2 actin,%gamma%2,%smooth%muscle,%enteric 37.56498059
CDH6 cadherin%6,%type%2,%KPcadherin%(fetal%kidney) 31.4185852
SERPINB2 serpin%peptidase%inhibitor,%clade%B%(ovalbumin),%member%2 19.86680984
TRHDE thyrotropinPreleasing%hormone%degrading%enzyme 19.25288868
IGF2BP1 insulinPlike%growth%factor%2%mRNA%binding%protein%1 13.80918063
MCAM melanoma%cell%adhesion%molecule 12.50668887
TCF21 transcription%factor%21 12.0038297
IGF2BP3 insulinPlike%growth%factor%2%mRNA%binding%protein%3 11.7173496
FBN2 fibrillin%2 10.91630903
LRRC17 leucine%rich%repeat%containing%17 9.045435431
CLDN1 claudin%1 8.724004662
SCN9A sodium%channel,%voltagePgated,%type%IX,%alpha%subunit 8.579889947
FOS FBJ%murine%osteosarcoma%viral%oncogene%homolog 8.251434031
NRK Nik%related%kinase 8.057150747
RPS4Y1 ribosomal%protein%S4,%YPlinked%1 7.947836788
ZNF804A zinc%finger%protein%804A 7.842136352
MYOCD myocardin 7.777665603
OLR1 oxidized%low%density%lipoprotein%(lectinPlike)%receptor%1 7.74750395
SHC3 SHC%(Src%homology%2%domain%containing)%transforming%protein%3 7.735594967
LYPD1 LY6/PLAUR%domain%containing%1 7.674553093
CHRM2 cholinergic%receptor,%muscarinic%2 7.526458053
SEMA3A sema%domain,%immunoglobulin%domain%(Ig),%short%basic%domain,%secreted,%(semaphorin)%3A7.371886778
DDX3Y DEAD%(AspPGluPAlaPAsp)%box%polypeptide%3,%YPlinked 7.361497967
VAT1L vesicle%amine%transport%protein%1%homolog%(T.%californica)Plike 7.159321511
RELN reelin 7.038143377
F2RL2 coagulation%factor%II%(thrombin)%receptorPlike%2 7.012426884
GPR126 G%proteinPcoupled%receptor%126 6.89230454
EIF1AY eukaryotic%translation%initiation%factor%1A,%YPlinked 6.741722186
SYT14 synaptotagmin%XIV 6.720129093
HIST1H4F histone%cluster%1,%H4f 6.582054187
RASGRF2 Ras%proteinPspecific%guanine%nucleotidePreleasing%factor%2 6.498205505
BEX1 brain%expressed,%XPlinked%1 6.147766087
SCARNA7 small%Cajal%bodyPspecific%RNA%7 6.145640844
GRIK2 glutamate%receptor,%ionotropic,%kainate%2 6.10727121
IGFBP5 insulinPlike%growth%factor%binding%protein%5 5.848619138
CENPV centromere%protein%V 5.391508782
NCKAP5 NCKPassociated%protein%5 5.355915772
ITGA2 integrin,%alpha%2%(CD49B,%alpha%2%subunit%of%VLAP2%receptor) 5.26922839
PRSS12 protease,%serine,%12%(neurotrypsin,%motopsin) 5.161990075
FOSB FBJ%murine%osteosarcoma%viral%oncogene%homolog%B 5.137711056
SNORD64 small%nucleolar%RNA,%C/D%box%64 4.856044325
ADAM19 ADAM%metallopeptidase%domain%19 4.7042054
LOC100133106 VCEW9374 4.69747348
CNIH3 cornichon%homolog%3%(Drosophila) 4.646847274
TNIK TRAF2%and%NCK%interacting%kinase 4.551138175
SYT1 synaptotagmin%I 4.39914689
UTY ubiquitously%transcribed%tetratricopeptide%repeat%gene,%YPlinked 4.386346964
MGARP mitochondriaPlocalized%glutamic%acidPrich%protein 4.380548893
SEMA3D sema%domain,%immunoglobulin%domain%(Ig),%short%basic%domain,%secreted,%(semaphorin)%3D4.378233328
NPTX1 neuronal%pentraxin%I 4.29936397
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Table 5-3 Genes with reduced expression in normal FL vs. AdBM MSC 
 
Data used are derived from published results from 3 normal AdBM samples (Walenda et al., 2013) 
and 5 normal FL MSC samples (data from my experiments presented in this chapter). 
 
 
Genes%with%decreased%expression%%in%normal%FL%MSC%vs.%AdBM%MSC
Gene%symbol Gene%Name Fold%Decrease
PRG4 proteoglycan%4 133.0564026
STEAP4 STEAP%family%member%4 40.60326271
SFRP4 secreted%frizzledOrelated%protein%4 40.51574696
CHI3L1 chitinase%3Olike%1%(cartilage%glycoproteinO39) 35.34577555
RBP4 retinol%binding%protein%4,%plasma 29.28836955
OLFML1 olfactomedinOlike%1 21.72029592
IL13RA2 interleukin%13%receptor,%alpha%2 20.64566424
PCSK1 proprotein%convertase%subtilisin/kexin%type%1 17.63877333
SCRG1 stimulator%of%chondrogenesis%1 17.30430843
ISLR immunoglobulin%superfamily%containing%leucineOrich%repeat 16.62137543
FNDC1 fibronectin%type%III%domain%containing%1 15.79891286
PDE1A phosphodiesterase%1A,%calmodulinOdependent 15.52043153
MFAP5 microfibrillar%associated%protein%5 14.88419508
SERPING1 serpin%peptidase%inhibitor,%clade%G%(C1%inhibitor),%member%1 14.66729775
CMKLR1 chemokineOlike%receptor%1 14.49252668
KCNJ15 potassium%inwardlyOrectifying%channel,%subfamily%J,%member%15 14.23305036
IBSP integrinObinding%sialoprotein 12.81816044
MMP13 matrix%metallopeptidase%13%(collagenase%3) 11.87087526
EBF2 early%BOcell%factor%2 11.52071349
SPON1 spondin%1,%extracellular%matrix%protein 11.26824475
SEPP1 selenoprotein%P,%plasma,%1 11.21762624
FAM20A family%with%sequence%similarity%20,%member%A 11.05278882
IGF1 insulinOlike%growth%factor%1%(somatomedin%C) 9.655748027
SFRP2 secreted%frizzledOrelated%protein%2 9.622998757
ABI3BP ABI%family,%member%3%(NESH)%binding%protein 9.549999896
DPT dermatopontin 9.496876248
TLR3 tollOlike%receptor%3 9.477144357
WISP2 WNT1%inducible%signaling%pathway%protein%2 9.353001792
PLXDC1 plexin%domain%containing%1 9.230263066
TNFSF10 tumor%necrosis%factor%(ligand)%superfamily,%member%10 8.923122929
MYO1D myosin%ID 8.415631841
PRELP proline/arginineOrich%end%leucineOrich%repeat%protein 8.167358216
TNFAIP6 tumor%necrosis%factor,%alphaOinduced%protein%6 8.013304647
ANGPTL1 angiopoietinOlike%1 7.902153565
PCOLCE2 procollagen%COendopeptidase%enhancer%2 7.887696323
CXCL16 chemokine%(COXOC%motif)%ligand%16 7.878795107
TLR4 tollOlike%receptor%4 7.77589813
SORBS2 sorbin%and%SH3%domain%containing%2 7.757935262
CP ceruloplasmin%(ferroxidase) 7.658489757
ECM2 extracellular%matrix%protein%2,%female%organ%and%adipocyte%specific 7.42190436
XG Xg%blood%group 7.2467227
IFI30 interferon,%gammaOinducible%protein%30 7.238073454
APBB1IP amyloid%beta%(A4)%precursor%proteinObinding,%family%B,%member%1%interacting%protein7.237885836
STMN2 stathminOlike%2 7.144238825
SMOC1 SPARC%related%modular%calcium%binding%1 7.060523665
PAPPA2 pappalysin%2 7.012414301
TSHZ2 teashirt%zinc%finger%homeobox%2 6.959997386
CHI3L2 chitinase%3Olike%2 6.944465548
GPNMB glycoprotein%(transmembrane)%nmb 6.848004082
CPNE8 copine%VIII 6.66295298
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FL MSC show markedly higher expression of IGFBP5, which codes for a protein 
that has been shown to bind and regulate IGF1 and IGF2. In some contexts 
IGFBP5 can increase the action of IGFs which could be important in FL (Pollak, 
2008). In addition, IGF2BP1 and IGF2BP3 were both expressed at higher levels in 
FL MSC and have previously been linked to fetal haematopoiesis (Copley et al., 
2013). Other genes of potential interest include RELN, which codes for the secreted 
reelin protein. This protein is known to be important in brain development and has 
been implicated in abnormal brain development in DS (Botella-López et al., 2010) 
but its role in haematopoiesis has not been explored. Finally, CD146 (also known as 
MCAM) was expressed at much higher levels (12.5-fold) in FL MSC compared to 
AdBM MSC in accordance with the flow cytometry findings; again the function of 
this cell surface protein is not yet known. 
Further analysis using GSEA identified enrichment of several gene sets in AdBM 
MSC related to interferon signalling (eg. BROWNE_INTERFERON_ 
RESPONSIVE_GENES, HECKER_IFNB1_TARGETS, BOSCO_INTERFERON_ 
INDUCED_ANTIVIRAL_MODULE, ZHANG_INTERFERON_RESPONSE) from the 
C2 collection (curated gene sets) of the Molecular Signatures Database (MSigDB; 
Figure 5-6A). This suggests that, compared to FL MSC, genes involved in interferon 
signalling are expressed at higher levels in the AdBM microenvironment compared 
to FL microenvironment. In addition, GSEA showed enrichment of a number of gene 
sets related to the cell cycle and DNA replication (Figure 5-6B), which is likely to 
correspond to the enhanced proliferation previously described in FL MSC (Martin 
and Bhatia, 2005) and which I also observed in my work (data not shown). 
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Figure 5-6 Enrichment of gene sets in normal FL and AdBM MSC 
A) GSEA identified enrichment of IFN-related gene sets in AdBM vs. normal FL MSC. B) GSEA 
identified enrichment of cell cycle related gene sets in normal FL vs. AdBM MSC. 
 
5.5   Comparison of gene expression in normal and DS FL MSC 
To explore differences in the normal and DS FL microenvironments I used 
microarray to compare gene expression in cultured MSC isolated from 3 DS FL 
samples compared to the 5 normal FL MSC samples. Analysis was performed as 
described above and revealed differential expression of 82 genes with a FC>2; 
compared to normal FL MSC, 33 genes were overexpressed in DS FL while 49 
genes were expressed at lower levels than normal FL. Interestingly, this is far fewer 
than the 898 genes found in the comparison between normal FL and AdBM MSC, 
which indicates that normal and DS FL MSC display relatively similar gene 
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expression profiles. Hierarchical clustering, using the differentially expressed genes, 
clearly delineated the two populations (Figure 5-7). 
 
Figure 5-7 Differentially expressed genes in normal FL vs. DS FL MSC 
Heatmap shows significantly differentially expressed genes with a FC>2 identified using LIMMA at 
p<0.05.  
 
Analysis of the differentially expressed genes based on chromosomal location 
showed a clear enrichment of Hsa21 genes in DS FL MSC (Figure 5-8A). Of the top 
100 significantly overexpressed genes in DS FL MSC, 23 were on Hsa21, far more 
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than would be expected by chance. As shown in Figure 5-8B, the fold change of all 
genes on each chromosome was around 1 in all chromosomes other than Hsa21 in 
which overall fold change was approximately 1.1. Although this is a relatively small 
difference, it clearly shows an overall upregulation of Hsa21 genes. This was 
confirmed using GSEA, which demonstrated enrichment of the Hsa21 gene set from 
the MSigDB C1 (positional gene sets) collection (Figure 5-8D). Importantly, most 
upregulated Hsa21 genes had a fold change of around 1.3-1.8, consistent with a 
dosage effect of T21 (Figure 5-8C; Table 5-4).  
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Figure 5-8 Enrichment of Hsa21 genes in DS FL MSC 
A) Chromosomal map shows clustering of upregulated genes on Hsa21. B) Increased expression of 
Hsa21 genes in DS FL MSC. C) Representative examples showing significant upregulation of Hsa21 
genes in DS FL MSC. D) GSEA identified enrichment of the Hsa21 gene set. 
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Table 5-4 Hsa21 genes with higher expression in DS FL MSC vs. normal FL 
MSC 
 
Comparison of key haematopoietic cytokines, including IGF1 and IGF2, showed no 
significant differences in expression between DS FL MSC and normal FL MSC 
apart from in the levels of IL6 and IL7 gene expression (Figure 5-9). There was a 4-
fold increase in IL6 expression in normal FL MSC compared to DS FL MSC which 
may be important since IL6 is an established regulator of haematopoiesis (Bernad 
Chromosome(21(genes(with(higher(expression(in(DS(FL(MSC
Gene(Symbol Gene(Name Fold(Increase
C21orf7 chromosome(21(open(reading(frame(7 3.7
DOPEY2 dopey(family(member(2 2.5
MIR155 microRNA(155 2.1
HLCS holocarboxylase(synthetase((biotinM(proprionylMCoAMcarboxylase((ATPMhydrolysing))(ligase) 1.9
C21orf91 chromosome(21(open(reading(frame(91 1.9
N6AMT1 NM6(adenineMspecific(DNA(methyltransferase(1((putative) 1.9
BACE2 betaMsite(APPMcleaving(enzyme(2 1.8
USP25 ubiquitin(specific(peptidase(25 1.7
RWDD2B RWD(domain(containing(2B 1.7
DNAJC28 DnaJ((Hsp40)(homolog,(subfamily(C,(member(28 1.7
LSS lanosterol(synthase((2,3MoxidosqualeneMlanosterol(cyclase) 1.6
MORC3 MORC(family(CWMtype(zinc(finger(3 1.6
NDUFV3 NADH(dehydrogenase((ubiquinone)(flavoprotein(3,(10kDa 1.6
TMEM50B transmembrane(protein(50B 1.6
GART phosphoribosylglycinamide(formyltransferase 1.5
CRYZL1 crystallin,(zeta((quinone(reductase)Mlike(1 1.5
PRMT2 protein(arginine(methyltransferase(2 1.5
ZNF295 zinc(finger(protein(295 1.5
TTC3 tetratricopeptide(repeat(domain(3 1.5
BRWD1 bromodomain(and(WD(repeat(domain(containing(1 1.5
WRB tryptophan(rich(basic(protein 1.5
MRPL39 mitochondrial(ribosomal(protein(L39 1.5
USP16 ubiquitin(specific(peptidase(16 1.5
PWP2 PWP2(periodic(tryptophan(protein(homolog((yeast) 1.5
C21orf59 chromosome(21(open(reading(frame(59 1.4
ATP5J ATP(synthase,(H+(transporting,(mitochondrial(Fo(complex,(subunit(F6 1.4
LTN1 listerin(E3(ubiquitin(protein(ligase(1 1.4
MCM3AP minichromosome(maintenance(complex(component(3(associated(protein 1.4
SOD1 superoxide(dismutase(1,(soluble 1.4
URB1 URB1(ribosome(biogenesis(1(homolog((S.(cerevisiae) 1.4
DSCR3 Down(syndrome(critical(region(gene(3 1.4
CCT8 chaperonin(containing(TCP1,(subunit(8((theta) 1.4
TRAPPC10 trafficking(protein(particle(complex(10 1.4
CBR1 carbonyl(reductase(1 1.4
YBEY ybeY(metallopeptidase((putative) 1.4
DYRK1A dualMspecificity(tyrosineM(Y)Mphosphorylation(regulated(kinase(1A 1.4
DIP2A DIP2(discoMinteracting(protein(2(homolog(A((Drosophila) 1.4
PFKL phosphofructokinase,(liver 1.3
FAM165B family(with(sequence(similarity(165,(member(B 1.3
C21orf33 chromosome(21(open(reading(frame(33 1.3
ITSN1 intersectin(1((SH3(domain(protein) 1.3
AGPAT3 1MacylglycerolM3Mphosphate(OMacyltransferase(3 1.3
IFNAR1 interferon((alpha,(beta(and(omega)(receptor(1 1.3
DONSON downstream(neighbor(of(SON 1.3
RRP1B ribosomal(RNA(processing(1(homolog(B((S.(cerevisiae) 1.3
CSTB cystatin(B((stefin(B) 1.3
SUMO3 SMT3(suppressor(of(mif(two(3(homolog(3((S.(cerevisiae) 1.2
IL10RB interleukin(10(receptor,(beta 1.2
SCAF4 SRMrelated(CTDMassociated(factor(4 1.2
PCNT pericentrin 1.2
LCA5L Leber(congenital(amaurosis(5Mlike 1.2
SON SON(DNA(binding(protein 1.2
PSMG1 proteasome((prosome,(macropain)(assembly(chaperone(1 1.2
SETD4 SET(domain(containing(4 1.2
POFUT2 protein(OMfucosyltransferase(2 1.2
RRP1 ribosomal(RNA(processing(1(homolog((S.(cerevisiae) 1.2
PTTG1IP pituitary(tumorMtransforming(1(interacting(protein 1.2
ATP5O ATP(synthase,(H+(transporting,(mitochondrial(F1(complex,(O(subunit 1.2
FAM207A family(with(sequence(similarity(207,(member(A 1.2
HMGN1 high(mobility(group(nucleosome(binding(domain(1 1.2
KRTAP19M5 keratin(associated(protein(19M5 1.2
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et al., 1994). Interestingly, IL7 expression was not detectable in DS FL MSC whilst it 
was expressed at a low level in normal FL MSC. It is tempting to speculate that this 
might be relevant to the reduced B lymphopoiesis seen in DS FL since IL7 is a 
major regulator of B cell development (Fry and Mackall, 2002). 
 
Figure 5-9 Expression of cytokine genes in DS FL MSC (n=3) vs. normal FL 
MSC (n=5) 
*p<0.05 
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5.5.1 Genes expressed at higher levels in DS FL MSC compared to normal FL 
MSC 
The differentially expressed genes in DS FL MSC compared to normal FL MSC with 
a FC>2 are shown in Table 5-5 and Table 5-6. These include several potential 
candidate genes that may play a role in mediating the abnormal fetal 
haematopoiesis in DS (red text in Table 5-5 and Table 5-6).  
 
Table 5-5 Genes with increased expression in DS FL MSC vs. normal FL MSC 
 
Genes%with%increased%expression%in%DS%FL%MSC%vs.%Normal%FL%MSC
Gene%Symbol Gene%Name Fold%Increase
SBSPON somatomedin%B%and%thrombospondin,%type%1%domain%containing 7.2
ERAP2 endoplasmic%reticulum%aminopeptidase%2 5.2
PSG4 pregnancy%specific%betaN1Nglycoprotein%4 4.9
RGS5 regulator%of%GNprotein%signaling%5 4.5
CCDC3 coiledNcoil%domain%containing%3 3.8
C21orf7 chromosome%21%open%reading%frame%7 3.7
ABCA8 ATPNbinding%cassette,%subNfamily%A%(ABC1),%member%8 3.4
KAL1 Kallmann%syndrome%1%sequence 3.4
CRYAB crystallin,%alpha%B 3.3
PDE1C phosphodiesterase%1C,%calmodulinNdependent%70kDa 3.2
MGP matrix%Gla%protein 3.2
ULBP1 UL16%binding%protein%1 3.0
DEPTOR DEP%domain%containing%MTORNinteracting%protein 2.8
IGFBP1 insulinNlike%growth%factor%binding%protein%1 2.7
ABCA9 ATPNbinding%cassette,%subNfamily%A%(ABC1),%member%9 2.6
CORO2B coronin,%actin%binding%protein,%2B 2.6
ADAMTS15 ADAM%metallopeptidase%with%thrombospondin%type%1%motif,%15 2.5
NUPR1 nuclear%protein,%transcriptional%regulator,%1 2.5
KLHL4 kelchNlike%4%(Drosophila) 2.5
ARL4C ADPNribosylation%factorNlike%4C 2.5
DOPEY2 dopey%family%member%2 2.5
LYVE1 lymphatic%vessel%endothelial%hyaluronan%receptor%1 2.4
TMEM171 transmembrane%protein%171 2.4
GHR growth%hormone%receptor 2.4
LIPH lipase,%member%H 2.4
MPP7 membrane%protein,%palmitoylated%7%(MAGUK%p55%subfamily%member%7) 2.3
UACA uveal%autoantigen%with%coiledNcoil%domains%and%ankyrin%repeats 2.2
ITGA7 integrin,%alpha%7 2.1
SEMA3D sema%domain,%immunoglobulin%domain%(Ig),%short%basic%domain,%secreted,%(semaphorin)%3D 2.1
MIR155 microRNA%155 2.1
SLC16A4 solute%carrier%family%16,%member%4%(monocarboxylic%acid%transporter%5) 2.0
BST1 bone%marrow%stromal%cell%antigen%1 2.0
DHCR7 7Ndehydrocholesterol%reductase 2.0
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Table 5-6 Genes with decreased expression in DS FL MSC vs. normal FL MSC 
 
  
Genes%with%decreased%expression%in%DS%FL%MSC%vs.%Normal%FL%MSC
Gene%Symbol Gene%Name Fold%Decrease
C3 complement%component%3 10.7
ITGA8 integrin,%alpha%8 10.5
PTGS2 prostaglandinKendoperoxide%synthase%2%(prostaglandin%G/H%synthase%and%cyclooxygenase) 8.3
MMP3 matrix%metallopeptidase%3%(stromelysin%1,%progelatinase) 7.8
CXCL6 chemokine%(CKXKC%motif)%ligand%6%(granulocyte%chemotactic%protein%2) 6.0
APOBEC3B apolipoprotein%B%mRNA%editing%enzyme,%catalytic%polypeptideKlike%3B 6.0
MME membrane%metalloKendopeptidase 5.7
SVEP1 sushi,%von%Willebrand%factor%type%A,%EGF%and%pentraxin%domain%containing%1 5.5
KIAA1324L KIAA1324Klike 5.4
IFI6 interferon,%alphaKinducible%protein%6 5.0
IFI44L interferonKinduced%protein%44Klike 4.8
MXRA5 matrixKremodelling%associated%5 4.6
FIBIN fin%bud%initiation%factor%homolog%(zebrafish) 4.4
IL6 interleukin%6%(interferon,%beta%2) 4.4
COLEC12 collectin%subKfamily%member%12 4.4
IFIT1 interferonKinduced%protein%with%tetratricopeptide%repeats%1 4.2
MX1 myxovirus%(influenza%virus)%resistance%1,%interferonKinducible%protein%p78%(mouse) 4.1
OLR1 oxidized%low%density%lipoprotein%(lectinKlike)%receptor%1 3.9
LRRN3 leucine%rich%repeat%neuronal%3 3.9
OAS2 2'K5'Koligoadenylate%synthetase%2,%69/71kDa 3.6
SERPINB2 serpin%peptidase%inhibitor,%clade%B%(ovalbumin),%member%2 3.5
CXCL2 chemokine%(CKXKC%motif)%ligand%2 3.4
ANGPT1 angiopoietin%1 3.3
NR4A2 nuclear%receptor%subfamily%4,%group%A,%member%2 3.3
PDE7B phosphodiesterase%7B 3.2
GREM2 gremlin%2 3.1
IFI44 interferonKinduced%protein%44 3.1
NBLA00301 Nbla00301 3.1
DHRS3 dehydrogenase/reductase%(SDR%family)%member%3 3.0
NRP2 neuropilin%2 2.9
HS3ST3B1 heparan%sulfate%(glucosamine)%3KOKsulfotransferase%3B1 2.8
GSTM1 glutathione%SKtransferase%mu%1 2.8
HERC6 HECT%and%RLD%domain%containing%E3%ubiquitin%protein%ligase%family%member%6 2.7
SNORA23 small%nucleolar%RNA,%H/ACA%box%23 2.6
CCL20 chemokine%(CKC%motif)%ligand%20 2.5
HAND2 heart%and%neural%crest%derivatives%expressed%2 2.5
CADPS Ca++Kdependent%secretion%activator 2.3
SLC39A8 solute%carrier%family%39%(zinc%transporter),%member%8 2.3
SNCA synuclein,%alpha%(non%A4%component%of%amyloid%precursor) 2.3
OAS1 2'K5'Koligoadenylate%synthetase%1,%40/46kDa 2.3
LYPD6B LY6/PLAUR%domain%containing%6B 2.3
NOG noggin 2.2
SNORA3 small%nucleolar%RNA,%H/ACA%box%3 2.2
C3orf62 chromosome%3%open%reading%frame%62 2.2
DKK1 dickkopf%1%homolog%(Xenopus%laevis) 2.1
OAS3 2'K5'Koligoadenylate%synthetase%3,%100kDa 2.1
NRG1 neuregulin%1 2.1
ADM adrenomedullin 2.0
PTGES prostaglandin%E%synthase 2.0
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In DS FL MSC, two genes were of particular interest. Firstly, IGFBP1, which codes 
for IGF Binding Protein 1, one of the six members of the IGFBP family, was 
expressed at almost 3-fold higher levels in DS FL MSC compared to normal FL 
MSC. IGFBP1 is one of a group of secreted proteins that bind to, and stabilise, 
IGF1 and IGF2, and regulate their access to IGF1R (Baxter, 2014). In addition, 
several studies have indicated that IGFBP1 may regulate cell function through IGF-
independent mechanisms (Baxter, 2014).  
The second candidate gene expressed at higher levels in DS FL MSC is the Hsa21 
microRNA (miR), MIR155. Although, generally associated with intracellular effects, 
previous work has demonstrated that miRs can be also be secreted, as active 
components of microparticles, and therefore may impact upon the 
microenvironment (discussed further below) (Xin et al., 2012).  
 
5.5.2 Genes with reduced expression in DS FL MSC compared to normal FL 
MSC  
Within normal FL MSC, in addition to IL6 as discussed above, two members of the 
CXC chemokine family, CXCL2 and CXCL6, were expressed at significantly higher 
levels in normal FL MSC than in DS FL MSC. Both have been shown to have 
important functions in haematopoiesis, particularly granulopoiesis (Fukuda et al., 
2007; Gijsbers et al., 2005). It is possible that reduced levels of CXCL2 and CXCL6 
might contribute to the reduced number of GMPs in DS FL although the role of 
these cytokines in human fetal haematopoiesis has never been investigated. 
Angiopoietin-1 (ANGPT1) was also expressed at higher levels in normal FL MSC 
compared to DS FL MSC. ANGPT1 encodes a secreted glycoprotein that is a key 
regulator of angiopoiesis and has recently been shown to be important for the 
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differentiation and long-term repopulating ability of murine HSPC (Ikushima et al., 
2013). 
 
5.5.3 GSEA of gene expression profiling data from normal and DS FL MSC 
Further analysis using GSEA identified a number of gene sets enriched in the two 
FL MSC populations. The most interesting of these, in relation to DS 
haematopoiesis, was an enrichment of interferon-related gene sets in normal FL 
(eg. HECKER_IFNB1_TARGETS, RADAEVA_RESPONSE_TO_IFNA1_UP, 
DER_IFN_ALPHA_RESPONSE_UP; Figure 5-10), consistent with a relative 
downregulation of this pathway in DS FL MSC. In addition, a number of individual 
interferon-related genes were expressed at significantly higher levels in normal FL 
compared to DS FL MSC (highlighted in blue in Table 5-6). 
 
Figure 5-10 Enrichment of IFN-related gene sets in normal FL MSC vs. DS FL 
MSC 
 
5.6 Comparison of gene expression in normal FL and FBM MSC 
The recent paper by Miyauchi and Kawaguchi showed that normal FL, but not FBM, 
MSC supported the growth of a ML-DS cell line (Miyauchi and Kawaguchi, 2014). 
However, although the authors suggested that this was due to a factor secreted by 
the FL MSC, they did not identify the relevant factor. To determine whether there 
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are any differences in the transcriptome of fetal MSC derived from the FL versus the 
FBM, I compared the gene expression profile of the normal FL MSC with that of 
MSC I isolated from normal FBM samples (n=4) using the same microarray 
platform. Assessment of differential expression identified 167 differentially 
expressed genes, 90 of which were expressed at higher levels in FL MSC while 77 
genes were expressed at higher levels in the FBM MSC compared to the FL MSC. 
Hierarchical clustering, using the differentially expressed genes, accurately 
delineated the two populations (Figure 5-11).  
 
Figure 5-11 Differentially expressed genes in normal FL vs. normal FBM MSC 
Heatmap shows significantly differentially expressed genes with a FC>2 identified using LIMMA at 
p<0.05.  
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Of the 77 genes expressed at higher levels in FL compared to FBM MSC, several 
have a known or potential role in haematopoiesis (Table 5-7). These include 
IGFBP5 and RELN, both of which were also increased in the analysis of normal FL 
MSC compared to AdBM MSC. This is extremely interesting as it could indicate one 
of the key differences between the FL microenvironment and the 
microenvironments that support haematopoiesis later in development and 
throughout adult life. It is possible that stromal cells undergo gradual changes 
during development and that high expression of IGFBP5 and RELN is unique to the 
FL microenvironment. It would therefore be useful to carry out further work to 
examine the function of these proteins in regulation of normal fetal haematopoiesis 
and leukaemias with their origin in fetal life, including TAM and ML-DS. 
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Table 5-7 Top differentially expressed genes in normal FL MSC vs. normal 
FBM MSC 
 
5.7 Comparison of DS FL and FBM MSC 
Finally I compared the transcriptional profiles of DS FL MSC and DS FBM MSC. As 
discussed earlier, FL appears to be an absolute requirement for the development of 
TAM in DS. At present, it is not known if the haematopoietic abnormalities identified 
in DS FL (Chou et al., 2008; Roy et al., 2012), are also present in DS FBM. 
Genes%differentially%expressed%in%normal%FL%MSC%vs%FBM%MSC
Gene%Symbol Gene%Name Fold%Increase
ITGA8 integrin,%alpha%8 8.4
OLR1 oxidized%low%density%lipoprotein%(lectinKlike)%receptor%1 7.7
FGF7 fibroblast%growth%factor%7 7.5
TRPA1 transient%receptor%potential%cation%channel,%subfamily%A,%member%1 7.4
VAT1L vesicle%amine%transport%protein%1%homolog%(T.%californica)Klike 6.5
MMP3 matrix%metallopeptidase%3%(stromelysin%1,%progelatinase) 6.2
RASGRF2 Ras%proteinKspecific%guanine%nucleotideKreleasing%factor%2 6.0
TCF21 transcription%factor%21 5.6
KYNU kynureninase 5.5
DPP4 dipeptidylKpeptidase%4 5.2
IFIT1 interferonKinduced%protein%with%tetratricopeptide%repeats%1 5.2
CHRM2 cholinergic%receptor,%muscarinic%2 5.0
LRRN3 leucine%rich%repeat%neuronal%3 4.9
IFI6 interferon,%alphaKinducible%protein%6 4.8
ANO4 anoctamin%4 4.5
RELN reelin 4.5
TNFSF4 tumor%necrosis%factor%(ligand)%superfamily,%member%4 4.4
IGFBP5 insulinKlike%growth%factor%binding%protein%5 4.4
SFRP1 secreted%frizzledKrelated%protein%1 4.3
IFITM1 interferon%induced%transmembrane%protein%1 4.2
COLEC10 collectin%subKfamily%member%10%(CKtype%lectin) 4.1
PDGFD platelet%derived%growth%factor%D 3.9
MX1 myxovirus%(influenza%virus)%resistance%1 3.9
C1S complement%component%1,%s%subcomponent 3.9
IFI44L interferonKinduced%protein%44Klike 3.9
Genes%upregulated%in%normal%FBM%MSC%vs%FL%MSC
Gene%Symbol Gene%Name Fold%Decrease
NEFM neurofilament,%medium%polypeptide 3.1
MMP16 matrix%metallopeptidase%16%(membraneKinserted) 3.1
SHISA2 shisa%homolog%2%(Xenopus%laevis) 3.2
KCNJ15 potassium%inwardlyKrectifying%channel,%subfamily%J,%member%15 3.2
DCLK1 doublecortinKlike%kinase%1 3.2
PDE3A phosphodiesterase%3A,%cGMPKinhibited 3.3
SPTLC3 serine%palmitoyltransferase,%long%chain%base%subunit%3 3.4
ZIC1 Zic%family%member%1 3.4
HOXA9 homeobox%A9 3.6
ABCA8 ATPKbinding%cassette,%subKfamily%A%(ABC1),%member%8 3.7
HOXA7 homeobox%A7 3.9
EBF3 early%BKcell%factor%3 4.0
ALPL alkaline%phosphatase,%liver/bone/kidney 4.0
SCRG1 stimulator%of%chondrogenesis%1 4.0
MEOX2 mesenchyme%homeobox%2 4.0
HOXD10 homeobox%D10 4.4
MGP matrix%Gla%protein 4.6
CCND2 cyclin%D2 4.6
SCUBE3 signal%peptide,%CUB%domain,%EGFKlike%3 4.7
CD24 CD24%molecule 5.3
KAL1 Kallmann%syndrome%1%sequence 5.6
FGF16 fibroblast%growth%factor%16 5.6
PRG4 proteoglycan%4 5.9
SORBS2 sorbin%and%SH3%domain%containing%2 5.9
CMKLR1 chemokineKlike%receptor%1 6.9
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However, as TAM is of FL origin, it is possible that differences in the FL and FBM 
microenvironments may provide additional insight into the mechanism through 
which haematopoiesis is disrupted.  
Interestingly, analysis of the gene expression profile of DS FL and BM MSC by 
microarray identified only 20 differentially expressed genes with FC>2 (Table 5-8). 
This is far fewer genes than found in the comparison of normal FL and normal FBM 
suggesting that DS MSC are remarkably similar in FL and FBM, at least at the 
transcriptome level.  It would therefore be interesting to determine the impact of T21 
on DS FBM haematopoiesis to ascertain if abnormalities similar to those found in FL 
are also present. Of the genes expressed at a higher level in DS FL compared FBM 
MSC, the only one with a known potential role in haematopoiesis is TXNIP. TXNIP 
was identified as one of the genes deleted on the long arm of chromosome 1 in 
patients with Thrombocytopenia Absent Radii (TAR) syndrome, a congenital 
disorder of platelet production (Klopocki et al., 2007). However, subsequent studies 
have excluded this as a causative gene in TAR (Albers et al., 2012). Recent studies 
have indicated that TXNIP is important for maintaining the HSC pool particularly 
under conditions of oxidative stress (Jung et al., 2013) and therefore further studies 
of this gene in fetal haematopoiesis would be of interest.  
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Table 5-8 Differentially expressed genes in DS FL MSC vs. DS FBM MSC 
 
 
5.8 Validation of candidate genes 
The microarray analyses have identified many potentially interesting differences 
between the various MSC populations. My initial aim in this section was to identify 
differences between the normal and DS FL microenvironments and so I chose to 
focus on the genes identified in this comparison. Using RT-qPCR, I went on to 
validate the genes of greatest interest; IGFBP1 and MIR155, which were 
upregulated in DS FL MSC and IL6, which was expressed at lower levels in DS FL 
MSC compared to normal FL MSC. As shown in Figure 5-12, RT-qPCR confirmed 
significantly higher expression of IGFBP1 and MIR155 in DS FL MSC. IL6 was also 
confirmed to be lower in DS FL MSC although this did not reach statistical 
significance.  
Genes%with%increased%expression%in%DS%FL%MSC%vs%DS%FBM%MSC
Gene%Symbol Gene%Name Fold%Increase
CEP170P1 centrosomal%protein%170kDa%pseudogene%1 2.0
HSP90AA6P heat%shock%protein%90kDa%alpha,%pseudogene 2.2
TMOD2 tropomodulin%2%(neuronal) 2.2
KLHL4 kelchTlike%4%(Drosophila) 2.3
ARRDC4 arrestin%domain%containing%4 2.5
FAM198B family%with%sequence%similarity%198,%member%B 2.6
CRISPLD2 cysteineTrich%secretory%protein%LCCL%domain%containing%2 2.9
DEPTOR DEP%domain%containing%MTORTinteracting%protein 3.2
THBS2 thrombospondin%2 3.3
PSG3 pregnancy%specific%betaT1Tglycoprotein%3 3.5
C7orf69 chromosome%7%open%reading%frame%69 3.7
TXNIP thioredoxin%interacting%protein 3.9
ERAP2 endoplasmic%reticulum%aminopeptidase%2 6.7
Genes%with%decreased%expression%in%DS%FL%MSC%vs%DS%FBM%MSC
Gene%Symbol Gene%Name Fold%Decrease
APOBEC3B apolipoprotein%B%mRNA%editing%enzyme 6.5
KIAA1324L KIAA1324Tlike 3.7
KLHL13 kelchTlike%13%(Drosophila) 3.1
SLC2A12 solute%carrier%family%2%,%member%12 2.9
GPR56 G%proteinTcoupled%receptor%56 2.5
C3orf62 chromosome%3%open%reading%frame%62 2.2
SHISA3 shisa%homolog%3%(Xenopus%laevis) 2.0
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Figure 5-12 RT-qPCR validation of selected differentially expressed genes in 
normal FL and DS FL MSC 
Selected genes were compared in normal FL MSC (n=5) vs. DS FL MSC (n=3). *p<0.05 
 
5.9 Development of a primary cell co-culture system 
Whilst the gene expression studies of FL MSC have identified some interesting 
differences between the DS and normal FL microenvironment, they are limited by 
the fact that differences in gene expression may not translate into functionally 
important differences in vivo either because they do not result in relevant 
differences in the amount of protein produced by the MSC or the protein may not be 
biologically active or multiple proteins may contribute to the differences in the DS FL 
microenvironment. To address this, I developed a co-culture system in which 
primary fetal haematopoietic cells were cultured on a layer of primary fetal stromal 
cells. I aimed to use this system to explore the effect on FL haematopoietic cell 
differentiation of culturing normal or DS FL HSPC on either normal or DS FL MSC 
and, potentially to investigate the effects of then inhibiting candidate genes or 
proteins of interest using shRNAs or antibodies.  
As a first step, normal and DS FL MSC were plated in 24-well plates (30,000 
cells/well), incubated to allow adherence at 80% confluence and normal FL HSPC 
(CD34+ Lin-) were then sorted and plated onto the MSC after 24 hours. I used the 
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same erythroid/megakaryocyte medium used in the liquid culture experiments 
detailed in Chapter 3 (StemSpan serum-free medium plus IL3, IL6, TPO and EPO). 
These cytokines were chosen as the microarray data and published ELISA data 
(Miyauchi and Kawaguchi, 2014) had shown that, other than IL6, they were not 
produced by FL MSC. Cultures were analysed by flow cytometry at day 7, day 10 
and day 14.   
Unfortunately, the initial system failed to support haematopoietic cell differentiation 
with almost no haematopoietic cells surviving by day 7 (Figure 5-13). 
 
Figure 5-13 Poor survival of normal FL haematopoietic cells cultured with 
non-irradiated FL MSC 
Representative flow cytometry plots show very low cell numbers in the live cell gate.  
 
Poor cell survival appeared to occur due to overgrowth of MSC in the co-cultures 
and I therefore changed the protocol to irradiate the FL MSC prior to plating. 
Following irradiation, MSC co-cultures supported haematopoietic cell proliferation 
and differentiation over the 14 day culture period (Figure 5-14A).  
The total number of live haematopoietic cells grown from normal FL CD34+ cells 
was slightly greater at all time points when cells were plated on DS FL MSC 
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compared to normal FL MSC, although the difference based on fold change did not 
quite reach significance (p=0.08 at day 14; Figure 5-14C).  
 
Figure 5-14 DS FL MSC promote proliferation of normal FL CD34+ cells in a 
MSC co-culture system 
A) Representative flow cytometry plots showing good cell viability at day 14 of culture. B) Absolute 
cell number of FL CD34+ cells cultured on normal FL (NFL) or DSFL MSC. C) Cell number 
expressed as FC in FL CD34+ cells cultured on NFL or DSFL MSC. 
 
Assessment of cell differentiation revealed the majority of cells were CD41+ 
megakaryocytes (Figure 5-15). This is in contrast to the liquid cultures conducted in 
the absence of MSC, which showed a predominance of erythroid cells. This 
suggests that both normal and DS FL MSC produce factors which promote 
megakaryocyte differentiation. Possible candidates are the IGF2 binding proteins 
(IGF2BP2 and IGF2BP3) which recent data suggest may play a role in fetal 
haematopoiesis (Copley et al., 2013) and which my data also showed are both 
expressed by FL MSC.  
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Figure 5-15 Relative erythroid and megakaryocyte differentiation of normal FL 
CD34+ cells co-cultured with normal FL MSC or DS FL MSC 
A) Relative differentiation assessed by flow cytometry at day 7, 10 and 14 of culture. B) 
Representative flow cytometry plots showing erythroid (GlyA) and megakaryocytic (CD41) 
differentiation of normal FL CD34+ cells co-cultured with NFL or DS FL MSC. 
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Importantly, the percentage of erythroid cells was higher when CD34+ cells were 
cultured on DS FL MSC, particularly at day 7 (p=0.06), suggesting promotion of 
erythroid differentiation (Figure 5-16A). The absolute number of erythroid cells, 
expressed as fold change, was also increased at all time points with DS FL MSC, 
and was significantly higher at day 14 (Figure 5-16B; p=0.005). In addition, whilst 
the megakaryocyte % was similar on normal FL and DS FL MSC, the fold change 
was higher when normal FL CD34+ cells were cultured in the presence of DS FL 
MSC (Figure 5-16C & D; p=0.06 at day 10).   
 
Figure 5-16 Erythroid and megakaryocytic differentiation of normal FL CD34+ 
cells co-cultured with normal FL or DS FL MSC 
A) Percentage erythroid differentiation of normal FL CD34+ cells after 14 days of co-culture. B) 
Absolute erythroid cell number (expressed as FC) of normal FL CD34+ cells after 14 days of co-
culture. C) Percentage megakaryocytic differentiation of normal FL CD34+ cells after 14 days of co-
culture. B) Absolute megakaryocyte cell number (expressed as FC) of normal FL CD34+ cells after 
14 days of co-culture. *p<0.01 
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5.10 Assessment of DS haematopoietic cells in a co-culture system  
I went on to conduct preliminary co-culture experiments using 2 DS FL CD34+ 
samples. Unfortunately, due to insufficient cell number it was only possible to sort 
cells for analysis at day 7 and day 10.  
In contrast to normal FL CD34+ cells, DS CD34+ cells did not show an increase in 
cell number when cultured on DS FL MSC (Figure 5-17A & B). Furthermore, DS 
progenitors underwent mainly erythroid differentiation (Figure 5-17C), unlike normal 
FL CD34+ cells, which had shown predominantly megakaryocyte differentiation.  
 
Figure 5-17 Proliferation and relative differentiation of DS FL CD34+ cells co-
cultured with normal and DS FL MSC 
A) Total haematopoietic cell number after 10 days of culture. B) Cell number, expressed as FC, after 
10 days of culture. C) Relative erythroid and megakaryocytic differentiation after 10 days of culture. 
 
However, as before, DS FL MSC promoted an early increase in erythroid % and 
absolute number apparent at day 7 of culture (p=0.06; Figure 5-18A and B). 
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Megakaryocyte differentiation was unchanged (Figure 5-18C and D). This indicates 
therefore, that DS FL MSC can promote erythroid differentiation in both normal and 
DS FL CD34+ cells. Further experiments are required to confirm this effect. 
 
Figure 5-18 Erythroid and megakaryocytic differentiation of DS FL CD34+ cells 
co-cultured with normal and DS FL MSC 
A) Percentage erythroid differentiation of DS FL CD34+ cells after 10 days of co-culture. B) Absolute 
erythroid cell number (expressed as FC) of DS FL CD34+ cells after 10 days of co-culture. C) 
Percentage megakaryocytic differentiation of DS FL CD34+ cells after 10 days of co-culture. B) 
Absolute megakaryocyte cell number (expressed as FC) of DS FL CD34+ cells after 10 days of co-
culture. 
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5.11 Discussion 
The results in this chapter evaluated the role of the FL microenvironment in 
perturbation of fetal haematopoiesis in DS using two complementary approaches. 
Firstly, I used comparison of gene expression of MSC isolated from second 
trimester normal and DS FL samples and further comparison with DS and normal 
FBM MSC at the same gestation and, in silico with AdBM MSC; and secondly, I 
carried out a functional assessment of the support function of these MSC using a 
crossover co-culture system.  
Through the use of microarray I have identified several differences in the 
transcriptional profiles of these cell populations and selected a number of genes 
that present interesting candidates for additional study. Perhaps unsurprisingly, FL 
and AdBM showed the greatest difference in gene expression profile with almost 
900 genes differentially expressed with FC>2 (Table 5-9). In contrast, there were 
only 167 differentially expressed genes when normal FL and FBM MSC were 
compared suggesting that ontogeny-related changes in gene expression may exert 
a greater influence than the site of haematopoiesis.  Around half as many genes 
were differentially expressed between normal and DS FL MSC consistent with a 
small, but significant difference which is likely to be secondary to the presence of 
trisomy 21 since there were no significant differences in the processing of these 
samples nor in the gestational age. Remarkably, comparison of the gene 
expression profile of DS FL and DS FBM MSC revealed differential expression of 
only 20 genes suggesting that strong similarity in the two microenvironments might 
exert similar effects on HSPC in DS FL and BM providing support for further 
investigation of FBM HSPC in DS.   
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Table 5-9 Number of differentially expressed genes with FC>2 
Comparison Number of genes with FC>2 
Normal FL vs AdBM MSC 898 
Normal FL vs Normal FBM MSC 167 
Normal FL vs DS FL MSC 82 
DS FL vs DS FBM MSC 20 
 
5.11.1 Differences in normal FL and AdBM MSC  
As has been shown previously, there are significant differences between normal FL 
MSC and AdBM MSC (Martin and Bhatia, 2005). My in silico analysis confirmed 
enrichment of the Wnt pathway in FL and Notch2 in AdBM. I also identified a 
number of other potentially important differences between these two populations. 
IGFBP5, an important mediator of IGF1 and IGF2 availability, was upregulated in 
FL, which may indicate a key role in the regulation of IGF signalling during fetal life. 
In addition, IGFBP5 has IGF-independent functions and has been shown to act as 
both a stimulator and inhibitor of cellular proliferation in different cell contexts 
(Baxter, 2014). The function of IGFBP5 within the haematopoietic microenvironment 
is unknown. The RNA binding protein genes, IGF2BP1 and IGF2BP3 were also 
overexpressed in FL MSC. These proteins are mainly expressed in the embryo 
although reactivation of IGF2BP expression has been described in some cancers 
(Bell et al., 2012). They have also both recently been implicated in the regulation of 
fetal haematopoiesis (Copley et al., 2013) and it is therefore important that their role 
in the fetal microenvironment is clarified.  
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5.11.2 DS FL MSC showed marked differences to normal FL MSC 
DS FL MSC showed a clear T21 gene expression 'signature' with upregulation of a 
large number of Hsa21 genes, as shown in other DS tissues (Aït Yahya-Graison et 
al., 2007; Lockstone et al., 2007; Vilardell et al., 2011). The majority of Hsa21 genes 
were expressed at ~1.5-fold higher levels than the same genes in normal FL MSC. 
It is possible that the aggregate effect of these modest changes in a large number 
of genes may be as important, or more important, than the effect of a single gene 
expressed at a higher level. Of particular interest is the MIR155 gene, which had 2-
fold greater expression in DS FL MSC and encodes the miR155 microRNA. MiR155 
has previously been linked to many cellular functions including the regulation of 
haematopoiesis (Elton et al., 2013) and its potential targets include many genes 
known to be involved in haematopoiesis including ETS1, JARID2, SPI1 and BACH1 
(Neilsen et al., 2013). It is expressed by HSPC and may play a role in the 
repression of haematopoietic lineage differentiation (Georgantas et al., 2007). 
Additionally it has been shown to be overexpressed in other human DS tissues 
(Sethupathy et al., 2007) and so further investigation into its role in the DS FL 
microenvironment is warranted. 
IGFBP1, another member of the IGFBP family, was also overexpressed in DS FL 
MSC. As with the other IGFBPs, IGFBP1 can regulate IGF availability and also has 
IGF-independent functions (Baxter, 2014). Intriguingly, IGFBP1 has been found to 
be elevated in the serum of patients with the MPD, polycythaemia vera, and to 
stimulate erythroid blast formation in vitro (Mirza et al., 1997). Given the potential 
importance of IGF signalling in DS FL haematopoietic progenitors, and its role in 
MPDs, IGFBP1 is an extremely attractive candidate for further investigation. In light 
of these findings, and following RT-qPCR validation, a new project has been 
established in our lab to investigate the function of IGFBP1 in fetal haematopoiesis.  
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Several cytokines also showed differential expression in normal and DS FL MSC. 
These include IL6, IL7, CXCL2 and CXCL6. It would be important to confirm this 
difference at the protein level, eg. by ELISA or Western blotting, and to assess the 
effects of these cytokines on fetal HSPC using the liquid culture and co-culture 
methods that I have developed during this project. In addition, GSEA revealed 
marked upregulation of the IFN system in normal FL MSC. IFN is a key regulator of 
immune function and can act as an anti-proliferative agent (De Andrea et al., 2002). 
In addition, exogenous IFN-α has been used as a therapy in several haematological 
disorders, including congenital dyserythropoietic anaemia and chronic myeloid 
leukaemia (Preudhomme et al., 2010). The IFN system is of particular interest in DS 
as a recent paper demonstrated that IFN-α markedly reduced the hyperproliferation 
seen in GATA1s murine megakaryocytic progenitors. The authors showed 
upregulation of the IFN pathway in adult versus fetal progenitors, suggesting that 
this alteration in activity limited disease to the fetal microenvironment. It is therefore 
possible that downregulation of the IFN pathway in the DS FL microenvironment 
also allows excessive megakaryocytic proliferation to occur during fetal life. Further 
work is necessary to establish the role of IFN signaling in human DS 
haematopoiesis. 
5.11.3 DS FL MSC promote erythropoiesis 
The establishment of an efficient primary cell co-culture system provides an 
excellent tool to functionally validate the microarray findings detailed above. In 
addition, I used the system to begin investigation of the role of normal and DS FL 
MSC in haematopoiesis, through the culture of normal and DS haematopoietic 
progenitors on normal FL or DS FL MSC. Using this technique, I showed that DS FL 
MSC promoted an increase in normal haematopoietic progenitor proliferation. In 
addition, DS FL MSC enhanced erythroid cell number in both normal and DS FL 
187 
 
progenitors, indicating that DS FL MSC can promote erythroid differentiation. 
However, as I have only conducted this experiment 3 times in normal FL CD34 cells 
and twice using DS FL CD34+ cells, it is essential that it is repeated to clarify if 
there is a true increase in erythroid differentiation. Given that DS FL HSC give rise 
to increased numbers of erythroid cells in clonogenic assays compared to normal 
FL (Roy et al, 2012) and microarray analysis within our lab (unpublished) has 
shown that DS FL CD34+ cells express significantly more erythroid genes than 
normal FL CD34+ cells, it is possible that this effect is mediated by DS FL MSC. It is 
interesting that DS FL progenitors also show an erythroid bias in the liquid culture 
system (Chapter 3) suggesting that the influence of the microenvironment in vivo 
may have already primed the cells towards the erythroid lineage. In addition, as 
mentioned above, IGFBP1 is increased in DS FL MSC and has been shown to 
promote erythroid differentiation in vitro (Mirza et al., 1997), suggesting a possible 
mechanism for this effect. 
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6 Discussion 
6.1 Background 
DS provides a unique disease model in which to investigate the multi-step aetiology 
of childhood leukaemia. Trisomy 21 essentially represents the ‘first hit’ in the 
development of leukaemia, thereby allowing the interrogation of haematopoiesis 
during this key window. As children with DS are at risk of both AML and ALL, the 
study of DS haematopoiesis can therefore inform our understanding of both these 
diseases.  
Work within our lab (Roy et al., 2012; Tunstall-Pedoe et al., 2008) and others (Chou 
et al., 2008) has clearly demonstrated disruption of haematopoiesis in the FL. 
Expansion of the HSC and MEP populations results in a marked megakaryocytic-
erythroid bias, laying the foundations for the acquisition of GATA1 mutations and 
the subsequent development of TAM and ML-DS. In general, it has been assumed 
that the megakaryocytic-erythroid phenotype is cell intrinsic, occurring as a result of 
trisomy 21. However, several factors implicate the microenvironment in the 
development of leukaemia in DS. Specifically, the timing of TAM, the spontaneous 
resolution in most cases and its association with liver pathology (Roy et al., 2009), 
strongly suggest that the FL is an absolute requirement for maintenance of this 
condition. However, although two recent papers have implicated two potential 
microenvironmental mediators of leukaemia development in DS; the IGF pathway 
(Klusmann et al., 2010) and the IFN pathway (Woo et al., 2013), the role of the DS 
FL microenvironment in the disruption of haematopoiesis and subsequent 
development of leukaemia remains largely unexplored. 
As discussed earlier, the fetal-specific nature of TAM raises two hypotheses; firstly 
that the normal FL microenvironment offers a unique microenvironment for support 
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of abnormal haematopoiesis in DS, or alternatively, that trisomy 21 alters the DS FL 
microenvironment providing the stimulus that drives disruption of FL 
haematopoiesis in DS. To examine these hypotheses, my project employed two 
distinct methodologies to investigate the role of the DS FL microenvironment in the 
disruption of haematopoiesis. To explore the first hypothesis, I utilised a candidate 
pathway approach, in which I explored the role of the IGF pathway in the regulation 
of normal and DS FL haematopoiesis.  Secondly, I used a broader screening 
method to compare the transcriptional landscape of the normal and DS FL MSC to 
allow identification of potential differences in these two microenvironments. Given 
the lack of knowledge of normal FL haematopoiesis, this work had the additional 
benefit of providing key information on the normal FL microenvironment.  
 
Therefore, the two aims of my project were: 
1. To investigate the hypothesis that IGF signalling acts as a driver of abnormal 
haematopoiesis in DS. 
2. To investigate the hypothesis that significant differences exist in the DS fetal 
liver niche through the characterisation of normal and DS fetal stromal cells.  
 
6.2 The IGF pathway displays developmental stage specificity 
Previous work had demonstrated the importance of the IGF pathway in fetal growth 
and development (DeChiara et al., 1990; Liu et al., 1993; Randhawa and Cohen, 
2005). Flow cytometry of HSPC suggested that FL progenitors were also reliant on 
the IGF pathway with significantly higher IGF1R surface expression than AdBM 
progenitors. In addition, several techniques confirmed that IGF2 was the major IGF 
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ligand produced in fetal life, as suggested previously (Randhawa and Cohen, 2005), 
confirming IGF2-IGF1R as the major axis of IGF signalling in FL haematopoiesis.  
Furthermore, functional studies testing the effects of exogenous IGFs on normal FL 
and AdBM progenitors, identified key differences in their response. Whilst IGF1 and 
IGF2 drove erythroid colony formation in both FL and AdBM progenitors, the effect 
differed depending on the concentration of EPO. Importantly, IGFs (particularly 
IGF2) stimulated erythroid colony formation in FL in the absence of EPO and at low 
EPO concentrations. In contrast, AdBM progenitors only responded to IGF when 
combined with high EPO concentrations. This suggests the existence of a fetal-
specific erythroid differentiation pathway that functions in the context of limited EPO. 
The EPO concentration in FL is not known but it is possible that that the IGF 
response seen in FL progenitors reflects the low EPO concentration present in the 
FL microenvironment. Murine studies would be needed to confirm this hypothesis.  
Alongside this increase in erythroid colonies, IGFs also reduced granulopoiesis with 
a reduction in GM colonies. This suggests that IGFs may play an important role in 
the determination of haematopoietic fate. 
Surprisingly, normal FL progenitors showed a limited response to IGF2 stimulation 
in the liquid culture system. Whilst this may indicate that the IGF response is only 
important in early erythroid differentiation it could also simply reflect differences in 
the liquid culture system including the use of StemSpan media and higher 
concentrations of EPO and SCF. Further experiments, particularly in the presence 
of low EPO concentrations, are necessary to confirm these findings.  
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6.3 IGF2 drives megakaryopoiesis in DS FL progenitors   
Klusmann et al have previously shown that ML-DS blasts show upregulation of the 
IGF1 receptor and are highly dependent on IGF signalling for survival (Klusmann et 
al., 2010). However, in contrast, I found that primary second trimester DS FL 
progenitors, which lack GATA1 mutations, expressed similar levels of IGF1R when 
compared to normal FL progenitors using flow cytometry and microarray. 
Nevertheless, despite this similarity in receptor expression, DS FL progenitors still 
showed an abnormal response to IGF2 stimulation.  
In both clonogenic assays and liquid cultures, exogenous IGF2 promoted significant 
megakaryocytic differentiation. Importantly, in the absence of IGF2, megakaryocytic 
differentiation, a hallmark of DS FL progenitors, was extremely limited, suggesting 
that IGF2 is required for this process. Whether other cytokines would produce 
similar effects is not known although previous work using EPO and TPO dose-
response assays failed to showed hypersensitivity to these cytokines (Chou et al., 
2008). Intriguingly, IGF1 did not promote megakaryocyte colony formation in 
clonogenic assays. This suggests that IGF1 and IGF2 mediate different effects 
despite binding to the same receptor (IGF1R). Additional experiments to assess 
downstream activation would be required to investigate this further. It is interesting 
to note that almost half of all ML-DS samples have mutations in one of the RAS 
pathway genes, one of the two pathways downstream of the IGF1 receptor 
(Yoshida et al., 2013). This could suggest that constitutive activation of the pathway 
is required for leukaemia development following cessation of fetal haematopoiesis.  
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6.4 The role of IGF2R in fetal haematopoiesis remains elusive 
The IGF2 receptor is essential for normal murine fetal growth and development (Lau 
et al., 1994; Ludwig et al., 1996; Wang et al., 1994). Interestingly, inherited 
mutations in the IGF2R gene have not been described in humans suggesting it is 
equally important in human fetal development. Despite this, there has been almost 
no research into its role in fetal development.  
Given that I had shown that IGF2 mediated fetal-specific effects within 
haematopoiesis, and that IGF2R is a major regulator of IGF2, I hypothesised that 
IGF2R would play a key role in fetal haematopoiesis. The variable level of IGF2R 
surface expression in different FL samples appeared to reinforce this hypothesis, 
suggesting functionality of the receptor. However, experiments using CB 
progenitors and an IGF2R null mouse model failed to identify a role for IGF2R in 
haematopoiesis. Nevertheless, a role for IGF2R in the regulation of fetal 
haematopoiesis cannot be entirely ruled out.  
CB progenitors were used due to the consistent pattern of IGF2R expression in this 
population, which allowed accurate sorting of IGF2R high and low populations. 
However, although CB progenitors are often employed as an easily accessible 
alternative to FL progenitors, they have inherent differences. In addition, given that 
IGF2R is constantly trafficking between cell surface and cytoplasm, it is possible 
that the IGF2R high/low populations that I sorted, only remained in this state 
transiently. Therefore, to further explore the role of IGF2R in fetal haematopoiesis it 
will be necessary to knock down the receptor in primary FL cells. Although, these 
experiments will be technically challenging, I have conducted preliminary 
experiments that suggest it will be feasible.  
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Despite failing to identify a role for IGF2R in fetal haematopoiesis, I did show a 
marked reduction in IGF2R expression in a ML-DS cell line (CMK) compared to 
another myeloid leukaemia cell line. Given that CMK had previously be shown to be 
hyper-responsive to IGF2 (Klusmann et al., 2010), it is possible that this is in part 
mediated by a downregulation of the IGF2R receptor. To explore this hypothesis 
further, I considered overexpressing IGF2R in the cell line to investigate whether 
this impacted on cell survival and proliferation. However, IGF2R is an extremely 
large gene (cDNA approximately 7.5Kb) and insertion was likely to prove extremely 
difficult. Therefore, alternative strategies will be necessary to establish the role of 
IGF2R in ML-DS. 
 
6.5 MSC show developmental stage and tissue specific 
characteristics 
As presented in chapter 5, gene expression profiling using microarray, identified 
many potentially interesting differences between MSC isolated from several 
different sources. Unsurprisingly the greatest difference was found between normal 
FL and AdBM MSC, indicating marked differences in these two microenvironments. 
Fewer differences were evident between normal FL and FBM suggesting that the 
microenvironment undergoes a gradual change during ontogeny. Importantly, high 
expression of two genes distinguished FL MSC from both FBM and AdBM MSC; 
IGFBP5 and RELN. As discussed earlier, both are secreted proteins and IGBP5 has 
already been linked to a role in haematopoiesis (Baxter, 2014). 
The main focus of this part of the project was to identify key differences between the 
normal FL and DS FL microenvironments. In total 82 genes were found to be 
differentially expressed at a FC>2, establishing a group of genes that may play a 
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role in the disruption of haematopoiesis in DS. Through review of the current 
literature I identified a number of genes as the most promising candidates for further 
study including IGFBP1, MIR155 and several cytokines (CXCL2, CXCL6, IL6). In 
addition, GSEA identified downregulation of the IFN pathway in DS FL MSC, which 
is of particular interest in the light of a recent publication showing a similar pattern in 
murine GATA1s fetal progenitors (Woo et al., 2013). Further experiments, including 
co-culture experiments as discussed below, are now required to investigate the role 
of these genes in the regulation of haematopoiesis in DS.  
 
6.6 DS MSC promote erythroid differentiation 
The coculture system described in chapter 5 provides a powerful system in which to 
investigate the role of the microenvironment in fetal haematopoiesis. Early 
crossover experiments using normal and DS FL MSC and normal and DS FL 
haematopoietic progenitors have indicated that DS FL MSC can promote erythroid 
differentiation. Given the marked megakaryocyte-erythroid bias displayed by DS FL 
progenitors in in vitro culture assays, this is an extremely exciting result as it 
suggests, for the first time, that the DS FL microenvironment plays a role in the 
disruption of haematopoiesis. Furthermore, recent data generated by a separate 
project in the lab using RNASeq has shown upregulation of erythroid genes in DS 
HSC, indicating an erythroid bias at the apex of the haematopoietic hierarchy (Irene 
Roberts, unpublished data). The co-culture findings suggest that the 
microenvironment may, at least in part, influence this phenotype through the 
promotion of erythroid differentiation pathways. 
It is now essential that the coculture system is utilised to functionally interrogate the 
microarray findings. Knockdown of genes shown to be overexpressed in DS FL 
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MSC could be employed within the coculture system to ascertain their importance in 
the regulation of haematopoiesis.  
 
6.7 Directions for future research  
As alluded to above, my results open up a number of directions for future research. 
Whilst I have identified differences in the DS FL microenvironment itself and in the 
response of DS progenitors to important growth factors, many questions remain 
unanswered.  
In particular, the transcriptional profiling of normal and DS FL MSC was essentially 
a screening exercise to characterise differences in these two microenvironments. It 
is now essential that the genes that I have identified as potentially mediating 
differences are investigated further using both conventional and co-culture systems. 
Importantly, in light of my results, a new project has already been established in our 
lab to investigate the function of IGFBP1 in fetal haematopoiesis. 
The response to IGF2 seen in DS FL progenitors suggests abnormalities in 
signalling of the two pathways downstream of the IGF1R; the PI3K/AKT/MTOR and 
RAS/MEK/ERK pathways. It is possible that IGF preferentially activates one of 
these pathways in DS progenitors thus driving megakaryocyte over erythroid 
differentiation. Already RNAseq work conducted in our lab has suggested increased 
expression in components of the RAS/MEK/ERK pathway suggesting that this 
pathway is of particular importance in DS fetal haematopoiesis (Irene Roberts, 
unpublished work). As the assessment of protein phosphorylation becomes more 
feasible in very small cell numbers, it would also be interesting to examine 
activation of these two pathways in normal and DS FL progenitors in the presence 
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and absence of IGFs, to ascertain whether there is preferential activation of the 
RAS/MEK/ERK pathway in DS.  
 
6.8 Conclusion 
For the first time, these studies have implicated the FL microenvironment in the 
disruption of haematopoiesis in DS. The presence of T21 in FL haematopoietic 
progenitors alters their response to IGF2, a key fetal growth factor, stimulating 
megakaryocyte development. In addition, DS FL MSC promote erythropoiesis in FL 
progenitors, further enhancing the megakaryocytic-erythroid bias inherent to DS 
haematopoiesis. Further work is now necessary to tease out the exact mechanisms 
by which these changes occur.   
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8 Appendices 
8.1 Appendix 1 
 
Surface Marker Fluorochrome Manufacturer 
Human Antibodies 
Lineage Cocktail FITC eBioscience 
CD34 PE/Cy7 eBioscience 
CD34 PerCP/Cy5.5 Biolegend 
CD38 Pacific Blue Exbio 
CD90 PE/Cy5 eBioscience 
CD123 PE Becton-Dickinson 
CD123 FITC Becton-Dickinson 
CD45RA APC Becton-Dickinson 
CD45RA FITC Becton-Dickinson 
CD71 FITC Biolegend 
CD235a Pacific Blue Biolegend 
CD11b PE/Cy7 Biolegend 
CD14 PE/Cy7 Biolegend 
CD41a APC Biolegend 
CD42b PE Biolegend 
CD73 PerCP/Cy5.5 Biolegend 
CD105 PE Biolegend 
CD146 PE/Cy7 Biolegend 
HLA-DR FITC eBioscience 
CD19 APC Becton-Dickinson 
CD45 Alexa Fluor700 eBioscience 
IGF1R PE Becton-Dickinson 
IGF2R APC ABD Serotec 
Insulin receptor PE Biolegend 
Murine Antibodies 
CD45 APC/Cy7 Becton-Dickinson 
B220 PE/Cy5 Becton-Dickinson 
Ter119 APC Becton-Dickinson 
Gr1 FITC Becton-Dickinson 
SCA1 PE/Cy7 Becton-Dickinson 
CKIT V450 Becton-Dickinson 
FLK2 APC Becton-Dickinson 
CD34 Alexa Fluor700 Becton-Dickinson 
CD150 PerCP/Cy5.5 Biolegend 
FCϒR APC Biolegend 
